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Abstract 
Conventional magnetic resonance imaging (MRI) is essential for the management of 
childhood brain tumours. However, it is increasingly being supplemented with functional 
techniques such as magnetic resonance spectroscopy (MRS). This thesis investigates how 
pre-treatment single voxel MRS can aid in diagnosis and surveillance of paediatric brain 
tumours and identify prognostic biomarkers. Data from multiple centres, scanners from 
three leading manufacturers and field strengths of 1.5 T and 3 T are incorporated. MRS 
was analysed using TARQUIN software with metabolite peaks fitted using a simulated 
basis set to provide metabolite concentrations. Univariate and multivariate statistical 
tests were used to compare variables. Multi-scanner spectroscopy detected significant 
differences in common and rare paediatric brain tumours. Diagnostic metabolite profiles 
were able to confirm tumour on follow-up imaging. Elevated creatine and total choline 
determined good prognosis in medulloblastoma. Myo-inositol and citrate aided in the 
characterisation of diffuse pontine gliomas (DIPG). While conventional MRI was unable to 
identify prognostic markers for DIPG, elevated taurine was found to be significantly 
associated with a better prognosis. The results encourage the use of MRS as an adjunct to 
conventional MRI in routine clinical practice. For future studies, accurate assignment of 
biomarkers will be determined in tumour tissue using in vitro high-resolution 
spectroscopy methods. 
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CHAPTER 1 
1 INTRODUCTION 
1.1 Brain Tumours and the Importance of Magnetic Resonance Imaging and Magnetic 
Resonance Spectroscopy 
Brain tumours are the most common solid tumour to present in children (Bleyer, 1999) 
with approximately 400 cases diagnosed each year within the United Kingdom (Northern 
Ireland Cancer Registry, 2011, ISD Scotland, 2011, Welsh Cancer Intelligence and 
Surveillance Unit, 2011, Office for National Statistics, 2010). Consequently, they are the 
leading cause of death from cancer in children accounting for around 32% of deaths 
(Stiller C, 2007). Rates of survival for brain tumours are now around 70% at five years 
compared to only 35% in the 1960s (Cancer Research UK) and while survival rates have 
significantly improved for other cancers, improvements for brain and spinal tumours have 
been comparatively steady. It should be noted that paediatric brain tumours consist of a 
diverse cohort thus improvements in survival are very tumour specific. Whilst some now 
have a very good prognosis, others have continued to present major challenges, 
highlighting the need for new techniques for investigation and management.  
The emergence of high resolution imaging, firstly Computed Tomography (CT) followed 
by Magnetic Resonance Imaging (MRI), both non-invasive methods of tumour tissue 
characterisation, has been crucial to the improvement of the clinical management of 
children with brain tumours (Panigrahy and Bluml, 2009). MRI scans are now performed 
on these children at multiple time points in their clinical management: initially at 
presentation to confirm the presence of a mass and aid diagnosis; prior to a surgical 
intervention, if recommended for staging and planning; following surgery to assess the 
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extent of resection; at approximately 3 monthly intervals during adjuvant treatment to 
monitor effectiveness; and at similar intervals after the end of treatment for tumour 
surveillance (Gill et al., 2013). Although the use of conventional MRI has become 
extensive, there are a number of significant limitations with the information that it 
provides.  
Diagnosis of a specific brain tumour at presentation is determined by its appearance on 
conventional MR images. The assessment of the anatomical and spatial information 
provided by MRI can pre-operatively reduce the number of possible diagnoses. However, 
it is not always tumour type or tumour grade specific and overlapping features are often 
seen in many of the heterogeneous tumours that present in children. Evidence has shown 
determining tumour grade can be difficult and studies in both adults and children have 
shown sensitivity of MRI can be limited (Law et al., 2003, Waldman, 2010, Panigrahy and 
Bluml, 2009, Hargrave et al., 2008). Changes in enhancement upon injection of a contrast 
agent and tumour appearances can aid in the assessment of tumour progression, 
however enhancement does not always reflect the changes in the underlying tumour. 
Alterations in enhancement can occur as a result of local tissue reaction to radiation 
therapy or ‘pseudo-progression’, as a result of the expansion of brain volume and 
changes in permeability of vessels caused by chemotherapeutic agents (Arthurs and 
Gallagher, 2011, Warren et al., 2000). Administration of chemotherapy can exhibit 
dramatic improvements in enhancement or ‘pseudo-response’ rather than true tumour 
response and differentiating between the two can be problematic (Clarke and Chang, 
2009, Batchelor et al., 2007). Surveillance imaging performed at timely intervals is used to 
assess the extent of residual disease. This requires careful planning with treatment 
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schedules to avoid over and/or underestimation of disease but does not always provide a 
definitive diagnosis. The assessment of apparent adverse tumour features has shown 
limited prognostic significance (Hargrave et al., 2008, Liu et al., 2009). Identifying 
prognostic markers would be useful, particularly for tumours that are diagnosed on 
clinical and imaging grounds alone. 
Although MRI is an essential tool for brain tumour assessment, the drawbacks outlined 
highlight that the benefits may be enhanced if supplemented with additional functional 
MR methods for example magnetic resonance spectroscopy (MRS). MRS can attempt to 
address the unanswered questions that conventional methods are unable to. 
Proton magnetic resonance spectroscopy (1H MRS) is a non-invasive, in vivo method that 
measures the biochemical information within a region of interest (ROI) defined as a 
voxel(s). The voxel(s) samples a volume of tissue, measuring the chemicals present within 
it thereby providing information on cellular metabolism. In theory, the ROI of choice can 
be within any tissue of the body but the technique is predominantly performed in the 
brain. Localisation of chemical information termed metabolites can be performed using 
two approaches, either as a single voxel method, single voxel spectroscopy (SVS) or multi-
voxel method, magnetic resonance spectroscopic imaging (MRSI). SVS acquires 
metabolite information from one voxel whereas MRSI acquires from multiple voxels thus 
providing chemical information across multiple regions in the tissue. The resultant output 
is a spectrum of peaks that correspond to the metabolites found in the tissue and each 
metabolite is determined by its position in the spectrum. A number of metabolites are 
commonly identified in the brain and these include n-acetylaspartate or NAA/tNAA, 
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(marker of neurons), creatine or Cr (marker of the energy state of cells), total choline or 
tCho (a marker of cell proliferation) and lactate or Lac (marker of abnormal energy 
metabolism). It should be noted that each signal peak can give rise to more than one 
metabolite, for example total choline is a sum of phosphocholine, glycerophosphocholine 
and free choline hence often referred to as total choline. Further details on these signals, 
their positions in spectrum and their roles are given in Chapter 3 (see section 3.5). 
When interpreted alongside conventional MRI, MRS can add new information to many 
clinical situations. Non-invasive diagnosis using MRS has been the focus of many research 
studies (Panigrahy et al., 2006, Harris et al., 2011, Davies et al., 2008, Kovanlikaya et al., 
2005) but is only the prelude to the improved characterisation of tumours. One of the 
most important strategies in the management of childhood cancer is the identification of 
prognostic factors, which have improved tumour characterisation and allow stratification 
of treatment according to risk (Zacharoulis and Moreno, 2009, Dufour et al., 2012). A 
number of prognostic MRS biomarkers have been discovered and await formal evaluation 
in a clinical trial setting (Wilson et al., 2013, Marcus et al., 2007). The non-invasive nature 
of MRS means scans can be performed at multiple time points, which is useful for 
monitoring the effectiveness of treatment. Identifying early markers of treatment 
response would be favourable and there is increasing evidence that MRS can provide 
these in some situations (Steffen-Smith et al., 2012, Laprie et al., 2005). Determining 
post-treatment residual masses on MRI can be challenging and there is promise that MRS 
could aid with this. Similarly, distinguishing radiotherapy related changes from recurrent 
tumour cannot always be achieved by conventional MRI and MRS could help provide 
extra valuable information.  
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1.2 Development of MR spectroscopy studies 
The field of MR spectroscopy has evolved and developed over time and is now showing 
encouraging results in many clinical scenarios. The initial focus of early spectroscopy 
studies was on adults with brain tumours with few reports on paediatric cohorts. The 
rarity of brain tumours in children has hindered its application in paediatrics resulting in 
small cohort numbers for studies (Howe et al., 2003, Castillo et al., 2000, Hattingen et al., 
2008a, Sibtain et al., 2007b, Wang et al., 1995). The tumours diagnosed in children and 
their clinical course differ from those that present in adults, with adult tumours often 
being more malignant (Jones et al., 2011). This prevents the application of the same 
spectroscopy findings in adult and paediatric cohorts (Porto et al., 2011, Jones et al., 
2011). 
With paediatric brain tumours most commonly located in the cerebellum, initial studies 
reported MRS findings for these tumours (Wang et al., 1995, Davies et al., 2008, Harris et 
al., 2008). MRS of rare tumours were reported as cases studies (Horská et al., 2001, Cirak 
et al., 2005). The main focus of initial studies was predominantly tumour diagnosis and 
characterisation with few studies focusing on prognosis. Studies probed the potential of 
spectroscopy to yield information during treatment monitoring, however this combined 
adult and paediatric cases into one (Weybright et al., 2005). 
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Figure 1.1 Comparison of MRS acquired pre-diagnosis at a) short TE and b) long TE from the same 
brain tumour patient (MB). Abbreviations: medulloblastoma, MB; mIns, myo-inositol; Tau, taurine; 
tCho, total choline; Cr, creatine; Glx, Glutamate+Glutamine; NAA, N-acetylaspartate; Lac, lactate; 
LMM0.9, lipids at 0.9 ppm; LMM1.3, lipids at 1.3 ppm 
The signal intensity of metabolites seen in the spectrum can change as a result of 
alteration of the parameter called echo time (TE). For example long TE (approximately 
135-270 ms) allows the detection of limited metabolites whereas short TE (approximately 
20 to 40 ms) allows the detection of more metabolites as shown in Figure 1.1. 
Despite the known benefits of short TE spectroscopy, initial studies were performed at 
long TE. This was because long TE provides metabolite profiles that are simpler to 
interpret with no dominance of lipids which are therefore easier to quantify (Figure 1.1) 
(Howe and Opstad, 2003, Panigrahy et al., 2010b). With improvements in metabolite 
quantitation, the value of short echo time spectroscopy is being highlighted. The 
increased metabolite information, reduces metabolite signal loss and increases signal-to-
noise ratio (SNR) (Panigrahy et al., 2010b). This has enabled the identification of tumour 
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subtype specific markers for aiding characterisation that is not possible at long echo time 
(Kovanlikaya et al., 2005, Panigrahy et al., 2006, Peet et al., 2007b, Wang et al., 1995). 
For the interpretation of results, simple methods such as peak height measurements 
were used initially. These were readily available and found to be effective (Wang et al., 
1995, Harris et al., 2007). With radiologists often not having access to spectroscopy 
analysis tools, this method can be easily applied using standard scanner manufacturer 
software. A study by Harris et al. (2007) demonstrated a flow scheme by which the 
spectroscopy of paediatric cerebellar tumours could aid diagnosis by measuring the peak 
heights determined by manufacturer software (Harris et al., 2007). The reproducible 
results obtained from multiple users illustrated the robustness of the technique. This 
could be useful for particular tumour types and while peak heights are easy to use they 
are only surrogates for metabolite concentrations as many metabolites do not consist of 
a single peak in one position but instead a number of overlapping peaks (Helms, 2008, 
Tong et al., 2004, Hattingen et al., 2008a). It is peak area determined by integration 
rather than peak height that is proportional to metabolite concentration. Early studies 
reported peak area findings relative to a metabolite in the spectrum. While ratios allow 
immediate inferences to be made, they eliminate determining the usefulness of the 
metabolite used as the denominator and assume it remains unchanged (Helms, 2008, 
Jansen et al., 2006). A number of studies have utilised Cr as a denominator assuming it to 
be stable in both normal brain and pathological states. However, this has now been 
shown to alter significantly resulting in confounding observations (Li et al., 2003). Fewer 
peaks are sufficient to aid diagnosis on a general level, but for complex analyses where 
comparisons are made between different subjects, tumour types, scanners and sequence 
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protocols this method is less useful. These pitfalls encouraged the move towards 
apparent absolute metabolite quantitation. 
Quantitation analysis software is often complex and very technical with a choice of 
different packages available to use. This often makes it difficult for an inexperienced 
spectroscopist to decide on the software to use and how to interpret the findings. 
Improved metabolite quantitation is seen when the MR spectrum is fit to a set of 
individual metabolite spectra, which can be acquired experimentally or be simulated 
(Wilson et al., 2010). The whole spectrum can be fitted automatically to produce a list of 
metabolites and their relative concentrations. The most commonly used software 
available commercially for this is LCModel (Provencher, 2001). The combination of 
metabolite fitting and using the water signal (acquired from an additional water scan 
taken at time of acquisition) as a concentration reference is proving to be a powerful 
technique for the automated processing of single voxel spectroscopy (SVS) data and is 
essential for consistency within and between studies (Tong et al., 2004). 
Simple statistical methods for assessing differences in metabolite information between 
tumours, although promising, do not use the information acquired to the full potential. 
This has led to the introduction of simple pattern recognition methods (Preul et al., 
1998). The main aim of these is to extract information from several input features to 
classify tumours. The most commonly used statistical tests include principal component 
analysis (PCA) and/or linear discriminant analysis (LDA) with some using the approach of 
a series of statistical tests to extract features from MRS data (Hagberg, 1998). Further 
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detail on these is given in chapter 4. Pattern recognition techniques are more powerful 
with large datasets.   
1.3 Advances in MRS 
Following an increase in the body of work on brain tumour diagnosis and 
characterisation, paediatric studies have become more focused on identifying prognostic 
information (Blüml et al., 2011, Yamasaki et al., 2011, Steffen-Smith et al., 2011). This is 
of particular interest in diffuse pontine glioma (DIPG), a tumour of the brain stem 
because it is diagnosed on clinical and imaging grounds alone (Hargrave et al., 2008). 
Tumours of the brain stem are extremely rare, accounting for 10-25% of brain tumours in 
children (Hargrave et al., 2006). MRS of a large cohort of brain stem tumours from a 
multi-centre cohort is investigated in this thesis. Larger cohort numbers are important to 
establish enough cases for a robust statistical analysis. Publications highlighting the 
benefits of using MRS have led to large studies including rare tumour types (Harris et al., 
2011) and this has been further explored to establish distinguishing features of rare 
tumour types to aid pre-operative diagnosis. The introduction of higher field strength 
scanners, the strength of which is determined in units of Tesla, is now on the increase. 
There is an increasing interest in how high field 3 Tesla (3 T) will provide benefits over 1.5 
T in clinical practice. Although theoretical benefits of the technique including increased 
SNR and peak separation are known, it is less well known how this translates in practice 
(Dagia and Ditchfield, 2008). While spectroscopy at 1.5 T is useful in many clinical 
scenarios there is still the need for an improved discrimination between different brain 
pathologies. A number of groups have performed comparisons with spectroscopy data 
collected at 1.5 T and 3 T to evaluate its use (Kim et al., 2006, Barker et al., 2001) but 
11 
 
paediatric studies making this comparison have not yet been published to our knowledge 
and this has been investigated in this body of work.  
Pattern recognition methods have become very popular with research groups for the 
classifying of brain tumours using MRS. They give excellent accuracy rates for tumour 
diagnosis but are not currently available for use in routine clinical settings. PCA and LDA 
can be performed on either the whole MR spectrum or a list of parameters which have 
been extracted from it, for example; metabolite concentrations (Davies et al., 2008, Hao 
et al., 2009). More complex methods, such as artificial neural networks and support 
vector machines, have also been used and shown to have high accuracy (Hao et al., 
2009). Spectroscopy classifiers can be further implemented with imaging, clinical and 
other information to increase the robustness and accuracy of the analysis to develop 
multimodal classifiers (Graves et al., 2001). This will become increasingly more important 
in clinical practice with the increasing implementation of functional imaging to support 
conventional sequences. Classification using these methods is most effective when a 
small number of diagnoses are being considered and the effect of combining tumour 
groups to give smaller numbers of larger classes has proven an effective strategy (Davies 
et al., 2008). A recent study by Vicente et al. (2013) has illustrated excellent diagnostic 
accuracy for a multicentre cohort of paediatric brain tumours and this has also been 
explored in this thesis (Vicente et al., 2013). The next focus for spectroscopy studies 
would be optimisation in search for prognostic markers. 
The current understanding of cancer pathogenesis is that genetic events, for example 
gain of functional genes termed oncogenes, lead to cancer cell transformation. This is a 
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multistep process where accumulation of genetic aberrations increases over time. 
Oncogenes are involved in signalling transduction cascades that are related to growth, 
division and survival of cells (Dang, 2012, Moestue et al., 2011). This has led to the 
discovery that oncogene targeted therapies can inhibit cancer signalling cascades and be 
used to treat cancer (Leitner et al., 2011). Monitoring these changes using MRS 
particularly at 3 T where spectral dispersion is greater, will prove useful as major 
metabolic pathways are regulated by oncogenic signalling pathways. A preliminary 
investigation of how the metabolic changes seen in medulloblastoma spectra can be 
explained by the signalling pathways identified has been explored. This is of particular 
interest as four molecular subgroups of the disease with varying prognoses have been 
identified. Each subgroup is speculated to have different dominant signalling pathway 
that aids pathogenesis (Taylor et al., 2012). 
The diagnosis of brain tumours on histopathology is determined using the World Health 
Organisation (WHO) grading scheme from I to IV (Louis et al., 2007). Mutations in two 
genes; isocitrate dehydrogenase I and II (IDH1 and IDH2), have been found to be 
prevalent in WHO grade II and III gliomas in adults (Yan et al., 2009, Balss et al., 2008). 
This led to the discovery that IDH mutant enzymes produce high levels of metabolite 2HG 
(2-hydroxyglutarate). 2HG is not easily measured using standard spectroscopy protocols 
but through manipulation of spectroscopy parameters the metabolite can be identified 
and measured. A study by Choi et al. (2012) was the first to show spectroscopy was able 
to identify a direct metabolic consequence of a genetic mutation in a cancer cell (Choi et 
al., 2012). It is hoped that a similar methodology can be applied to other tumour types 
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and that manipulating spectroscopy parameters will enable sequences to be optimised 
for a more tailored approach during treatment monitoring. 
Most applications of spectroscopy in paediatrics have been for brain tumours and brain 
lesions. In adults spectroscopy has been well studied in breast and prostate lesions 
(Morse et al., 2009, Costello et al., 1999) but these very rarely occur in children. With the 
introduction of high field scanners, researchers have worked on addressing the pitfalls of 
performing spectroscopy on body lesions, such as renal and liver masses to develop the 
technique for use in clinical practice. Technical issues for example motion artefacts 
associated with diaphragm and/or heart and ineffective water suppression need to be 
addressed (Fischbach and Bruhn, 2008, Katz-Brull et al., 2005). With the practical 
drawbacks of the technique, the method is currently being developed as a research tool 
before its application in a clinical setting. 
 
1.4 Aims and Objectives 
Overall Aims 
The aims of this work were to investigate how single voxel MRS can non-invasively aid in 
diagnosis, prognosis and surveillance of brain tumours in children. The research focuses 
on the use of multi-centre and multi-scanner data, analysis of tumour subgroups and the 
incorporation of data at the higher field strength of 3 T. 
Objectives 
1. To compare in vivo mean metabolite profiles of brain tumours in children with the 
inclusion of both common and rare types at 1.5 T and 3 T  
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2. To investigate the use of metabolites and metabolite profiles as diagnostic aids in 
paediatric brain tumours 
3. To determine how metabolite profiles of brain tumours differ from diagnosis to 
first relapse and investigate how this can help to accurately diagnose and 
characterise tumour relapse or progression  
4. To investigate the variability of in vivo metabolite profiles within subgroups of 
brain tumours, in particular medulloblastoma and brain stem tumours  
5. To establish biomarkers of prognosis in medulloblastoma and diffuse intrinsic 
pontine glioma 
6. To determine whether the higher field strength of 3 T demonstrates an 
improvement in metabolite determination and quality of data acquired in 
paediatric patients 
1.5 Thesis organisation and contributions  
The classification of paediatric brain tumours and a comprehensive review of the current 
published MRS literature for these tumours have been summarised in chapter 2. The 
theory of MRS pertinent to the research is outlined in chapter 3 and followed by a 
summary of the statistical methodology used to analyse the spectroscopy data in chapter 
4. 
Chapter 5 focuses on characterising metabolite profiles in a large cohort of paediatric 
brain tumours obtained on multiple scanners at multiple centres including 1.5 T and 3 T. 
Mean metabolite concentrations are determined and compared for various tumour 
groups and an investigation into the use of metabolites in tumour diagnosis undertaken, 
meeting objectives one and two. Multi-centre studies in the MRS of childhood brain 
tumours are lacking and there are none which are large enough to investigate the rarer 
tumours or report results at two field strengths. These weaknesses have failed to show 
the robustness of the technique thus this chapter aims to overcome this.  
15 
 
To meet objective three, Chapter 6 presents a study in which paired comparisons of 
metabolites at diagnosis and first tumour relapse are made within a heterogeneous 
cohort of malignant tumours. The use of metabolite profiles in diagnosing tumour relapse 
is explored. Previous studies of tumour MRS at diagnosis and relapse have focused on 
adults and used single metabolites or their ratios. Brain tumours in children have a 
different spectrum of disease to those in adults and the tumours have varied metabolite 
profiles highlighting the importance of paediatric specific studies. This work has been 
presented as an oral presentation at the 16th Annual Scientific meeting of the British 
Chapter of the ISMRM, 2010 and poster presentation at the 20th British Chapter ISMRM 
Postgraduate, 2011. 
Chapter 7 uses metabolite concentrations to identify markers of prognosis in 
medulloblastoma and makes comparisons with other clinical factors related to prognosis 
and used in treatment stratification to meet objective 4. Unlike previous analyses that 
have identified metabolites of prognostic significance in heterogeneous cohorts of brain 
tumours, this study is the first to present markers specific to a subtype, medulloblastoma. 
This is of particular interest in light of recent reports that medulloblastoma consists of 
four different molecular subgroups with varying prognoses. Part of this work has been 
previously presented as an oral presentation at the 17th Annual Scientific meeting of the 
British Chapter of the ISMRM, 2011. This work has also been presented as a poster at 3rd 
Annual Cancer Research UK and EPSRC Cancer Imaging conference, 2012 and at the 44th 
Congress of the International Society of Paediatric Oncology (SIOP) the abstract of which 
is now printed in Paediatric Blood and Cancer. 
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Chapter 8 investigates MRS of brain stem tumours. Spectroscopy is potentially valuable 
for these tumours as they are often diagnosed on clinical and imaging grounds alone and 
commonly the cause of diagnostic dilemmas. This multi-centre analysis investigates both 
diagnostic and prognostic markers in these tumours meeting objectives four and five. 
This study of rare tumours is large compared to previous analyses and is supported by the 
inclusion of multi-centre data. This work was presented as an oral presentation at the 21st 
British Chapter ISMRM Postgraduate Symposium, 2012 and is currently In Press for 
publication in Neuro-oncology. 
Chapter 9 details the analysis of spectroscopy data acquired at a higher field strength of 3 
T and compares it to 1.5 T data, objective six. To the best of our knowledge this is the first 
analysis that aims to determine whether the higher field strength of 3 T shows any 
benefits for spectroscopy in terms of metabolite determination and quality of data 
acquired in a paediatric population of patients. This is particularly important with the 
increasing introduction of higher field strengths in clinical practice. This work has been 
previously presented as an oral presentation at IPEM conference, “3 T or not 3 T?”, 2013. 
The final chapter includes the conclusions drawn from this work and discusses future 
work.  
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CHAPTER 2 
2 PAEDIATRIC BRAIN TUMOURS AND THE APPLICATION OF MRS 
2.1 Brain tumours in children and adults 
Brain tumours comprise of approximately 20-25% of all cancer diagnoses in children 
between 0-14 years of age, with approximately 10% of tumours occurring in 15-19 year 
olds (Gurney and Bondy, 2006). Adults and children’s brain tumours are known to be 
different with those in children found to be more heterogeneous (Slavc, 2011). Adult 
brain tumours are either WHO grade III astrocytoma, anaplastic astrocytoma (AA) or 
glioblastoma multiforme (GBM, grade IV) whereas paediatric brain tumours consist of 
WHO grades I to IV with pilocytic astrocytoma (PA, grade I), medulloblastoma (MB, grade 
IV) and ependymoma (EP, grade II or III) being the most common. The majority of 
tumours in children occur infratentorially in the cerebellum, whereas in adults most occur 
supratentorially (Vézina, 2005). The therapeutic strategies for adults and children also 
vary. The role of chemotherapy in children has been found to be more effective than in 
adults and radiotherapy is mostly administered to children above the age of three due to 
the expected long-term side effects. In general the outcome of children with brain 
tumours is more favourable than in adults however, this does vary between tumour types 
(Pollack, 1999). Environmental risk factors as a cause of cancer in children are rare and 
only previous exposure to ionizing radiation has been confirmed to be linked (McKinney, 
2004). Evidence has shown that many childhood cancers occur as a result of aberrations 
in early developmental processes (Gurney and Bondy, 2006). There are a small number of 
genetic risk factors that predispose children to brain tumours. These include 
neurofibromatosis type 1 and 2 (pilocytic astrocytoma, low-grade gliomas, 
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ependymoma), Turcot syndrome (medulloblastoma and high-grade glioma), Li-Fraumeni 
syndrome, Gorlin syndrome, and von Hippel-Lindau syndrome (hemangioblastoma) but 
these account for only a small proportion of tumours (Dubuc et al., 2010, Carlotti et al., 
2008). 
2.2 Classification of childhood brain tumours 
For children who have surgery, their brain tumour is classified by histopathology and 
graded using the 2007 WHO Classification of Tumours of the Central Nervous system 
(Louis et al., 2007). For those who do not have surgery, the tumours are diagnosed on 
characteristic clinical and imaging findings. Figure 2.1 summarises the approximate 
incidence of common CNS tumours in children (Gurney and Bondy, 2006) 
 
Figure 2.1 Pie chart demonstrating the approximate incidence of common central nervous system 
tumours in children. The figure includes both those diagnosed on histopathology and clinical and 
imaging grounds (Gurney and Bondy, 2006). 
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2.2.1 Glial 
Glial tumours make up approximately 60% of brain tumours in children. Pilocytic 
astrocytoma (PA) and ependymoma (EP) are the most common subtypes diagnosed from 
this diverse group (Gurney and Bondy, 2006). 
Astrocytomas 
Astrocytomas are the most commonly occurring glial tumours in children, making up, 
approximately 50% of all brain tumours. Their behaviour and treatment depend greatly 
on their grade. PA, classified as WHO grade I tumour with a low mitotic rate, rarely 
infiltrates the surrounding brain. It can occur in various locations in the brain but is 
particularly common in the cerebellum and optic pathway (Gan and Haas-Kogan, 2010). 
Children with mutations in the neurofibromatosis 1 (NF-1) gene have an increased risk of 
developing PA, particularly in the optic pathway (Listernick et al., 2007). The prognosis of 
patients diagnosed with PA is generally very good with some studies reporting a five-year 
survival of 100% and 10 year survival of 95.8%, following diagnosis (Burkhard et al., 
2003). Cerebellar tumours have an excellent prognosis but supratentorial tumours of the 
optic pathway and thalamus are more difficult to treat. Those in the optic pathway often 
present with visual loss and preserving vision is a major challenge (Gurney and Bondy, 
2006). Some PA metastasise and a recent more aggressive variant, pilomyxoid 
astrocytoma, has been recognised by the WHO classification (Komotar et al., 2004). 
Identifying these more aggressive variants by non-invasive imaging is the current goal. 
Diffuse astrocytomas (DA, grade II) have a more varied course, with some having a very 
poor prognosis. These tumours can be heterogeneous and often consist of high grade 
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areas within the tumour resulting in the progression of the whole tumour to a higher 
grade lesion (Broniscer et al., 2007). The clinical course of these patients and progression 
of tumour is difficult to predict based on MRI (Wessels et al., 2003). High grade (grade III 
and IV) astrocytomas including AA (III) and GBM (IV) are aggressive tumours with a poor 
prognosis (Piette et al., 2008). 
EP makes up approximately 6-10 % of brain tumour diagnoses with over half of cases 
diagnosed below the age of 5 (Smyth and Rubin, 2010, Blaney et al., 2006). The majority 
are located in the intracranial region with two thirds arising in the posterior fossa. 
Metastases are rare but the management of the tumour in the primary site is often 
challenging. They are classified as either WHO grade II or III. The current treatment 
strategy for these tumours is surgical resection, followed by radiotherapy if the child is 
old enough and chemotherapy in the very young (Mack and Taylor, 2009, Zacharoulis and 
Moreno, 2009). Overall survival ranges from 39% to 64% at 5 years (Kilday et al., 2009). 
2.2.2 Embryonal 
Embryonal tumours are highly malignant tumours seen predominantly in children. 
Primitive neuroectodermal tumours are the largest subgroup of embryonal tumours. 
Primitive Neuroectodermal Tumours (PNET)/Medulloblastoma (MB) 
PNET are composed of poorly differentiated neuroepithelial cells (Sandberg and Stone, 
2008). Distinct subgroups are seen, characterised by their location with those found in 
the cerebellum termed medulloblastoma and those found elsewhere as supratentorial 
PNET (CNS PNET). Whilst closely related histologically, they have been shown to form 
separate groups on gene expression analysis (Pomeroy et al., 2002). The five-year survival 
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rate for the group as a whole is around 40-70% but differs between the groups and also 
varies with stage and age at diagnosis (Sandberg and Stone, 2008). Multiple signalling 
pathways have been associated with the growth and development of MB. Some of the 
developmental pathways include WNT (Wingless-related integration site), c-Met, erB2, 
SHH (Sonic Hedgehog), Notch and Chromosome 17 abnormalities. There is an interest in 
using these prognostic groups and their pathways as targets for new therapy (Guessous 
et al., 2008) .  
2.2.3 Rare tumour types  
Atypical Teratoid Rhabdoid (ATRT) 
ATRT is a rare embryonal tumour with a highly malignant nature. The tumour is classified 
as WHO grade IV with a poor prognosis and arises in very young children. The true 
incidence is unknown as it has only recently been identified as a separate entity but is 
speculated to be around 1-2% (Heck et al., 2013). ATRT was the first tumour for which a 
candidate tumour suppressor gene was found. INI1 gene is found to be either mutated or 
deleted in ATRT (Reddy, 2005, Heck et al., 2013) . 
Choroid Plexus tumours 
Choroid plexus tumours represent 3% of brain tumours in children and are often 
diagnosed below the age of five. Two of the more commonly occurring choroid plexus 
tumours are choroid plexus papilloma (CPP) and choroid plexus carcinoma (CPC) of which 
CPP is WHO grade I and CPC is WHO grade III. This is reflected in the poor five-year 
survival of CPC which is around only 26%. Surgery is usually the treatment of choice 
although this can prove problematic in CPC due to its high vascularity (Due-Tønnessen et 
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al., 2001). More recently difficulties in distinguishing between CPP and CPC on 
histopathology have resulted in an additional intermediate WHO grade choroid plexus 
tumour, atypical choroid plexus papilloma (WHO grade II) being identified (Wrede et al., 
2009).  
Pineal Tumours 
Pineal tumours are those defined as arising from the pineal body and surrounding 
structures. Although the overall incidence of tumours in this region is rare (0.5-2%) the 
different types that present are diverse. The incidence of pineal tumours depends on the 
age and ethnicity of the patient (Echevarría et al., 2008). Germ cell tumours, germinomas 
(GER) are the most common and have a long term survival rate of over 90% (Konovalov 
and Pitskhelauri, 2003) whereas pineoblastomas, a category of supratentorial primitive 
neuroectodermal tumours (sPNETs) found in the pineal gland are highly malignant with 
varying prognosis dependent on age (Gilheeney et al., 2008, Tate et al., 2012). The 
infrequent presentation of these tumours makes them difficult to diagnose and manage 
(Packer et al., 2000). 
Neuronal and mixed 
Ganglioglioma(GG) 
Gangliogliomas (GG) are WHO grade I tumours composed of a mixed histology of 
astrocytes and atypical ganglion cells. The tumours can occur in any region of the brain 
and have an incidence of 2-10%. The primary treatment strategy is surgical resection 
following which prognosis is good (Rocco and Tamburrini, 2006, Castillo, 1998). 
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Craniopharyngioma (Cranio)  
Craniopharyngioma (Cranio) is a non-glial intracranial tumor derived from embryonal 
tissue. The tumour is relatively rare representing 6-9% of all childhood brain tumours. 
Cranio (WHO grade I) are slow growing tumours and symptoms often present 1-2 years 
prior to a formal diagnosis being made. The overall five-year survival in children is around 
85% (Muller, 2008, Garnett et al., 2007). 
2.2.4  Classification of tumours with no histopathology 
Many childhood brain tumours are diagnosed without histopathology and instead 
diagnosed based on clinical and imaging grounds alone. Improving the diagnosis of these 
tumours using a non-invasive method is of great interest.  
Brain Stem Tumours (BST) and Diffuse Pontine Gliomas (DIPG) 
Brain stem gliomas account for 10-20% of CNS tumours among children (Donaldson et al., 
2006). They are usually diagnosed using clinical criteria and conventional MRI 
characteristics, with a biopsy only being performed if the diagnostic criteria are not met.   
The majority of brain stem gliomas are made up of DIPG. DIPG historically have a very 
poor prognosis partially because of the location of the tumour but also because of its 
poor response to adjuvant treatment. The median time for progression is around 5-6 
months with mean survival under 12 months (Hargrave et al., 2006). Very few studies 
have performed biopsies on these patients; however it is now becoming apparent that 
the lack of biopsy material is hindering the advances in treatment for these patients 
resulting in a limited understanding of the biology of these tumours. The studies that 
have presented cases where DIPG have been biopsied found the majority to be 
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astrocytomas, usually of grade II or III (Hargrave et al., 2006). A different study found at 
autopsy the majority of these tumours were GBM (Remke et al., 2011). Key differences in 
MRS have been previously reported for DIPG and other astrocytomas (Panigrahy et al., 
2008). The remaining 20% of brain stem tumours are focal and are either low grade or 
high grade astrocytomas (Sanai and Prados, 2010). NF-1 positive patients are also prone 
to developing diffuse brain stem lesions, which are less aggressive but often result in 
diagnostic dilemmas on conventional sequences (Listernick et al., 2007) . 
Optic Pathway Gliomas 
Tumours of the optic pathway, particularly in children with NF-1 are commonly not 
biopsied due to the risks posed to vision and also because they are invariably PA (Gan and 
Haas-Kogan, 2010). 
Germ Cell Tumours 
Germ cell tumours can be located anywhere in the midline of the brain with the pituitary 
and pineal glands being the most common sites. Surgical resection is not part of the 
management for most malignant germ cell tumours and therefore a non-invasive 
diagnosis could entirely avoid surgery. For secreting germ cell tumours, a non-invasive 
diagnosis is already achieved using serum markers, however non-secreting tumours 
require a biopsy (Kendi et al., 2004, Blaney et al., 2006). 
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2.3  Application of magnetic resonance spectroscopy in paediatric brain tumours 
2.3.1  Non-invasive diagnosis and characterisation 
The most studied application of SVS is its use as a non-invasive diagnostic aid. A review of 
MR reports compared with final pathology at Los Angeles Children’s Hospital found that 
83% of cases were correctly diagnosed by radiologists between January 2005 and 
November 2007 after the introduction of MRS, compared with only 63% of cases 
between June 2001 and January 2005, a result that was statistically significant. To prove 
this was not simply a learning effect, the older set of cases were re-reviewed and an 
improvement from 63% to 71% was seen. Although this partially attributed to more 
thorough imaging workup, the accuracy is still short of that seen in the group where MRS 
is available. This provides evidence for the importance of MRS in aiding diagnosis and 
characterisation of brain tumours as an adjunct to MRI (Panigrahy et al., 2010b). The use 
of MRS with statistical tests and pattern recognition methods using metabolites is a 
powerful method of yielding accurate and robust results. The metabolic features of 
normal paediatric brain and common paediatric brain tumours have been reported in a 
number of studies and a summary of the current literature has been reported below. 
A number of metabolites are commonly identified in brain and brain tumour spectra. The 
mostly commonly identified and their roles are listed below. These include: 
 Total Choline (tCho), peak at ~3.2 ppm, marker of cell turnover 
 Creatine (Cr), peaks at ~3.02,3.94 ppm, marker of abnormal energy metabolism 
 N-acetylaspartate (NAA/tNAA), peak at ~2.0 ppm, presence of neurons 
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 Myo-inositol (mIns), peak at 3.6 ppm, involved in the activation and proliferation 
of glial cells 
 Glutamine (Gln), Glutamate (Glu) and Glutamate+Glutamine (Glx), peaks around 
2.0-2.6 ppm. Gln is the storage form of Glu, involved in every metabolic task of 
proliferating tumour cells and Glu is an excitatory neurotransmitter 
 Taurine (Tau), ~3.3 ppm, role as osmolyte and apoptotic marker 
 Glucose (Glc), peaks at ~ 3.43, 3.80 ppm, provides energy for all proliferating cells 
 Lactate (Lac), peak at ~1.3 ppm, marker of anaerobic metabolism and aerobic 
glycolysis 
 Citrate (Cit), ~2.6 ppm, marker of malignant progression 
 Glycine (Gly), ~ 3.6 ppm, inhibitory neurotransmitter and antioxidant 
 Scyllo-inositol (sIns), ~3.34 ppm, precursor of mIns and related to membrane 
synthesis 
 Lipids and macromolecules (LMM), peaks at ~0.9, 1.3, 2.0 ppm, marker of 
membrane degradation, apoptosis and necrosis 
 Guanidinoacetate (Gua), ~3.78 ppm, precursor of creatine 
 Alanine (Ala), ~1.48 ppm, non-essential amino acid 
Further detail on these metabolites is given in 3.5. 
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Normal paediatric brain 
Features of normal brain spectroscopy include elevated NAA, decreased tCho, decreased 
lipids at 0.9 ppm and 1.3 ppm (Davies et al., 2008). 
It should be noted that metabolites are not homogenously distributed across all 
structures of the brain. The regional variation in the concentration of metabolites within 
the brain in children has been previously studied using single voxel MRS (Pouwels et al., 
1999). 
Single voxel MRS was performed on 97 children who were either healthy or suffered from 
mental retardation, movement disorders, epilepsies, neoplasm, or vascular 
malformation. Metabolite quantitation was performed in the cortical grey and white 
matter, cerebellum, thalamus and basal ganglia in six age groups from infancy to 
adulthood and measured metabolites included NAA, Cr , tCho, mIns, Glu, Gln and Tau. 
Results show NAA is elevated in the grey matter, cerebellum and thalamus particularly 
during the first few years of life and remains constant in the white matter and basal 
ganglia. Creatine is highest in the cerebellum, followed by the basal ganglia, thalamus, 
grey matter and white matter. Choline containing compounds are highest in cerebellum 
and the lowest in the grey matter. Concentrations of mIns remain constant in most brain 
regions except for the cerebellum where the highest levels are observed. Glu and Gln are 
on the whole constant throughout the brain. However, a 50% reduction in Gln is seen in 
white matter from early childhood to adulthood. Tau is found to decrease with age in 
both the grey matter and the cerebellum, with the highest concentrations in infancy. 
Lower concentrations of Tau are seen in the white matter and thalamus and again 
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decrease with age whereas concentrations remain constant in the basal ganglia (Pouwels 
et al., 1999). 
Pilocytic Astrocytoma (PA)  
Spectroscopy studies include comparisons of PA with normal brain, ependymoma (EP), 
medulloblastoma (MB), and all other childhood brain tumours (All Other), respectively. A 
comparative study has also been performed between childhood and adult PA.  
PA versus uninvolved brain 
A study by Davies et al. (2008) compared 12 PA spectra with four control spectra acquired 
from four patients, in remission, for posterior fossa tumours where SVS was performed 
on non-involved brain. Qualitative analysis of the PA mean spectra showed very low Cr at 
3.0 ppm with a high tCho/Cr and moderate levels of lipids and Lac. In addition, a 
discernible tNAA peak was seen (Davies et al., 2008). 
PAs vs. All other tumours 
Panigrahy et al. (2006) compared PA from all locations in the brain with all other brain 
tumours (All Other). No difference between PA located supratentorially (n=6) and 
infratentorially (n=11) was seen, resulting in a pooled analysis forming a single group. The 
analysis revealed the most significant differentiators between PA and All Other, were low 
mean levels of Cr, mIns, Tau and tCho. Evaluation of concentration ratios demonstrated 
low Cr/tCho was the most significant differentiator of PAs from All Other. Mean levels of 
Glutamate+Glutamine (Glx)/Cr, NAA/Cr, NAA/tCho and Gln/tCho in PA were significantly 
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higher than in All Other. The ratios of mIns/tCho, Tau/tCho and Tau/ Cr were significantly 
lower in PA (Panigrahy et al., 2006). 
PA vs. EP and MB 
Davies et al. (2008) compared PA, EP and MB. Myo-inositol was shown to be the only 
significantly different metabolite between the three tumours when performing three 
pair-wise comparisons, with highest mean values in EP and lowest in PA. Significantly 
lower Cr and higher NAA were found in PA when compared to MB and EP. Tau, 
phosphocholine (PCh) and Glu were significantly lower and Gln significantly higher in PA 
when compared to MB. Lipids+macromolecule (MMs) peaks at 1.3 and 2.0 ppm were 
significantly lower in PA compared to MB (Davies et al., 2008). 
PA in adults vs. PA in children 
While PA is relatively common in children (25%), their incidence in adults is very rare 
(2%). Although classified as WHO grade I in both, their clinical course varies (Porto et al., 
2010b) with adult PA exhibiting a more aggressive nature (Johnson et al., 2012). It is 
unclear why this difference is seen but is speculated to be due to differences in tumour 
biology, for example paediatric low grade gliomas do not possess the same molecular 
abnormalities as those in adults. Tumour suppressor gene P53 is found to be frequently 
mutated in adult tumours but is rare in paediatric patients (Sievert and Fisher, 2009). 
A study by Porto et al. (2010) investigated the differences in MRS between PAs in adults 
(n=5) and children (n=11). The analysis demonstrated a trend towards higher mean tCho 
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in adults and higher mean Cr in paediatric PAs, although not significant. It should be 
noted the study consisted of a very small cohort of patients (Porto et al., 2010b). 
PA in different locations of the brain 
A study by Harris et al. (2008) compared MRS of PA on the basis of location. The presence 
of a peak at 3.65 ppm due to mIns and Gly was the most prominent difference when 
qualitatively comparing the mean spectra from nine infratentorial and 12 supratentorial 
PA. Long TE spectra acquired from three supratentorial PA suggested the contributions 
from glycine were small; attributing the difference due to mIns. A more pronounced 
broad peak of Glx (around 2.0-2.5 ppm) and lipids+MMs were also seen in the 
supratentorial cases. Significantly higher mIns and Glx was observed in supratentorial 
PAs. A trend towards lower Cr was seen in cerebellar PAs. Orphanidou-Vlachou et al. 
(2013) found significantly higher Cr , sIns , Tau and mIns in supratentorial PAs with optic 
pathway gliomas when compared with infratentorial PAs (Orphanidou-Vlachou et al., 
2013). Harris et al. (2008) confirmed the difference in mIns was not due to regional 
differences in uninvolved brain (Harris et al., 2008). 
Medulloblastoma (MB) 
Studies have used MRS to identify and characterise MB, compared with normal brain, 
other childhood brain tumours and common cerebellar tumours. 
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MB versus uninvolved brain 
Qualitative analysis of MB mean spectra (n=18) compared to four control spectra 
revealed high tCho, very low NAA and a small Tau peak. A large variability is seen in the 
lipids+MMs and Lac region (Davies et al., 2008). 
PNET vs. All other tumours 
Kovanlikaya et al. (2005) investigated whether the quantitation of Tau could improve the 
differentiation of PNET from other common brain tumours in paediatric patients. From a 
cohort of 29 patients, 13 of which were PNET, elevated Tau was found to be most 
significant discriminator between PNET and All Other with the exception of a patient with 
a GER. Significantly elevated levels of tCho were also seen in PNET. Evaluation of 
metabolite ratios demonstrated significantly elevated Tau/tCho and Tau/Cr and 
significantly reduced NAA/tCho in PNET compared to All Other (Kovanlikaya et al., 2005). 
Panigrahy et al. (2006) also found Tau to be the most prominent signal in MB spectra. 
Mean tCho, Ala and Gua were found to be significantly elevated in MB compared to All 
Other. Significantly decreased NAA/tCho , Gln/tCho , Glx/tCho and Gln/Cr were also seen 
in MB compared to All Other (Panigrahy et al., 2006). 
MB vs. PA and EP 
A significantly narrower choline peak width was seen at 3.2 ppm in MB when compared 
with both PA and EP. Tau, PCh and Glu were significantly higher, while Gln was 
significantly lower in MB. Lipids+MMs peaks were in general higher in MB when 
compared to PA and EP. However, this was only significant for the components at 1.3 and 
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2.0 ppm, when compared with PA, and the component at 0.9 ppm, when compared to EP 
(Davies et al., 2008). 
Ependymoma (EP) 
MRS of ependymomas in children has been investigated in a number of studies including 
comparisons with uninvolved brain and other tumour types.  
EP versus uninvolved brain 
EP demonstrates a prominent mIns peak and low levels of NAA. Lac and lipids+MMs were 
found to vary considerably (Davies et al., 2008). 
EP vs. All Other 
Panigrahy et al. (2006) found a large range of mIns concentrations when comparing EP 
and anaplastic ependymomas (A-EP) providing evidence for the spectral heterogeneity 
between tumours (Panigrahy et al., 2006). Davies et al. (2008) also found a high variability 
of mIns shown by the reported standard deviation (Davies et al., 2008).  
Despite the differences seen by Panigrahy et al. (2006) EP spectra were pooled due to 
small numbers. Reduced mean NAA was the most significant differentiator between 
EP+A-EP and All Other. Evaluation of concentration ratios demonstrated significantly 
reduced NAA/Cr and NAA/tCho (Panigrahy et al., 2006). Davies et al. (2008) found mIns to 
be significantly higher in EP compared to all tumours and EP with a significantly lower 
LMM0.9 when compared to MB (Davies et al., 2008). 
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Low grade gliomas (LGG) 
A large study of low grade gliomas (n=69) demonstrated significant subtle differences 
between closely related subtypes. Comparison of glial with glioneuronal tumours showed 
significantly increased Cr and significantly decreased LMM0.9 and LMM1.3 in 
glioneuronal tumours. Significantly higher Cr, NAA and mIns and significantly lower Lac 
were seen in DA when compared with PAs+optic pathway gliomas (Orphanidou-Vlachou 
et al., 2013). 
More rare tumour types 
Pilomyxoid Astroyctomas 
Pilomyxoid astrocytomas (PmA), a more aggressive variant of PA is currently 
indistinguishable from PA on conventional imaging. A study by Cirak et al. (2005) 
compared two PmA with two PAs using magnetic resonance spectroscopic imaging 
(MRSI). Total choline was higher in PA compared to the PmA, an unexpected finding in a 
less malignant tumour however, the cohort was too small to draw firm conclusions (Cirak 
et al., 2005). 
Anaplastic astrocytoma (AA)  
Very few studies have reported MRS of anaplastic astrocytomas due to their rarity. 
Panigrahy et al. (2006) comparison of AA with low grade astrocytomas found highly 
variable concentrations of tCho. Significantly lower mean Gua, LMM0.9 and LMM1.3 
were seen in AA plus low grade astrocytomas when compared with All Others. 
Significantly reduced Glu/Cr and Gua/Cr were also observed (Panigrahy et al., 2006). 
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Citrate (Cit) was found to be a prominent feature of some AA (Blüml et al., 2011, Seymour 
et al., 2008). 
Glioblastoma Multiforme (GBM) 
GBM is a relatively uncommon tumour in children and is often difficult to differentiate on 
conventional imaging. Chang et al. (2003) performed a multimodal MR study on 11 
patients with GBM, of which three had SVS. Analysis of spectra by determining area 
under peak demonstrated a reduction in the amplitude of NAA and elevation of tCho. A 
low NAA/Cho ratio was found to be a valuable aid for precise targeting of stereotactic 
biopsies. However, these findings were only observational (Chang et al., 2003). 
Choroid Plexus tumours  
Although choroid plexus tumours are relatively rare, case studies have looked at 
metabolic features of these tumours in order to differentiate the diagnosis of choroid 
plexus papilloma (CPP) and choroid plexus carcinoma (CPC). Choroid plexus tumours have 
also been compared to other brain tumours. Results should be interpreted with caution, 
as these studies consist of small cohort numbers. 
Choroid plexus tumours vs. All Other 
Choroid plexus tumours demonstrate spectra with low levels of metabolite information. 
The main peaks observed in both tumours are tCho and mIns. 
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Choroid plexus papilloma (CPP) vs. All Other 
Myo-inositol was the most prominent feature of CPP on qualitative analysis with 
significantly elevated concentrations. CPP also demonstrated reduced mean tCho, Cr, Gln, 
LMM0.9 and LMM1.3 when compared with All Other.  
Choroid plexus carcinoma (CPC) vs. All Other  
Significantly reduced mean NAA, Glx, Cr and no sIns was seen in CPC compared to All 
Other. Mean tCho was high when compared with All Other, but did not reach 
significance. Reduced NAA/tCho was the most significant discriminators of CPC from All 
Other. Other significant ratios included reduced Cr/tCho, NAA/Cr, mIns/tCho, Glu/tCho 
and Glx/tCho (Panigrahy et al., 2006). 
CPP vs. CPC 
The most striking feature seen on qualitative analysis comparing the two tumours was 
the presence of a prominent mIns peak in the three patients with CPP, not seen in CPC 
(Panigrahy et al., 2006).  
Horska et al. (2001) included spectroscopy results from only two patients, one patient 
with CPP and the other with CPC. Both cases had low NAA but CPC possessed higher 
levels of tCho than the CPP in keeping with its more malignant course (Horská et al., 
2001). 
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Germ cell tumours 
For germ cell tumours located in deep midline structures in the brain, commonly the 
pineal gland, a non-invasive diagnosis would be advantageous. The location makes it 
difficult to biopsy and more than 90% are curable without surgery.   
Pineal Germinoma vs. All Other 
Increased LMM1.3, prominent tCho and Tau were seen on qualitative analysis of a typical 
GER spectrum. GER showed significantly reduced mean tCho and mIns compared to All 
Other. Significantly elevated Glx/tCho and Glu/tCho and significantly reduced mIns/Cr 
and NAA/Cr were also observed (Panigrahy et al., 2006). 
Harris et al. (2011) reported spectroscopy of germ cell tumours to be dominated by 
lipids+MMs and as a result making is difficult to distinguish other metabolite peaks. 
However, a small peak around 3.35 ppm attributed to Tau was seen (Harris et al., 2011). 
2.3.2  Prognosis 
Most spectroscopy studies that have searched for markers of prognosis have done so 
from a heterogeneous cohort of brain tumours with a particular focus on biomarkers for 
high and low grade tumours. Few studies have used spectroscopy to identify subtype 
specific markers. 
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Low vs. High grade 
Lipids and tCho 
Analysis of MRSI acquired from 23 high grade (III+IV) compared with 43 low grade (I+II) 
tumours, both of which were determined by histopathology, found tCho and 
lipids+lactate (L) to be significantly elevated in the high grade tumours.  
For each case, metabolite signals in the tumour were normalised to the mean of the Cr 
signal in non-involved brain and intermediate echo time of 65 ms used to minimise the 
contribution of the Lac signal. A linear combination of tCho and 0.49 L was proposed as 
the best discriminator with a 91% accuracy for classifying tumour grade. Logistical 
regression revealed that both biomarkers to be significant independent predictors of 
tumour grade  (Astrakas et al., 2004).  
Glycine (Gly) 
Glycine has been identified in a number of in vitro studies to increase with WHO grade 
(Lehnhardt et al., 2005, Carapella et al., 1997). The metabolite is often overlooked due to 
its strong overlap with the multiplet peak of mIns but at long TE MRS Gly is more readily 
identifiable. 
 A study by Davies et al. (2009) identified Gly as a feature in paediatric brain tumours. The 
comparison 18 high grade (III or IV) with 17 low grade (I or II) paediatric brain tumours 
classified using the WHO criteria revealed high grade tumours possessed significantly 
increased levels of normalised Gly while no difference was seen between normalised 
mIns based on grading (Davies et al., 2009). 
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Whilst grade is strongly associated with prognosis, tumours with the same grade can 
behave very differently (Taylor et al., 2012) and studies of event free survival and overall 
survival are required to establish the accuracy of recognized prognostic biomarkers. 
2.3.3 Survival 
A study by Marcus et al. (2007) extended Astrakas’ (2004) study to investigate whether 
the biomarkers of grade were also associated with survival in children with CNS tumours. 
MRSI was performed on a cohort of 76 children on a heterogeneous cohort of tumours 
including all WHO grades. Univariate analysis showed that tCho, L, tCho/NAA and tumour 
grade were significantly different between survivors (n=58) and non-survivors (n=18). 
Receiver operating characteristics (ROC) curve analysis found tCho (AUC=0.725) and L 
(AUC=0.687) to be good discriminators between the two cohorts. The combined index 
tCho + 0.1L were a more accurate and more specific predictor than tCho or tCho/NAA.  
Total Choline + 0.1L was the only independent predictor of survival (Marcus et al., 2007) . 
A study by Wilson et al. (2013) found increased lipids at 1.3 ppm and sIns predicted poor 
survival and increased Gln and NAA predicted improved survival in a cohort of 115 pre-
treatment paediatric brain tumours (Wilson et al., 2013). 
2.3.4 Progression 
MRSI performed on 27 children, during treatment for a neuroglial brain tumour, showed 
the percentage change in tCho was significantly greater in patients who had progressive 
examinations compared to stable disease. Total choline/NAA was determined to be the 
most important prognostic indicator of tumour progression with significantly higher 
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levels in patients with progressive outcomes. Probability of tumour progression was 55 
times greater for patients with a 20% change in tCho/NAA (Tzika et al., 2004). 
Another study evaluated MRSI on 27 recurrent brain tumours and found maximum 
tumour tCho/NAA ratio to be predictive of outcome in children with recurrent brain 
tumours (Warren et al., 2000). 
Citrate (Cit)  
A retrospective analysis by Seymour et al. (2008) of MRS from 85 paediatric brain tumour 
patients with 615 spectra from 469 subjects showed spectra from DIPG, an EP and an AA 
with a signal at 2.6 ppm consistent with citrate. Diffuse brain stem gliomas had the 
highest mean concentration of Cit compared to all tumours. Significantly lower levels of 
Cit were detected in MB and PA compared to diffuse brain stem gliomas (Seymour et al., 
2008). 
Bluml et al. (2011) analysis demonstrated grade II astrocytomas with disease progression 
in <2 years following diagnosis to have significantly higher levels of mean Cit compared to 
grade II astrocytomas that exhibited stable disease for >2 years. Significantly higher Cit/Cr 
and reduced NAA was seen in grade II astrocytomas with disease progression. However, 
Cit was only identified in a subgroup of paediatric grade II astrocytomas destined for 
aggressive behaviour, detecting a possible subgroup of tumours with a metabolically 
different course (Blüml et al., 2011). 
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Tumour type specific markers 
Metastatic PA vs. non-metastatic infratentorial PA 
Orphanidou-Vlachou et al. (2013) found trends towards higher tCho and Glx in metastatic 
PA at presentation (n=2) when compared with infratentorial PA (n=19) (Orphanidou-
Vlachou et al., 2013). 
Metastatic and non-metastatic MB 
Peet et al. (2007) comparison of MRS of MB patients with localised (n=8) and metastatic 
disease (n=8) found those that presented with metastatic disease had increased tCho, 
decreased lipids and Lac. Total choline was found to be correlated positively with 
histopathological indicator of tumour cell proliferation, Ki67 index. These findings imply 
that tumours that have metastasised at diagnosis have a different biology to localised 
tumours, growing more rapidly and metastasising earlier (Peet et al., 2007a). 
Diffuse pontine gliomas (DIPG) 
Steffen Smith et al. (2011) evaluated changes in both SVS and MRSI of 38 DIPGs at first 
MRS and follow-up. Total choline/NAA was found to be the only variable predictive of 
patient survival on first MRS. Patients with higher SVS tCho/NAA values at their first scan 
were at greater risk of mortality. No predictive variables were seen with MRSI (Steffen-
Smith et al., 2011). 
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Yamasaki et al. (2011) found the presence of Lac and a high tCho/NAA in DIPGs to be 
correlated with shorter overall survival. Citrate was speculated to be associated with a 
good prognosis in this cohort (Yamasaki et al., 2011). 
2.3.5 Treatment monitoring 
Tumour monitoring at present involves performing serial MRI scans to provide 
measurements of the size of the tumour. Scans are mostly performed at three-monthly 
intervals whilst on treatment and so significant delays in the detection of ineffective 
treatment are incurred. A number of studies have used MRS both SVS and/or MRSI at 
follow-up. The development of new non-invasive methods, which can provide surrogate 
biomarkers of early treatment response or failure, would be a major advance in the 
clinical management of brain tumours. 
A comparison of pre-treatment MRS and first on treatment MRS in children with PA 
identified significant decreases in mIns in patients with tumour progression. The median 
time between the two MRS studies was 2.1 months compared with a median time to 
progression using conventional criteria of 12.2 months. This indicates MRS can identify 
early biomarkers of progression during treatment monitoring (Harris et al., 2008). 
A comparison of Cit levels at baseline and follow-up in DIPG found levels had significantly 
decreased at baseline to final MRS (Seymour et al., 2008). Another study found DIPG 
patients with an increased tCho/NAA at follow-up were at greater risk of death compared 
to patients with stable or decreased levels. Increases in the variance of MRSI tCho/NAA 
was associated with decreased patient survival (Steffen-Smith et al., 2011). 
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These studies demonstrate that changes in metabolite profiles of tumours occur over 
time and could aid in treatment monitoring. In keeping with most studies investigating 
imaging in cancer, MRS was performed to coincide with conventional imaging, however, 
it may be that MRS can provide earlier biomarkers of treatment response but these 
would need testing in a study specifically designed to investigate this hypothesis (Arthurs 
and Gallagher, 2011). 
2.3.6 Surveillance scans and the detection of recurrent disease 
MRI monitoring of children with brain tumours following treatment is routine. One of the 
challenges that radiologists face are diagnosing the changes seen in the brain following 
radiation treatment and the presentation of new contrast enhancing lesions. 
Differentiating tumour recurrence and post radiation change is difficult and a number of 
studies have investigated whether MRS can be used to overcome this. 
A study by Weybright et al. (2005) used 2D MRSI to evaluate new areas of contrast 
enhancement in patients with brain tumours that had been previously treated with 
conventional fractionated radiation therapy (Weybright et al., 2005). It should be noted 
that the study included both adults and children. 26 patients (age range 5-54 years) with 
a range of tumour diagnoses including 24 gliomas (grade I to IV) and a PNET, a MB, an EP 
and one case of acute promyelotic leukaemia were included in the study. The 
confirmation of tumour recurrence was seen in 16 patients and radiation changes in 12 
patients based on follow-up imaging or histopathology results. MRS was performed on 
both the contrast enhancing lesion and normal appearing white matter and peak areas of 
metabolites in the same voxel were used to calculate metabolite ratios. Significantly 
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higher tCho/Cr was seen in those patients with recurrence or residual tumour compared 
to those with radiation injury. Those in the radiation injury group had significantly higher 
tCho/Cr ratios than normal appearing white matter. The lesions in the tumour group also 
had significantly higher tCho/NAA ratios than those in the radiation injury group and 
significantly higher tCho/NAA ratios than normal appearing white matter. NAA/Cr ratios 
were significantly lower in the lesion group compared to those in the radiation injury 
group. Analysis has shown that none of the lesions classified as radiation injury had 
tCho/Cr or tCho/NAA ratios above 1.8. Using tCho/Cr or tCho/NAA ratios with values 
above 1.8 as tumour recurrence enabled 27 out of 28 patients to be correctly classified 
with either recurrent tumour or radiation injury assuming radiation injury was diagnosed 
accurately (Weybright et al., 2005). 
Smith et al. (2009) compared the spectroscopy of patients deemed to have tumour 
recurrence compared with radiation injury. Patients with tumour recurrence had 
significantly higher mean values of tCho/Cr and tCho/NAA) than those with radiation 
changes but lower mean values of NAA/Cr. Total choline/NAA was found to be predictive 
of tumour recurrence determined by using logistic regression and ROC curve analysis. 
Every unit increase in tCho/NAA was found to increase the odds of tumour recurrence by 
13-fold (Smith et al., 2009). 
It is to be noted that these studies have been performed on a cohort of both adults and 
children with a heterogeneous group of tumour types. Metabolite values are known to 
vary greatly between tumour types and this may need to be taken into account. Less than 
half of these patients have had a biopsy confirmed diagnosis of recurrence or radiation 
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injury so classification is dependent on clinical and imaging grounds only. However, these 
studies haves shown the potential for MRS to be an effective tool in discriminating 
between tumour recurrence and radiation change. 
2.4 Summary  
Children’s tumours are known to be more heterogeneous, less aggressive and more 
responsive to treatment than those that present in adults. Their classification is 
performed either on histopathology or clinical and imaging grounds alone. The value of 
MRS in brain tumours has led to expansion of research in the field. The current published 
spectroscopy literature for paediatric brain tumours has been comprehensively reviewed. 
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CHAPTER 3 
3 MAGNETIC RESONANCE SPECTROSCOPY 
3.1 Theory 
This chapter outlines a brief overview of the theory behind magnetic resonance 
spectroscopy. More detailed information is available in a number of well-known MR 
textbooks (de Graaf, 2007b, Mukherji, 1998, Levit, 2001). 
Proton magnetic resonance spectroscopy is a non-invasive, in vivo method that measures 
the biochemical information within a region of interest (ROI) termed voxel, thus providing 
information on cellular metabolism. Spectroscopy uses the signal from protons (1H) 
within chemicals observed in the ROI to produce a spectrum (Panigrahy et al., 2010b). 
The localisation of the signal can be performed using two approaches as either single 
voxel (SVS) or multi-voxel technique, MRSI. The theory for single voxel spectroscopy will 
be exclusively explored for this thesis. 
 
Figure 3.1 1H MR spectrum acquired from a single volume of interest in the brain. Voxel positions 
included to specify location from where spectrum was obtained. Abbreviations: Ins, myo-inositol; Cho, 
total choline; Cr, creatine; Cr2, 2nd Creatine peak ; NAA, N-acetylaspartate; Lac, lactate; ppm, parts 
per million. 
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Following conventional MRI, a voxel is placed on a ROI that covers a volume that pre-
defines where the spectra are acquired from (example given in Figure 3.1 specific to a ROI 
in a brain tumour). The resulting spectrum consists of two axes. The x-axis, known as the 
chemical shift axis, is the measure of the signal or metabolite position in the spectrum 
relative to a fixed reference. The chemical shift axis can be reported in either Hz or ppm. 
Hz determines the frequency at which the protons precess and this differs at different 
field strengths making it difficult to compare spectral profiles. To overcome this, 
metabolite peak positions are reported in ppm, a scale independent of field strength. To 
express chemical shift in ppm the following calculation is applied, where δ is chemical 
shift (ppm), ν and νref are the resonant frequencies of the compound under investigation 
and the reference compound respectively, measured in Hz (Figure 3.2) (de Graaf, 2007a) 
 
Figure 3.2  An equation representing the definition of chemical shift, where δ is chemical shift, ν is the 
resonant frequency of the compound being investigated, νref is the resonant frequency of the 
reference compound multiplied by 106 (de Graaf, 2007a). 
Most in vivo MR spectra range from 0.5 to 9.0 ppm but the lack of metabolite information 
observed downfield of 4.7 ppm results in this being rarely shown. Instead spectra extend 
from 0.5 ppm to around 4.5 ppm as shown on the MR scanner output in Figure 3.1. 
The y-axis measures the signal intensity which is proportional to the apparent 
concentration of the chemical seen in the ROI (Figure 3.1) (Panigrahy et al., 2010b).  
The positioning of each peak in the spectrum is a result of chemical shift. The nucleus of 
an atom consists of both protons and neutrons, surrounded by orbiting electrons. When 
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the atom is placed in an externally applied magnetic field (B0), protons precess and 
induce their own local magnetic field known as the effective magnetic field (Beff). The 
density of electrons surrounding each nucleus can vary and as a result the B0 plus Beff can 
differ at each nucleus which results in the phenomenon known as chemical shift (Kwock, 
1998). Chemicals usually have more than one proton and each proton gives an MR 
detectable signal. Protons within the same chemical environment experience the same 
magnetic field resulting in identical chemical shifts. This results in a spectrum consisting 
of a collection of peaks at different radiofrequencies representing proton nuclei in 
different chemical environments.  
Nuclei in close proximity to one another influence each other’s Beff. Nuclei experiencing 
the same chemical shift are termed equivalent and those experiencing different chemical 
shifts, nonequivalent. Equivalent nuclei produce no observable peak splitting. However, if 
there is more than one proton in a molecule and these protons are nonequivalent, then a 
coupling between these occurs, called spin-spin coupling or J coupling (de Graaf, 2007a) 
causing resonance peaks to split. Instead of one signal as would be seen for the 
equivalent nuclei, signals at two or more resonant frequencies are observed (Klose, 
2008).  
3.2 Spectroscopy acquisition 
3.2.1 Select region of interest  
It is important to ensure that the voxel is placed fully over the ROI to obtain a good 
quality spectrum that is representative of the pathology being assessed. To assess 
accurate voxel positioning the ROI is placed using imaging from planes of all three axes 
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(Figure 3.1). Voxel placement should be away from bone, scalp and air interfaces and 
should not be dominated by normal brain.  
3.2.2 PRESS 
A number of single volume localisation sequences can be used for acquisition of MRS 
data. The acquisition method use for the studies in this thesis was Point-RESolved 
Spectroscopy (PRESS) (Bottomley, 1987). The PRESS acquisition is based on a spin echo 
sequence with a 90° radiofrequency pulse (RF) followed by two 180° RF pulses so that the 
primary spin echo is refocused again by the third pulse. As demonstrated in the Figure 3.3 
from the paper by Klose (2008) the volume is excited in a stepwise method with each 
pulse having a slice selective gradient on one of the three principal axes (x,y,z). The initial 
90° radiofrequency pulse is applied in the z-axis depicted in Figure 3.3a followed by the 
first 180° pulse in the y-axis in Figure 3.3b and final 180° pulse in x-axis depicted in Figure 
3.3c. The order of the gradients used is given as an example and can be altered (Klose, 
2008). The aim of slice selective gradient is to ensure that only the protons located in the 
ROI experience the three RF pulses. It should be noted that contributions to the signal 
from the border of the ROI can still occur. This is overcome by the use of spoiler gradients 
also depicted in Figure 3.3. 
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Figure 3.3 Volume selection using the PRESS sequence with three simultaneously applied 
radiofrequency pulses. a) The first 90°radiofrequency pulse is applied in the z axis 
followed by b) 180° radiofrequency pulse in the y and finally an c) 180° radiofrequency 
pulse in the x. The three radiofrequency pulses within the sequence are marked and the 
selected regions after each pulse are shown for a cubic object. Redrawn from Klose 
(Klose, 2008). Abbreviations: rf, radiofrequency pulse; Gz, field gradient along z axis; Gy, field 
gradient along y axis; Gx , field gradient along x axis; ms, milliseconds. 
3.2.3 Shimming 
The purpose of shimming is to produce a homogenous magnetic field over the ROI. This 
ensures equivalent nuclei experience the same magnetic field. A good shim results in 
good peak resolution and high SNR. Whereas, a poor shim results in broad metabolite 
peaks or spectral linewidth. An approximation of this can be determined by measuring 
the full-width-half-maximum (FWHM) of the peak. The greater the value the more 
52 
 
difficult it is to distinguish nearby peaks for example overlapping Cr and tCho peaks. The 
FWHM of the water peak is a good determinant of field homogeneity (Kwock, 1998). 
3.2.4 Water suppression 
 
Figure 3.4 The Gaussian chemical shift selective (CHESS) pulse sequence  
The water signal (4.7 ppm) is 10,000-fold greater than the metabolite signals seen in the 
spectrum. This results in an over dominance of the water and limited metabolite 
information (Castillo et al., 1996) which can be overcome by employing water 
suppression. The two most commonly used methods are chemical shift selective (CHESS) 
and the water elimination Fourier transform technique (WEFT) although CHESS is more 
frequently used. CHESS consists of a 90° frequency selective pulse centred over the 
proton water resonance frequency (Figure 3.4) whereas WEFT consists of a 180° pulse. 
The pulses in both methods are applied before the implementation of the PRESS 
sequence (Kwock, 1998). 
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3.2.5 Acquiring a water spectrum 
Following data acquisition from the lesion, an additional water spectrum (unsuppressed 
water spectrum) is obtained from the same volume. This is used as an internal reference 
signal for quantitation of metabolite signal intensities (Graaf, 2010). A number of studies 
have reported differences in water content in different pathologies. Brain tumours, for 
example exhibit an increased water content compared to healthy tissues (Jansen et al., 
2006). This analysis does not account for differences in water content in the ROI, instead  
the water unsuppressed spectrum is referenced assuming the water concentration of 
white matter (35.88 mol/L) (Baker et al., 2008). While it is known the water concentration 
varies for grey and white matter, it is often assumed this difference is small. There are 
few studies that investigate pathology specific changes. A more in- depth discussion 
regarding the assumptions made are described by Ernst et al. and Gasprovic et al. (Ernst 
et al., 1993, Gasparovic et al., 2006). 
3.3 Pre-processing 
The acquired signal is obtained in the form of a free induction decay or FID. The time 
dependence of the signal intensity is called the FID (de Graaf, 2007a). Analysis of data is 
divided into two main stages, pre-processing and quantitation both of which can be 
performed in either the time domain or frequency domain (Mandal, 2012). The time 
domain is the raw data domain, so the same as the measured signal (FID), whereas the 
frequency domain is that of the processed signal so once the FID has been Fourier 
transformed to obtain a spectrum of peaks (Poullet et al., 2008). Several software 
packages are available for analysis of spectroscopy data including LCModel (Provencher, 
2001), QUEST (Mansson et al., 2006) and TARQUIN (Wilson et al., 2011). The analysis of 
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raw data in this thesis was performed using TARQUIN software (Wilson et al., 2011) thus, 
the pre-processing and quantitation methods described below are specific for the 
analysis of data with TARQUIN. 
The pre-processing steps the data undergoes are as follows: 
3.3.1 Water removal by Hankel Singular Value Decomposition (HSVD) 
As previously discussed the signal of the water peak is significantly larger than that of the 
metabolites. Using HSVD model (Barkhuijsen et al., 1987), the water signal is constructed 
and subtracted from the FID to remove the residual water peak thus leaving only 
metabolite information for analysis. 
3.3.2 Zero and first order phase correction  
Phase correction is applied to avoid inverted or out-of-phase peaks. These are corrected 
using zero and first order correction. The initial estimate for phase correction is 
performed by comparing the phase of the data to the magnitude spectra. This enables 
easier inspection of the spectral peaks and enables the quality of the spectroscopy to be 
assessed reliably (Wilson et al., 2011). 
3.3.3 Automatic referencing  
Although the resonance of the water signal is known, minor frequency shifts due to small 
inhomogeneities in the applied magnetic field can occur and determining this accurately 
is essential for the fitting of peaks. To overcome this, cross correlation between the 
absolute value of acquired spectrum and reference spectrum is determined. The 
reference spectra used in this analysis included peaks at 2.01, 3.22 and 3.03 assigned to 
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NAA, tCho and Cr respectively expected in brain spectra and extended to lipid peaks at 
1.28 and 0.9 ppm for brain tumour data (Wilson et al., 2011). 
3.3.4  Basis set simulation  
The metabolite basis set used in the analysis is simulated from previously reported 
chemical shift and J-coupling values (Govindaraju et al., 2000). Lipids and MMs are added 
to basis set using particular parameters – taken from LCModel (Provencher, 2001) (ppm, 
FWHM in ppm and amplitude (au)). 
3.3.5 Signal model 
Signal modelling in TARQUIN uses the approach of modelling the experimental data as a 
linear combination of modified simulated basis signals. 
3.3.6 Fitting with constraints 
The first points of the FID typically contain distortions and broad signals with the last 
points containing a high contribution of noise (de Graaf, 2007a). Both can be difficult to 
model and as a result are removed. Removing the elements that cause baseline 
interferences, eliminates the need for baseline correction (Wilson et al., 2011). 
3.4 Peak fitting and quantitation 
The quantitation of metabolites using TARQUIN is also performed in the time domain. 
Short TE spectra can often be complex with overlapping peaks that can be difficult to 
determine separately and as a consequence challenging to accurately quantitate. To 
overcome this, the whole spectrum is fit to a set of individual metabolite spectra acquired 
by simulation. Fitting can be applied automatically resulting in a list of quantifiable 
metabolites and their relative concentrations. The combination of metabolite fitting and 
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use of the water signal as a concentration reference is proving to be a powerful technique 
for the automated processing of SVS data and allows a set of metabolite concentrations 
to be expressed in standard units of millimolar (mM). The spectrum is then Fourier 
transformed for visualisation. 
3.5  Interpretation of the metabolites measured using 1H MRS 
In vivo spectroscopy contains three different components; water, metabolites (<2000Da 
and concentration >1mM) and lipids and macromolecules (Hajek and Dezortova, 2008). 
The resulting spectrum acquired from a human brain consists of approximately 18-20 
metabolites and nine lipid and macromolecular components. It should be noted that the 
metabolite profiles alter in different pathologies including differences between normal 
brain and brain pathology and between different pathologies themselves often resulting 
in the presence and absence of different metabolites (Figure 3.5) (Panigrahy et al., 
2010b). The main metabolites observed in brain spectra and their roles in the brain 
and/or brain pathology are given in detail below. 
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Figure 3.5 Comparison of MRS acquired from a) normal brain and b) brain tumour (MB) at short echo 
time. Abbreviations: MB, medulloblastoma; mIns, myo-inositol; Tau, taurine; tCho, total choline; Cr, 
creatine; Glx, Glutamate+Glutamine; NAA, N-acetylaspartate; Lac, lactate; LMM0.9, lipids at 0.9 ppm; 
LMM1.3, lipids at 1.3 ppm. 
N-acetyl aspartate (NAA) 
NAA, seen around 2.0 ppm is the one of the most abundant metabolites present in 
normal brain. It is known marker of neuronal and axonal integrity and the most reliable 
biomarker of pathological disease in the brain with decreased levels found in all brain 
related disease spectra including brain tumours (Gujar et al., 2005). 
N-acetylaspartylglutamate (NAAG) found on the shoulder of the NAA peak, around 2.04 
ppm is very closely linked with NAA. Reductions in NAA levels correspond to reductions in 
NAAG or an underestimation of NAA levels with NAAG levels remaining unvaried (Moffett 
et al., 2007). 
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Creatine (Cr)                               
Cr is made of at least two compounds , creatine and phosphocreatine with peaks at 3.02 
ppm and 3.94 ppm respectively (Rosen and Lenkinski, 2007). The main role of Cr is in 
energy storage and transmission where Cr through phosphocreatine provides phosphate 
for ATP. In early studies, Cr has often been taken as a reference metabolite as its levels 
remain relatively stable in normal brain and were thought to be relatively unchanged in 
diseases states. However, Cr is now known to vary in pathology therefore it should be 
interpreted with caution when used in metabolite ratios (Nasrallah et al., 2010, Vigneron 
et al., 2001). 
Glutamate (Glu), glutamine (Gln) and Glutamate+Glutamine (Glx)  
Glu and Gln, often reported as a sum, Glx, are a broad group of resonances found 
between 2.0-2.6 ppm. The complex spectral overlap between the two metabolites makes 
it difficult to separate the two signals below 3 T and consequently, resulting in them 
being measured as one entity. 
Glu has many roles including as an excitatory neurotransmitter. Gln is an amino acid 
precursor and a storage form of glutamate (Panigrahy et al., 2010a). They have been 
found to be indicators of altered brain tumour metabolism in adults (Howe and Opstad, 
2003). 
Myo-inositol (mIns) 
Myo-inositol is a simple sugar that resonates at 3.6 ppm. The metabolite is an osmolyte 
and astrocyte marker, however its functions are not well understood (Panigrahy et al., 
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2010a, Castillo et al., 2000). Myo-inositol is known to be involved in cell membrane and 
myelin sheet structures and increased membrane turnover or damage to myelin sheets 
can result in increased levels. It is also associated with an activation of glial cells. For glial 
tumours, the increased mIns may reflect the cellular density of reactive astrocytes but is 
also increased in membrane turnover of highly proliferating tumour cells  (Hattingen et 
al., 2008b). Brain tumours exhibit varying concentrations of mIns speculated to be 
because of altered membrane metabolism (Harris et al., 2008, Panigrahy et al., 2006, 
Callot et al., 2008, Panigrahy et al., 2010a). 
Total choline (tCho)  
Choline is a complex peak assigned around 3.2 ppm that consists of major contributions 
from three components; free choline, glycerophosphocholine and phosphocholine. The 
peak is often referred to as total choline (tCho) due to the difficulty in separating the 
contributions of individual metabolites. Choline is involved in membrane synthesis and 
breakdown with increasing levels associated with cell proliferation. There is increasing 
evidence of elevated choline levels, when compared to normal brain, being 
representative of malignancy (Peet et al., 2007b, Marcus et al., 2007, Astrakas et al., 
2004, Ronen et al., 2001, Smith et al., 2009, Spampinato et al., 2007).  
Glucose (Glc) 
Glc has a complex spectral pattern with two in vivo peaks assigned at 3.43 ppm and 3.80 
ppm. However, the close overlap with other metabolites often makes it difficult to 
determine the contribution of Glc. Glc provides energy for all proliferating cells and is 
expected to decline in malignant cells (Panigrahy et al., 2006).  
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Lactate (Lac)  
Lac forms a doublet peak at 1.3 ppm. The metabolite is a marker of anaerobic 
metabolism and aerobic glycolysis. The various possible origins makes the interpretation 
of Lac levels difficult. It is present in very low concentrations in normal brain and elevated 
concentrations in brain pathologies (Panigrahy et al., 2010a). The increase of Lac levels 
following hypoxia, are of great interest in clinical MRS studies particularly where blood 
flow is impaired for example following stroke, trauma or formation of a tumour. Lac 
levels are variable in brain tumours (Govindaraju et al., 2000, Astrakas et al., 2004, Davies 
et al., 2008). 
Taurine (Tau)  
Tau, found around 3.3 ppm is a less commonly detected metabolite. Due to the close 
overlap with a number of metabolites it can be difficult to identify. The role of Tau is not 
fully understood but it is speculated to have a number of roles including as an 
osmoregulator and modulator of the action of neurotransmitters. There is evidence to 
suggest that an intracellular accumulation of osmolytes such as Tau is a key factor in 
protecting cells from hyperosmotic stress. Hyperosmolarity triggers cell shrinkage, 
oxidative stress, DNA damage amongst other affects that render cells susceptible to 
apoptosis (Brocker et al., 2012). Taurine also has a role as a neuro-protective chemical 
that prevents the accumulation of free radicals again preventing DNA damage. Both roles 
of Tau provide a cell survival advantage for tumour cells  (Blüml et al., 2013). Tau has 
been detected in increased levels in a number of brain tumours (Moreno-Torres et al., 
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2004, Panigrahy et al., 2006, Opstad et al., 2009, Kovanlikaya et al., 2005, Harris et al., 
2011). 
Scyllo-inositol (sIns) 
Scyllo-inositol is a less commonly observed metabolite that forms a singlet peak at 3.34 
ppm. A positive correlation of sIns with mIns both in normal controls and pathology 
implies a relationship between the two metabolites although its role is poorly understood 
(Swanson et al., 2003). Scyllo-inositol has been detected in a number of brain tumours 
(Kaiser et al., 2005, Govindaraju et al., 2000). 
Glycine (Gly) 
Glycine, Gly, a singlet peak at 3.55 ppm is better observed at long TE due to its close 
overlap with mIns. The roles of Gly include as an inhibitory neurotransmitter and 
antioxidant (Govindaraju et al., 2000, Davies et al., 2009). Gly has been found to be 
increased in brain tumours particularly increased with WHO grade (Davies et al., 2009, 
Lehnhardt et al., 2005, Carapella et al., 1997). 
Citrate (Cit) 
Citrate, Cit, an intermediate product of the tricarboxylic acid cycle (TCA cycle) resonates 
around 2.6 ppm. The concentrations of this metabolite are found to be low in the human 
brain with possible causes of accumulation thought to be metabolic, pathological or both. 
Citrate has been reported to be involved in malignant progression (Seymour et al., 2008). 
The peak has also been observed in various paediatric brain tumours and has been found 
to be prominent in DIPG spectra (Costello et al., 1999, Seymour et al., 2008). 
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Lipids and macromolecules (LMM) 
Lipids and macromolecules consist of broad resonances. The main lipid assignments are 
found around 0.9 ppm, 1.3 ppm and 2.0 ppm. Lipid levels seen in normal brain are very 
low but are known to increase in brain tumours. The observed increases in signal can be 
as a result of membrane degradation, necrosis and/or apoptosis (Tzika et al., 2003, Tzika 
et al., 2002). Macromolecule assignment is more difficult to determine as they become 
masked by lipid signals. Their presence is considered to be due to cytosolic proteins or 
lipids (Barker and Gillard, 2005, Panigrahy et al., 2010a). Lipid levels observed in 
metabolite profiles have been found to be indicators of tumour growth and can vary in 
response to treatment (Peet et al., 2007b, Astrakas et al., 2004). 
Assessment of lipid signals in suspected tumour spectra should be conducted with 
caution. It is important to ensure that the voxel positioning before acquiring MRS was 
correct, as an increase in lipid can also be a result of out of volume lipid contamination 
from proximity to bone for example skull or from cysts (Rosen and Lenkinski, 2007). 
Guanidinoacetate (Gua) 
Guanidinoacetate, Gua, forms a peak around 3.78 ppm although its assignment is 
currently tentative. The peak has been identified in many brain tumour spectra but its 
role unknown (Panigrahy et al., 2006). Gua is a precursor of Cr synthesis and is closely 
associated with Cr (Longo et al., 2011).  
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Alanine (Ala) 
Alanine, Ala, forms a doublet around 1.48 ppm similar to that of Lac. There are very few 
reports of Ala in paediatric brain tumours. However, it has previously been identified as a 
feature in adult meningiomas (Howe et al., 2003). 
3.6 Summary  
The resonances detected in MRS occur as a result of two phenomena, chemical shift and 
coupling. This chapter summarises the brief theory behind NMR with signposting to key 
texts for further detail. The PRESS acquisition sequence has become the most frequently 
used method for single voxel data in a clinical environment.  The raw data in this thesis 
has been processed using TARQUIN software, listing the pre-processing steps used prior 
to obtaining metabolite concentrations. Accurate peak fitting and quantitation is 
challenging but with automated methods, MRS is becoming increasingly powerful in the 
assessment of brain tumours. The metabolites seen in in vivo brain spectra, including 
their identified roles have been summarised. 
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CHAPTER 4  
4 METHODS 
4.1 MRS acquisition  
Multicentre ethical approval was given for all the studies and parental consent obtained. 
Single voxel proton MRS was performed between July 2003 and October 2012 on a 
paediatric population of patients (Age range: 0.1 to 16.4 years) during routine MRI scans 
for a suspected brain tumour that identified a tumour lesion, prior to treatment. The 
analysis also included a small cohort of paediatric patients with inherited metabolic 
disorders. MRS was performed after conventional MRI which included T1 weighted and 
T2 weighted sequences for the inherited metabolic disorder patients and after additional 
T1 weighted post contrast sequences for the brain tumour cohorts (Blaney et al., 2006). 
Spectroscopy data was acquired from 5 different centres including Birmingham Children’s 
Hospital, Birmingham (BCH), Royal Marsden Hospital, Sutton (RMH), Great Ormond 
Street, London (GOS), Royal Liverpool Children’s Hospital, Liverpool (RLC) and Queen’s 
Medical Centre, Nottingham (QMC) at both 1.5 T and 3 T. Data was acquired from six 
different scanners from three different manufacturers including 1.5 T Siemens Symphony, 
1.5 T Siemens Avanto, 1.5 T GE Signa Excite, 1.5 T Phillips Intera, 1.5 T Phillips Achieva and 
a 3 T Phillips Achieva TX. Data was incorporated into the different analyses where 
deemed appropriate and as a result the studies consisted of multi-scanner analyses from 
single or multiple centres. Three studies consisted of data from multiple centres (Chapter 
5, 8 and 9) and remaining were single centre analyses because of the lack of available 
follow-up data. Spectroscopy was performed using a point-resolved spectroscopy 
sequence (PRESS) in all cases with short TE ranging from 23-37 ms and long TE 135-144 
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ms at 1.5 T with a TR 1500 ms and a range of signal averages (NSA) from 128 to 256 
depending on voxel size. The ROI for each acquisition ranged from 3.38 cm3 to 8 cm3. At 3 
T the core protocol for short eco time comprised of TE 37-41 ms and at long echo time 
135-144 ms with a TR 2000 ms and 96-128 NSA. The ROI for each of these acquisitions 
varied from 2.2 cm3 to 8 cm3. Voxel placement was entirely within the tumour as 
delineated by the conventional MRI with the enhancing component maximised, or over 
brain pathology (in the cases of metabolic disease) in the left basal ganglia or the right 
parietal white matter. A water unsuppressed MR spectrum (16 NSA) was acquired 
following the acquisition using the same parameters. It is important for the voxel size for 
both the metabolite and water unsuppressed spectrum, for the same voxel position to 
correspond. Referencing to the water allows for comparisons between different volume 
acquisitions to be made. 
4.2 Processing 
Raw spectroscopy data was exported from the scanner and analysed using TARQUIN 
software (Wilson et al., 2011). It was chosen over other spectroscopy analysis packages 
for its use of simulated basis sets to fit metabolites. Simulated basis sets are generated 
computationally from the knowledge of the chemical properties of each metabolite and 
the pulse sequence parameters. The advantages of using simulated basis sets are that 
they can be generated very quickly for each metabolite in each experiment particularly 
where pulse sequence parameters have been altered. The small variations in echo time 
and repetition time for the data acquisitions on different scanners is more easily 
accounted for and less time consuming using a simulated method, than repeating single 
metabolite solution experiments for input into the experimental basis set each time a 
67 
 
parameter is changed. This is particularly advantageous for the data analysed in this 
thesis because of the combination of two field strengths (Wilson et al., 2010). The 
acquired raw data was fit to a linear combination of 25 metabolite basis functions 
generated at the correct field strength and echo time (see APPENDIX 1). In some analyses 
the extended basis set was used to include more recently reported metabolites, glycine 
and citrate (Davies et al., 2009, Seymour et al., 2008, Wilson et al., 2011). The uncertainty 
of the metabolite fits was assessed using Cramer-Rao Lower Bounds (CRLBs) (Cavassila et 
al., 2001). CRLB determine the precision of the fit of individual metabolites in the spectra 
calculated by standard deviation in mM. This is an important parameter to observe, as 
meaningless fit results that have extremely high estimated errors can as a consequence 
give false results. This is often seen with less well determined metabolites. The area 
under the unsuppressed water peak was used as an internal reference signal for 
quantitation of metabolite signals with concentrations reported in mM, assuming the 
water content of white matter (Jansen et al., 2006).  
4.3 Quality control  
All spectra in the analyses were assessed using the set quality control (QC) criteria (Davies 
et al., 2008). These included having conventional MRI and voxel location available for 
each case. Accurate voxel positioning was confirmed using the three imaging planes 
(example given in Figure 4.1) and voxel placement was verified to be >3mm away from 
bone, scalp and air and not dominated by normal brain. Spectra acquired from voxels 
that encompassed cyst and/or necrotic areas were excluded. In addition to this, spectra 
were required to meet TARQUIN quality control values for three parameters which were 
(1) full-width half-maximum (FWHM), a determinant of spectral width; (2) signal-to-noise 
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ratio (SNR), calculated as either SNR from the spectral residual or SNR MAX from spectral 
noise; and (3) Q, a measure of fit quality. Spectra were required to have a FWHM of 
<0.150 ppm, a SNR >5 and Q determined for each spectrum to be <2.5. Visual inspection 
of baseline abnormalities and major artefacts were also performed.  
 
Figure 4.1 Example of voxel positioning over a medulloblastoma tumour in the a) coronal, b) sagittal 
and c) axial MRI plane 
It should be noted that voxel placement is important for the assessment of spectra. Voxel 
placement over low or high grade elements within the same tumour will result in 
different spectral characteristics. This is likely to impact the results obtained. To 
overcome this, the voxel is aimed to be placed to maximise the solid enhancing 
component which expected to correspond to the most malignant part of the tumour. To 
reduce the number of variables that affect the spectra, a common protocol particularly 
across multiple centres is used. However, if the voxel is required to be placed in the same 
position on follow-up for longitudinal studies this may be problematic (Ricci et al., 2000). 
This is less likely to be an issue for tumour spectroscopy data as the clinical question will 
vary at different time points in MR imaging follow-up that will consequently result in a 
varied voxel placement. 
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4.4 Statistical analysis  
All statistical analysis was performed with R Statistical Software (R Development Core 
Team, 2011) (Version 2.13.1) on the metabolite concentrations (mM) quantified using 
TARQUIN (Wilson et al., 2011). The version of TARQUIN, with the specific use or not of 
the extended basis set for each analysis, has been noted in each chapter. This varies for 
each study, because the analyses were performed over a three-year period. TARQUIN is 
periodically updated to accept new data formats, fix bugs, include new metabolites and 
improve user interaction. As result the most up-to-date version available was used at the 
start of each study’s analysis. Although determination of CRLB for all metabolites across 
spectra was not formally tested in this body of work, metabolites Asp and GABA with 
previously reported high CRLB were excluded (Davies et al., 2008). Lipids and 
macromolecules at 0.9 ppm (LMM0.9), 1.3 ppm (LMM1.3) and 2.0 ppm (LMM2.0) were 
reported mostly as combined signals unless specified. A P value of <0.05 was considered 
to be statistically significant. Corrections for multiple comparisons are not usually applied 
in MRS studies (Panigrahy et al., 2006). However, other studies have demonstrated that 
these corrections are essential to control Type I error thus highlighting the importance of 
accounting for significant differences observed due to chance (Streiner and Norman, 
2011). In this thesis the Bonferroni correction (significance value divided by the number 
of variables being tested) was used to calculate P values where large numbers of 
variables were tested and reported in their respective chapters. The conservative method 
assumes all variables are independent which for metabolites is unlikely to be true. As a 
result Bonferroni corrected P values were calculated but not applied (Bland and Altman, 
1995). It should be noted that results that demonstrate P values greater than the 
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Bonferroni corrected value may be less significant. Power analysis has been performed 
for small cohorts that demonstrated no significant differences. 
Paired and unpaired Student’s t-test (Student, 1908), Mann-Whitney U-test (Mann and 
Whitney, 1947) and Wilcoxon signed ranked test (Wilcoxon, 1945) were used to compare 
means and probability of differences in metabolite concentrations or two imaging 
variables between two tumour types. Student’s t-test’s were used to compare means 
where analysis included variables that followed a normal distribution. Mann-Whitney U-
test (Mann and Whitney, 1947) was used for independent tumour cohorts and Wilcoxon 
signed ranked test for paired analyses with both tests making no assumption regarding 
the distribution of the data (Wilcoxon, 1945). 
For comparisons between more than two means, greater than two tumour groups 
(independent samples), ANOVA (Speed, 1987) was used where variables followed a 
normal distribution and Kruskal Wallis test where this had not been established (Kruskal 
and Wallis, 1952). 
Principal component analysis (PCA) (Pearson, 1901) was used to determine the variability 
of the pre-treatment metabolite profiles of the tumour groups that had been selected as 
inputs. PCA was used an unsupervised method where the maximum number of principal 
components (i.e. the principal metabolites) was reached when 95% of the cumulative 
variance or the minimum group size -1, if the number of components that reached 95% 
exceeded this. Each point on a PCA plot represents a single case and those with similar 
metabolite profile characteristics will cluster together (Pearson, 1901, Harris et al., 2008). 
Linear Discriminant Analysis (LDA), a supervised dimension reduction method was applied 
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to the PCA scores (the point given to each case on the PCA plot)  to produce diagnostic 
classifiers (Fisher, 1936). Leave-one out analysis (LOOCV) (Geisser, 1975) based on the 
LDA was used as a cross validation technique for the classifier. A posterior probability was 
outputted for each classification group per tested case to determine how likely it was 
that the case fell into the given groups. The classification with the highest probability was 
taken as the predicted classification group. Cases with > 80% posterior probability were 
deemed as good quality and reliable classifications. 
A receiver operating characteristics (ROC) (Egan, 1975) curve is a method of visualising 
and determining cut-offs for classifiers (Fawcett, 2006). The curve is constructed with the 
sensitivity on the y-axis plotted against (1-specificity) on the x-axis for each possible cut-
off value. The inputs for the plot were either metabolite concentrations for each case for 
a single metabolite as prognostic markers, or a combinatory model of metabolites. The 
accuracy of a diagnostic test from an ROC curve can be determined by the area under the 
curve or the AUC. An AUC of 0.5 corresponds to random chance and the perfect 
classification produces a curve up to the top left corner or an AUC of 1.0. Using the curve, 
a combination of specificity and sensitivity is used to select an optimal cut-off value 
(Linnet et al., 2012). This optimal cut-off was then used to evaluate the classifiers and 
visualise their performance using Kaplan-Meier curves.  
Kaplan-Meier curves were constructed to compare the survival of different tumour 
cohorts over time using censoring to account for current patient status at the point of last 
follow-up (Kaplan and Meier, 1958). By censoring the data, cases lost during follow-up, or 
those that die or survive before the end of the study can be accounted for (Rich et al., 
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2010). These were constructed using metabolite concentrations where ROC curves 
determined the cut-off or using discreet variables. This method was employed to identify 
markers of prognosis. The difference between the two curves, so difference in survival 
between the two groups, was tested for using a log-rank test (Mantel, 1967, Cox, 1972). 
Cox-Regression analysis was performed to investigate the effect of variables on the 
survival of patients by determining a hazard ratio (Cox, 1972). This method was used 
confirm the significance of prognostic metabolite markers identified using Kaplan-Meier 
curves. 
4.5 Summary 
This chapter initially summarises the cohort and the centres involved in the studies in the 
chapters to follow. The core acquisition protocol used including TE, TR, the number of 
averages and size of ROI are given and specific details for each study have been expanded 
in their respective chapters. TARQUIN data is processed with the use of a simulated basis 
sets, shown to have a number of advantages over experimental basis sets. For an 
accurate interpretation of analysed spectroscopy data, it is important that it is assessed 
using a quality control criterion and this is common for all the data assessed in this thesis. 
With many metabolites quantitated and in some cases subtle changes observed, 
univariate and multivariate statistical methods are employed to use all the information 
obtained and to determine significant differences. 
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CHAPTER 5 
5 CHARACTERISATION OF METABOLITE PROFILES OF PAEDIATRIC BRAIN 
TUMOURS 
5.1 Introduction 
For over 20 years, Magnetic Resonance Imaging (MRI) has been the primary method of 
choice for the non-invasive diagnosis and characterisation of brain tumours in adults and 
children (Poussaint, 2001, Kuperman, 2000, Bryant et al., 2010). Although this modality 
illustrates exceptional anatomical and spatial information, conventional sequences are 
unable to provide functional understanding (Rao, 2008). Conventional MRI gives limited 
indication of tumour type and grade and provides no prognostic or treatment monitoring 
markers. This often leads to diagnostic dilemmas, where an accurate pre-operative 
diagnosis is essential for the clinical management of patients. 
Preliminary studies of single voxel spectroscopy, published around 20 years ago were 
shown to aid in the characterisation of adult brain tumours (Bruhn et al., 1989, 
Langkowski et al., 1989). The potential of the technique lead to an interest in its use in 
paediatric neuro-oncology (Sutton et al., 1992). Early spectroscopy studies were 
performed at long echo time with limited metabolite information, mainly tCho, Cr, 
possibly tNAA and Lac. It soon became evident that short echo time spectroscopy was a 
more useful characterisation tool because it provided more metabolite information and 
had a greater SNR (Panigrahy et al., 2006). Results were mostly reported as trends of 
increases or decreases in metabolites relative to a reference metabolite, mostly Cr 
(Horská et al., 2001, Wang et al., 1995, Howe et al., 2003). However, the use of these 
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relative quantitation methods has demonstrated a number of disadvantages hindering its 
application to potentially useful clinical scenarios.  
Firstly, the use of ratio based reporting results in the elimination of a potentially useful 
metabolite in the spectrum. Secondly, the most commonly used metabolite Cr, initially 
assumed to be stable in pathological states, has now been shown to alter significantly, 
resulting in confounding observations (Li et al., 2003). Reporting of ratios does not reveal 
whether changes are occurring in the numerator, denominator or even both (Jansen et 
al., 2006).  
This has been overcome by using water as an internal reference for robust absolute 
metabolite quantitation, expressed in standard units of mM. This is achieved by taking an 
additional water reference scan from the same voxel. Analysis is now preferentially 
performed using automated software packages containing metabolite fitting methods, 
using basis sets in combination with the water as a reference metabolite. This 
demonstrates a powerful method of processing SVS data (Provencher, 2001, Wilson et al., 
2011). As a result, subsequent studies have been able to differentiate between closely 
related metabolite profiles of brain tumours and have allowed the detection of tumour 
specific markers (Kovanlikaya et al., 2005, Panigrahy et al., 2006).  
More recently, pattern recognition methods have become very popular with researchers 
for the classification of brain tumours using MRS. They often give excellent accuracy rates 
for tumour diagnosis but are not currently available for use in a routine clinical setting. 
Pattern recognition methods commonly used are based on multivariate statistics and can 
be performed on either the whole MR spectrum or a list of parameters for example 
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metabolite concentrations extracted from it (Davies et al., 2008, Hao et al., 2009). The 
most commonly used multivariate techniques include PCA and LDA (Opstad et al., 2007). 
Classification using these methods is most effective when a small number of potential 
diagnoses are being considered. The effect of combining tumour groups to give smaller 
numbers of larger classes has proven an effective strategy (Davies et al., 2008). 
Despite the developments that have been made in MRS, the majority of studies are single 
centre and single scanner based consisting of small cohort numbers. This makes it 
difficult to demonstrate how robust the technique is and the benefits of using it. Cohorts 
often consist of common subtypes with spectroscopy of rarer tumours merely reported 
as case reports (Horská et al., 2001, Porto et al., 2010a, Chang et al., 2003). 
The aims of this chapter were to measure metabolite concentrations of common and rare 
paediatric brain tumours using short-echo time spectroscopy and to establish 
distinguishing features from a large multi-scanner cohort of paediatric brain tumours in 
order to aid in their pre-operative diagnosis as an adjunct to conventional MRI. 
5.2 Method 
5.2.1 Patients 
This is a retrospective analysis from a study in which single voxel 1H MRS was performed 
on children between July 2003 and October 2012 during routine MRI for a suspected 
brain tumour that identified a tumour lesion, prior to treatment. All spectra were 
checked for QC (section 4.3). Following this, a cohort of good quality spectra for inclusion 
in the study was established. Cases were subdivided into corresponding diagnostic 
subtypes (Table 5.1-5.5) and were included in the analysis if full diagnostic information 
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was available to determine the tumour group. Full diagnostic information included 
classification and grading of tumour tissue following surgery (biopsy or surgical resection) 
by histopathology performed using the 2007 WHO Classification of Tumours of the 
Central Nervous system (Louis et al., 2007). For those cases that did not have surgery, 
tumours were diagnosed on clinical and imaging findings alone. No tumour grade was 
determined for these tumours. To ensure spectral profiles were representative of the 
tumour types been investigated, diagnostic subgroups with only three or more cases 
available were included. Two cases had more than one good quality pre-treatment 
spectrum available. For these the earliest spectrum was used in the analysis. The cases 
were divided into the two different field strengths and further subdivided into echo 
times. Flow diagrams for patients included in the study at 1.5 T (Figure 5.1) and 3 T 
(Figure 5.2) are given. At 1.5 T, all spectroscopy was performed on five different scanner 
models from three different scanner manufacturers at five centres (BCH, QMC, RMH, RLC 
and GOS). These included the Siemens Symphony, Siemens Avanto, GE Signa Excite, 
Phillips Intera and Phillips Achieva. At 3 T all spectroscopy was performed on the Phillips 
Achieva at two centres (QMC and RLC). 
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Figure 5.1 Flow diagram of patients studied at 1.5 T. 
 
Figure 5.2 Flow diagram of patients studied at 3 T. 
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Table 5.1 Patient demographics of the most common paediatric brain tumours (>10) in the cohort 
with short echo time MRS at 1.5 T.  
 
Subjects WHO grade Age (mean ± SD) Sex (F/M) 
All Cases 142 I-IV       7.4 ± 4.5 55 / 87 
Tumour Type 
Pilocytic Astrocytoma (PA) ***** 35 I/II 7.2 ± 4.3 17/18 
Medulloblastoma (MB) **** 42 IV 6.9 ± 3.6 12/30 
Ependymoma (E) ***  10 II/III 5.1 ± 5.7 4/6 
Diffuse Pontine Glioma (DIPG) 12 N/A  6.8 ± 3.4 7/5 
 
Note: -  
*** includes tanycytic and anaplastic 
**** includes classic, desmoplastic and large cell 
***** includes pilomyxoid 
N/A not diagnosed on the basis of histopathology so no WHO grading available 
Table 5.2 Patient demographics of the rare paediatric brain tumours (<10) in the cohort with short 
echo time MRS at 1.5 T. 
Tumour Type Subjects WHO grade Age (mean ± SD) Sex (F/M) 
Anaplastic Astrocytoma (AA) 3 III 9.5 ± 5.8 2/1 
Atypical Teratoid Rhabdoid Tumour (ATRT) 5 IV 1.6 ±1.6 2/3 
Choroid plexus Papilloma (CPP) 3 I 3.0 ± 2.6 0/3 
CNS Primitive Neuroectodermal Tumour (CNS PNET) 3 IV 8.3 ± 5.5 2/1 
Craniopharyngioma (CRANIO) * 3 I 7.4 ± 2.3 2/1 
Diffuse astrocytoma (DA)**  5 II/III 11.0 ± 6.6 4/1 
Ganglioglioma (GG) 5 I 11.8 ± 4.6 3/2 
Germinoma (GER) 7 N/A 12.9 ± 2.2 1/6 
Glioblastoma Multiforme (GBM) 9 IV 8.4 ± 4.5 2/7 
 
Note: -  
* includes classic and adamantinomatous 
** includes classic, fibrillary and gemistocytic 
N/A not diagnosed on the basis of histopathology so no WHO grading available  
Table 5.3 Patient demographics of the cohort with long echo time MRS at 1.5 T. 
 Subjects WHO grade Age (mean ± SD) Sex (F/M) 
All Cases 20 I and IV 7.9 ± 3.7 8/12 
Tumour Type 
Pilocytic Astrocytoma (PA)  10 I 9.1 ± 4.1 6/4 
Medulloblastoma (MB) 10 IV 6.8 ± 2.7 2/8 
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Table 5.4 Patient demographics of the cohort with short echo time MRS at 3 T. 
 Subjects WHO grade Age (mean ± SD) Sex (F/M) 
All Cases 15 I and IV 6.7 ± 3.2 8/7 
Tumour Type 
Pilocytic Astrocytoma (PA)  8 I 8.5 ± 2.4 4/ 4 
Medulloblastoma (MB) 7 IV 4.5 ± 3.0 4/3 
 
Table 5.5 Patient demographics of the cohort with long echo time MRS at 3 T 
 Subjects WHO grade Age (mean ± SD) Sex (F/M) 
All Cases 10 I and IV 9.6 ± 4.4 6/4 
Tumour Type 
Pilocytic Astrocytoma (PA)  5 I 9.1 ± 4.2 2/3 
Medulloblastoma (MB) 5 IV 10 ± 5.0 4/1 
 
5.2.2 MRS acquisition and quantitation of metabolite concentrations and lipid 
intensities 
MRS was performed following conventional MRI. The spectroscopy protocol at 1.5 T 
consisted of short TE ranging from 23-37 ms and long TE 135-144 ms with a TR 1500 ms 
and a range of averages 128-256 depending on voxel size. At 3 T, short echo time 
comprised of TE 37-41 ms and at long echo time 135-144 ms with a TR 2000 ms and 128 
averages. All spectra were analysed using TARQUIN (version 4.2.4 with extended basis 
set) fitting to a linear combination of 25 metabolite basis functions generated at the 
correct field strength and echo time (see APPENDIX 1) (Wilson et al., 2011). All spectra 
were assessed using the quality control (QC) criteria (section 4.3). 
5.2.3 Statistical analysis 
Asp and GABA were excluded due to their high CRLBs. Lipids and macromolecules at 0.9 
ppm (LMM0.9), 1.3 ppm (LMM1.3) and 2.0 ppm (LMM2.0) were reported as combined 
signals. The Mann-Whitney U-test (Mann and Whitney, 1947) was performed to compare 
1.5 T short echo time spectroscopy of low (WHO grade II and II) with high grade ( WHO 
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grade III and IV) tumours. This comparison was made between the cases in the final 
analysis that had a confirmed WHO grade classification only. Mann-Whitney U-tests were 
also performed to compare one tumour type with all other tumours pooled (All Other) 
and for comparing between tumour types that are often included in a differential 
diagnosis on conventional MRI sequences. Comparisons between MB and PA at 1.5 T long 
TE were also undertaken. Mann-Whitney U-tests were also used to compare PA with MB 
at 3 T at both short and long TE.  With 18 variables tested, a Bonferroni corrected 
significance of 0.002 (P<0.002) was calculated. A diagnostic classifier for discriminating 
between the three most common tumour subtypes, MB, PA and EP was constructed from 
the available short TE 1.5 T data. Metabolite concentrations and lipids+MM were first 
inputted into the PCA (Pearson, 1901) to reduce the number of variables, followed by 
LDA on the PCA scores for each case (Fisher, 1936). The maximum number of principal 
components (PCs) was reached when 95% of the cumulative proportion of variance was 
accounted for resulting in nine PCs as inputs. Accuracy of the classifier was determined 
using leave-one-out cross-validation (LOOCV) (Geisser, 1975). Spectroscopy data acquired 
at short TE 1.5 T from MB cases on four different scanners (Siemens Symphony, Siemens 
Avanto, GE Signa Excite, Phillips Intera) was compared using a Kruskal Wallis test (Kruskal 
and Wallis, 1952). Metabolite concentrations and standard deviations (SD) have been 
reported for each of diagnostic subtypes. 
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5.3 Results 
5.3.1 Metabolic features of common childhood brain tumours 
 
Figure 5.3 Mean spectra for a) pilocytic astrocytomas (n=35), b) diffuse astrocytomas (n=5), c) 
anaplastic astrocytomas (n=3) and d) glioblastoma multiforme (n=9). The solid black line depicts the 
mean with SD indicated by the shaded region (1.5 T and short TE).
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Table 5.6  Mean absolute concentrations (mM) ± SD of short echo time pre-treatment paediatric brain tumours at 1.5 T compared using Mann-Whitney U-
test. 
Note: - * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001, versus All Other tumours 
A. includes classic and adamantinomatous B. includes classic, fibrillary and gemistocytic C. includes tanycytic and anaplastic D. includes classic, 
desmoplastic and large cell E. includes pilomyxoid 
Metabolites 
(mM ± SD) 
AA 
(n=3) 
ATRT 
(n=5) 
CPP 
(n=3) 
CNS 
PNET 
(n=3) 
CRANIOA 
(n=3) 
DA B 
(n=5) 
DIPG 
(n=12) 
E C 
(n=10) 
GG 
 (n=5) 
GER (n=7) 
GBM 
(n=9) 
MB D 
(n=42) 
PA E 
(n=35) 
All 
Other 
(n=142) 
Ala 0.14+0.2 0.21+0.5 0.98+1.3 0.38+0.5 0.11+0.2 0.12+0.2 0.33+0.4 0.21+0.4 0.46+0.3 0.04+0.1 0.25+0.5 0.49+0.9 0.39+0.7 0.36+0.7 
Cit 2.07+1.6 0.45+0.3 0.33+0.4 0.29+0.3 0.12+0.1 0.62+0.6 1.03+0.6** 0.73+0.4 0.49+0.5 0.76+0.4 0.61+0.5 0.59+0.4 0.40+0.3** 0.60+0.5 
Cr 4.17+1.8* 1.48+2.2 0.76+1.3 0.59+0.5 0.22+0.1** 2.18+1.5 2.85+1.4* 4.37+2.4** 2.35+0.7 1.26+0.4 1.24+0.9 2.87+1.3**** 0.92+0.8**** 2.10+1.7 
tCho 1.22+0.4 1.87+1.7 2.24+2.3 1.63+1.5 0.28+0.3** 0.94+0.4 1.16+0.6* 2.00+1.1 1.32+0.5 1.19+0.6 1.82+1.3 3.57+1.5**** 1.05+0.4**** 1.99+1.5 
Glc 3.49+1.0* 2.71+4.4 3.25+0.8 0.01+0.02 0.9+0.9 1.41+1.8 2.67+1.5* 1.06+1.2 1.28+1.3 2.55+1.6 1.38+1.5 0.62+1.0**** 2.81+1.9**** 1.74+1.9 
Gln 3.01+1.0 2.03+2.4 1.41+1.8 2.22+0.1 2.22+1.5 3.21+1.1 3.65+4.2 3.15+1.9 4.02+1.8 3.14+2.1 4.08+3.0 2.86+2.6 3.53+1.9 3.17+2.4 
Glu 4.11+2.5 2.44+2.1 2.71+1.7 2.10+2.6 0.37+0.7* 1.81+1.4 1.95+1.3 2.77+1.8 3.14+1.1 4.93+1.4*** 1.17+1.6* 3.03+2.2 1.68+1.4* 2.44+2.0 
Glx 7.11+1.7 4.47+2.7 4.12+2.6 4.32+2.5 2.60+0.9* 5.02+1.7 5.60+3.8 5.92+3.4 7.16+2.6 8.06+2.5* 5.25+3.2 5.89+3.4 5.20+2.2 5.61+2.9 
Gly 0* 0.87+1.2 3.32+3.3 1.60+2.8 0.54+0.6 0.04+0.1* 1.17+2.1 3.44+3.3 1.59+1.1 1.41+1.6 1.31+1.0 3.45+2.3**** 0.63+1.1*** 1.87+2.2 
Gua 0.41+0.4 1.36+2.7 0.42+0.7 0.51+0.9 0.97+0.9 0.38+0.5 0.66+2.1 0.61+1.0 0.47+0.4 0.49+1.3 0.42+0.7 1.14+1.1**** 0.23+0.5* 0.67+1.1 
mIns 11+2.0** 1.07+1.8 8.11+9.7* 1.91+2.8 0 2.83+2.3 5.95+3.3**** 6.14+4.9** 1.28+1.9 1.19+1.3 0.74+0.9 0.8+2.0**** 0.70+0.9 2.07+3.4 
Lac 0.64+0.6* 3.43+2.3 2.67+3.6 4.76+3.0 3.74+1.5 1.73+1.4 0.71+0.9**** 1.60+1.0 1.85+0.7 2.84+4.6 5.24+4.0** 2.67+1.8 2.32+1.9 2.50+2.3 
LMM0.9 2.98+1.7 10.4+4.4 7.53+8.3 6.30+2.3 6.16+3.0 3.65+2.8 2.21+1.7**** 4.96+3.5 2.92+1.0 5.04+4.2 9.13+5.1* 6.9+3.3**** 4.29+2.3* 5.55+3.7 
LMM1.3 3.62+2.1 41+25** 12.6+18 15+14 9.37+7.0 5.40+6.2 2.99+2.3**** 15+16 2.92+2.1* 18+22 14+6.1 17+13**** 6.1+4.3**** 12+13 
LMM2.0 7.94+1.3 12+5.7 5.79+3.0 7.19+2.6 5.69+2.0 9.90+6.4 6.02+3.0*** 12.+7.5 8.43+2.6 9.38+3.2 12+2.4* 11+3.0**** 6.54+2.8**** 9.07+4.2 
tNAA 1.54+1.7 1.12+0.9 0.29+0.5* 1.18+0.4 1.00+0.7 1.81+0.5 2.52+1.1*** 1.07+0.7 1.79+0.9 1.23+0.7 1.02+0.9 1.25+0.8 1.55+0.8 1.42+0.9 
sIns 0.18+0.2 0.10+0.2 0.37+0.5 0.16+0.2 0 0.08+0.08 0.27+0.3 0.47+0.4* 0.09+0.2 0.29+0.4 0.07+0.1 0.49+0.5**** 0.05+0.1**** 0.26+0.4 
Tau 1.39+1.4 1.36+2.1 0.95+0.9 0.43+0.7 0.41+0.4 0.23+0.4 0.40+0.5 0.89+1.3 0.35+0.4 1.86+1.5 0.1+0.3** 2.68+2.3**** 0.64+1.0 1.28+1.79 
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Figure 5.4 Mean spectra for a) pilocytic astrocytomas (n=10) and b) medulloblastomas (n=11). The 
solid black line depicts the mean with SD indicated by the shaded region (1.5 T and long TE). 
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Figure 5.5 Mean spectra for a) pilocytic astrocytomas (n=8), b) medulloblastoma at short TE (n=7), c) 
pilocytic astrocytoma (n=5) and d) medulloblastoma at long TE (n=5). The solid black line depicts the 
mean with SD indicated by the shaded region (3 T and short and long TE). 
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Table 5.7 Mean absolute concentrations (mM) ± SD of long echo time pre-treatment paediatric brain 
tumours at 1.5 T with P values determined using Mann-Whitney U-test. 
Metabolite concs 
(mM ± SD) MB (n=10) PA (n=10) 
Ala 0.99±0.8 0.37±0.5 
Cit 1.46±1.3 0.61±0.7 
Cr 7.96±6.2 0.90±0.8 ** 
tCho 10.4±5.9 1.52±0.9 ** 
Gly 3.83±2.5 0.36±0.5 ** 
Lac 2.62±2.2 2.09±1.7 
tNAA 2.23±1.8 1.10±0.5 
Note: - * P<0.05, ** P<0.01  
Table 5.8 Mean absolute concentrations (mM) ± SD of short echo time pre-treatment paediatric brain 
tumours at 3 T with P values determined using Mann-Whitney U-test. 
Metabolites concs 
(mM ± SD) 
MB (n=7) PA (n=8) 
Ala 0.31±0.5 3.3±4.2 
Cit 0.47±0.2 0.78±0.5 
Cr 3.80±1.3 1.55±1.2 ** 
tCho 4.99±2.0 2.11±1.1 ** 
Glc 6.37±4.5 2.57±2.0 * 
Gln 2.39±1.6 2.72±1.7 
Glu 3.38±0.6 4.99±4.0 
Glx 5.77±1.9 7.71±5.2 
Gly 3.79±2.5 0.57±0.6 ** 
mIns 0.69±1.7 2.08±2.5 
Lac 2.14±2.5 1.91±1.6 
LMM0.9 5.24±1.8 6.09±2.4 
LMM1.3 25.3±7.0 13.5±6.7 ** 
LMM2.0 10.1±4.6 7.85±3.2  
tNAA 0.78±0.3 2.33±1.0 *** 
sIns 0.46±0.7 0.08±0.1 
Tau 6.65±6.0 1.91±1.6 * 
Note: - * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 
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Table 5.9 Mean absolute concentrations (mM) ± SD of long echo time pre-treatment paediatric brain 
tumours at 3 T with P values determined using Mann-Whitney U-test. 
Metabolite concs 
(mM ± SD) MB (n=5) PA (n=5) 
Ala 0.74±0.7 1.17±0.7 
Cit 0 0 
Cr 10.1±3.1 2.85±1.9 ** 
tCho 13.4±5.7 3.99±3.0 * 
Gly 5.27±4.6 0.52±0.7 
Lac 3.54±3.1 1.86±1.3 
tNAA 1.86±0.9 1.73±1.1 
Note: - * P<0.05, ** P<0.01  
Pilocytic Astrocytoma (PA) 
Histopathological subtypes of PA occurring in different locations in the brain were pooled 
as one group in this analysis. 
Characteristic features of the PA spectra (Figure 5.3a) were readily detectable Lac, 
decreased Cr and increased tNAA. Compared with All Other, PA had significantly 
decreased mean Cit (P<0.01), Cr (P<0.0001), tCho (P<0.0001), Glu (P<0.05), Gly (P<0.001), 
LMM0.9 (P<0.05), LMM1.3 and LMM2.0 (P<0.0001) and sIns (P<0.0001) and significantly 
increased Glc (P<0.0001) (Table 5.6). At long TE significantly less Cr, tCho and Gly (P<0.01) 
was observed in PA than was found in MB (Figure 5.4a and Table 5.7). At 3 T short TE PA 
had significantly lower Cr (P<0.01), tCho (P<0.01), Glc (P<0.05), Gly (P<0.01), LMM1.3 
(P<0.01) and Tau (P<0.05), and significantly higher tNAA (P<0.001) when compared to MB 
(Figure 5.5a and Table 5.8). At 3 T long TE MRS demonstrated significantly lower Cr 
(P<0.01) and tCho (P<0.05) in PA than MB (Figure 5.5c and Table 5.9) 
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Figure 5.6 Mean spectra for a) medulloblastomas (n=42), b) central nervous system primitive 
neuroectodermal tumours (n=3) and c) atypical teratoid rhabdoid tumours (n=5). The solid black line 
depicts the mean with SD indicated by the shaded region (1.5 T and short TE) 
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Medulloblastoma (MB) 
The most prominent feature of the MB mean spectra (Figure 5.6a) was Tau. Other 
features include elevated tCho, decreased mIns and elevated lipids+MMs at 1.3 ppm. On 
comparison with All Other subtypes, MB exhibited the most difference in metabolites and 
lipids+MMs and with the highest significance. MB spectra demonstrated significantly 
elevated concentrations of mean Cr, tCho ,Gly, LMM0.9, LMM1.3 and LMM2.0, sIns and 
Tau and decreased mean Glc and mIns (P<0.0001 for all) (Table 5.6). Significantly 
increased Cr, tCho and Gly (P<0.01) were seen at long TE when compared to PA (Figure 
5.4b and Table 5.7) 
MB spectra acquired at short TE at 3 T had significantly higher Cr, tCho, Gly, LMM1.3 
(P<0.01), Glc and Tau (P<0.05) and significantly lower tNAA (P<0.001) compared to PA 
(Figure 5.5b & Table 5.8). Significantly higher Cr (P<0.01) and tCho (P<0.05) was seen at 
long TE at 3 T in MB (Figure 5.5c and Table 5.9) 
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Figure 5.7 Mean spectra for a) all ependymomas (n=10), b) WHO grade II ependymomas (n=7) and c) 
WHO grade III ependymomas (n=3). The solid black line demonstrates the mean with SD indicated by 
the shaded region (1.5 T and short TE). 
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Ependymoma (EP) 
Qualitative analysis of the EP mean spectra (Figure 5.7a) showed highly elevated mIns 
and elevated Cr. Comparison of EP grade II (Figure 5.7b) and grade III (Figure 5.7c) on 
qualitative analysis show an increase in LMM1.3 and decrease of mIns with increasing 
grade. Compared to All Other, EP had significantly elevated mean concentrations of mIns, 
Cr (P<0.01) and sIns (P<0.05) (Table 5.6). 
 
Figure 5.8 Mean spectra for diffuse pontine gliomas (n=12). The solid black line depicts the mean 
spectra with SD indicated by the shaded region (1.5 T and short TE).* 
* The additional two patients included in the mean spectra had no water files so were not included in 
the statistical analysis 
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Diffuse Intrinsic Pontine Glioma (DIPG) 
The DIPG mean spectra (Figure 5.8) possessed a prominent Cit, increased Cr, mIns and 
tNAA and decreased Lac, LMM0.9 and LMM1.3. Significantly elevated mean Cit (P<0.01), 
Cr, Glc (P<0.05), mIns (P<0.0001) and tNAA (P<0.001) and decreased mean tCho (P<0.05), 
Lac, LMM0.9, LMM1.3 and LMM2.0 (P<0.0001) were found in DIPG when compared to All 
Other (Table 5.6). 
 
Figure 5.9 Mean spectra for a) choroid plexus papilloma (n=3), b) craniopharyngioma (n=3), c) 
ganglioglioma (n=5) and d) germinoma (n=7). The solid black line depicts the mean with SD indicated 
by the shaded region (1.5 T and short TE). 
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5.3.2 Metabolic features of rare childhood brain tumours 
Anaplastic Astrocytoma (AA) 
On qualitative analysis the AA mean spectra (Figure 5.3c) showed low LMM0.9 and 
LMM1.3, prominent Cit and high mIns. Compared with All Other, AA had significantly 
increased mean Cr, Glc (P<0.05) and mIns (P<0.01) and decreased Lac (P<0.05). No Gly 
(P<0.05) was quantified in these tumours (Table 5.6). 
Atypical Teratoid Rhabdoid Tumour  
ATRT mean spectra (Figure 5.6c) exhibited elevated LMM1.3 which was found to be 
significantly different to All Other (P<0.01, 40.9 vs. 12.0) (Table 5.6). 
Choroid Plexus Papilloma (CPP) 
The most prominent features of the CPP mean spectra (Figure 5.9a) were low Cr and high 
mIns. Compared with All Other, CPP demonstrated significantly increased mean mIns and 
decreased tNAA (P<0.05). 
CNS Primitive Neuroectodermal Tumour (CNS PNET) 
Qualitative analysis demonstrated high levels of LMM1.3 (Figure 5.6b). No significantly 
different metabolites or lipids+MMs (P>0.05) were identified when compared to All Other 
(Table 5.6). 
Craniopharyngioma (Cranio) 
The tumour mean spectra consisted of low levels of metabolites and high lipids+MMs 
(Figure 5.9b). This is consistent with All Other comparisons where significantly decreased 
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mean Cr (P<0.01), tCho (P<0.01), Glu (P<0.05) and Glx (P<0.05) were observed (Table 5.6). 
It should be noted that low metabolite levels was not characteristics for all Cranio and 
overlap with PA spectra has been previously observed. 
Diffuse astrocytoma (DA) 
Qualitative analysis demonstrated readily detectable Cit and high tNAA (Figure 5.3b). 
Significantly decreased mean Gly (P<0.05) was the only differentiator from All Other 
(Table 5.6). 
Ganglioglioma (GG) 
On qualitative analysis elevate Glx was seen (Figure 5.9c). GG had significantly lower 
LMM1.3 (P<0.05) when compared with All Other (Table 5.6). 
Germinoma (GER) 
GER mean spectra demonstrated readily detectable Tau and elevated LMM1.3 (Figure 
5.9d). Compared with All Other, GER consisted of significantly increased mean Glu 
(P<0.05) and Glx (P<0.05) (Table 5.6).  
Glioblastoma Multiforme (GBM) 
A characteristic spectral feature of GBM was high LMM1.3 (Figure 5.3d). Significantly high 
mean Lac (P<0.01), LMM2.0 (P<0.05) and low Glc (P<0.05) and Tau (P<0.01) were seen 
when compared to All Other (Table 5.6). 
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Low (WHO grade I and II) vs. high grade tumours (WHO grade III and IV) 
Statistical analysis comparing low (n=65) and high grade (n=58) tumours demonstrated 
significantly higher Cr, tCho, Gly, Gua, LMM0.9, LMM1.3, LMM2.0, sIns (P<0.001 for all), 
Cit (P<0.01), Tau (P<0.01) and Lac (P<0.05) and significantly lower Glc (P<0.001) and mIns 
in high grade tumours (Table given in APPENDIX 2). 
5.3.3 Comparison of tumour types that are often included in a differential diagnosis 
Table 5.10 Differentiation between tumour metabolite profiles at 1.5 T comparing those that are often 
included in differential diagnoses on conventional radiology using Mann-Whitney U-test with P values 
reported. 
 
ATRT (n=5) EA (n=10) PAB (n=35) 
MB (n=42) ↑ Cr * ↓ Cr * ↑ Cit** 
 
↑ Gly ** ↑ tCho  ** ↑ Cr **** 
 
↓ LMM0.9 * ↓ mIns *** ↑ tCho **** 
 ↓ LMM1.3 * ↑ LMM0.9 * ↓Glc **** 
 ↑ sIns * ↑ Tau ** ↑ Glu ** 
   
↑ Gly **** 
   
↑ Gua **** 
   
↑ mIns * 
   
↑ LMM0.9 **** 
   
↑ LMM1.3 **** 
   
↑ LMM2.0 **** 
   
↑ sIns **** 
   
↑Tau **** 
 
DAc (n=5) GBM (n=9) 
 DIPG (n=12) ↑m Ins* ↑ Cit* 
 
  
↑ Cr *** 
 
  
↑ mIns *** 
 
  
↓ Lac *** 
 
  
↓ LMM0.9 *** 
 
  
↓ LMM1.3 **** 
 
  
↓ LMM2.0 *** 
 
  
↑ tNAA ** 
 
  
↑ Tau * 
 
Note: - * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001  
A. includes tanycytic and anaplastic B. includes pilomyxoid C. includes classic, fibrillary and gemistocytic D. 
includes classic, desmoplastic and large cell 
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Distinguishing MB from ATRT showed MB to have significantly higher Cr (P<0.05), Gly 
(P<0.01) and sIns and significantly decreased LMM0.9 and LMM1.3 (P<0.05). 
Comparisons between MB and EP demonstrated MB to have significantly increased tCho 
(P<0.01), LMM0.9 (P<0.05) and Tau (P<0.01) with significantly decreased Cr (P<0.05) and 
mIns (P<0.001). Compared with PA, MB had a number significantly higher metabolites 
including Cr, tCho, Gly, Tau, LMM0.9, LMM1.3 and LMM2.0 (P<0.0001) excluding Glc that 
was significantly lower (P<0.0001) (Table 5.10). 
The only discriminator between DIPG and DA was mIns with DIPG having significantly 
higher concentrations (P<0.05). To distinguish metabolite profiles of GBM from DIPG, 
DIPG was found to have significantly increased Cit (P<0.05), Cr (P<0.001), mIns (P<0.001), 
tNAA (P<0.01) and Tau (P<0.05) with significantly decreased Lac, LMM0.9, LMM1.3 and 
LMM2.0 (P<0.001) (Table 5.10). 
 
Figure 5.10 Box and whisker plot comparing levels of lipids at 1.3 ppm (L1.3) in DIPG and GBM 
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Box and whisker plots analysis comparing tumour types that often result in differential 
diagnosis on MRI exhibited no discriminatory metabolites or lipids+MMs. A comparison 
of lipids (lip1.3a+lip1.3b) alone at 1.3 ppm (L1.3) was found to discriminate GBM from 
DIPG (Figure 5.10) with higher levels found in GBM. 
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5.3.4 Classification of common brain tumours by metabolite profile 
 
Figure 5.11 Results of the three way classifier between MB, PA and EP showing a a) scatter plot of the 
discriminant function scores for each tumour type b) discriminant function 1 coefficients and c) 
discriminant function 2 coefficients of the standardised metabolite profile.  
The diagnostic three way classifier showed a good separation between the three tumour 
types with highly clustered regions seen for each tumour (Figure 5.11a). MB scored highly 
in discriminant function 1, characterised by high tCho, sIns, Gua and Tau and PA with high 
tNAA and Lac (Figure 5.11b). PA was distinguished from EP by high tNAA with EP 
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characterised by high mIns (Figure 5.11c). LOOCV demonstrated a success rate of 86% 
with the correct classification of 71 out of 83 cases all with a posterior probability above 
80%. 
5.3.5 Scanner comparisons 
Table 5.11 Mean absolute concentrations (mM) ± SD of short echo time MB spectra acquired on 4 
different scanners at 1.5 T prior to treatment with comparisons made using Kruskal-Wallis test. 
Metabolite concs 
(mM ± SD) 
P value GE Signa 
Excite 
Phillips 
Intera 
Siemens 
Symphony 
Siemens 
Avanto 
Cr 0.03 3.68±0.34 1.99±1.11 2.76±1.40 3.52±0.65 
Gua 0.008 3.32±1.06 0.87±0.91 0.85±0.70 1.23±0.84 
Cr and Gua were the only significant metabolites found when comparing metabolite 
concentrations measured in MB from spectra acquired on four different scanner models 
at 1.5 T (Siemens Symphony (n=27), Siemens Avanto (n=6), GE Signa Excite (n=4), Phillips 
Intera (n=5) (Table 5.11). 
5.4 Discussion 
5.4.1 Metabolite profiles for characterising paediatric brain tumours 
Mean metabolite concentrations of common and rare paediatric brain tumours 
determined by quantitative short echo time spectroscopy were shown to differ from one 
tumour type to another. The reported differences show MRS has the potential to aid in 
diagnosis and characterisation. The variations in in vivo concentrations of metabolite 
pathway intermediates observed in MRS are likely to be explained by differences in 
tumour biology. Although the number of metabolites which can be quantified by in vivo 
MRS is limited, many have been linked to important processes in the pathogenesis of 
cancer. Establishing how these are linked may provide an insight into the favoured 
pathways for pathogenesis. 
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Total choline (tCho) 
The highest levels of tCho were seen in MB and CPP and lowest levels in Cranio, DA and 
PA mostly in agreement with previous studies with the exception of CPP (Panigrahy et al., 
2006, Davies et al., 2008, Vicente et al., 2013). Higher grade tumours have shown 
significantly elevated tCho levels as previously reported (Astrakas et al., 2004). 
Activated choline metabolism is a known metabolic hallmark of cancer (Glunde et al., 
2011). Elevated levels of choline containing compounds are associated with cell 
proliferation and malignant transformation with a role in cell membrane synthesis and 
breakdown (Glunde et al., 2011). The expected elevated levels of tCho seen in MB (grade 
IV) and lower levels in Cranio (grade I), DA (grade II) and PA (grade I) are consistent with 
the association of tumour malignancy. The unexpected increased levels seen in CPP 
(grade I) is likely to be an effect of small group size (n=3).  
The metabolism of choline is influenced by changes in the tumour microenvironment 
(Glunde et al., 2011). An increase in metabolic activity of tumour cells results in a hypoxic 
environment that acidifies extracellular pH (Gillies et al., 2002). These changes result in 
an decrease of GPC and an increase in PCh in brain tumours compared to normal brain 
tissue (Usenius et al., 1994). Many studies have shown an increase in the expression and 
activity of choline kinase α, an enzyme that regulates the conversion of PCh from free 
choline to be directly associated with cell proliferation and malignancy. GPC is 
responsible for contributing to the production of PCh (Glunde et al., 2011). Thus choline 
metabolism is controlled by the interplay of enzymes involved in the Kennedy pathway 
modulated by oncogenic signalling. The deregulation of these pathways is a common 
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feature in cancer and the differences in the pathway affected, results in differences in 
tumour pathogenesis (Glunde et al., 2011, Righi et al., 2009). However, the close overlap 
between in vivo measurements of choline containing compounds makes it difficult to 
infer which genes are involved in mediation of the pathway for targeted therapies (Tzika 
et al., 2007). 
Alternatively, phosphorous spectroscopy or 31P MRS enables the measurement of the 
relative concentrations of PCh and GPC due to the greater chemical shift separation 
between the two metabolites (reported values of 0.007 ppm using proton vs. 0.13 ppm 
using phosphorous) (Loening et al., 2005). The method is currently limited by low 
sensitivity and abundance of phosphorus metabolites, however with the availability of 
high field scanners the technique looks promising in aiding the investigation of tumour 
biology (Qiao et al., 2006). 
Creatine (Cr) 
High levels of Cr were seen in EP and AA and low levels in Cranio, CNS PNET, CPP and PA. 
High grade tumours possessed higher Cr levels. Previous studies have reported high levels 
in EP and AA (Panigrahy et al., 2006). Cr was also found to be low in PA compared to 
other cerebellar tumours (Davies et al., 2008). 
Creatine is an essential component of energy metabolism and is thereby a marker of the 
energy state of cells (Martinez-Bisbal and Celda, 2009). It is responsible for energy 
storage and transmission where Cr, through phosphocreatine provides phosphate for ATP 
(Nasrallah et al., 2010, Vigneron et al., 2001). This process is catalysed by creatine kinase 
and it is hypothesised that the downregulation of the enzyme is responsible for the 
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decrease in Cr suggesting a likely pathway of choice in these tumours for pathogenesis 
(Patra et al., 2012). The current understanding is that highly malignant, active tumours 
exhibit a high metabolic rate of activity resulting in the depletion of energy stores and a 
hypoxic environment. A marker of these changes is decreased levels of Cr in tumours 
(Rao, 2008, Tzika et al., 2001). This cohort demonstrates low levels of Cr in low grade 
tumours, with the exception of CNS PNET. Other studies have shown that there is no 
specific trend associated with malignancy when comparing spectroscopy of brain 
tumours (Panigrahy et al., 2006). 
N-acetylaspartate (tNAA) 
Total N-acetylaspartate in the brain tumours was variable but generally low. The highest 
tNAA was seen in DIPG and lowest concentrations in CPP. Previous studies have found 
higher tNAA in PA compared to other cerebellar tumours, although not significant (Davies 
et al., 2008).  
Total N-acetylaspartate is a known marker of neuronal and axonal integrity and most 
reliable marker of pathological disease in the brain (Gujar et al., 2005). It does not appear 
to provide information on tumour metabolism and instead mostly used as a cell type 
marker. For example increased tNAA in DIPG is likely to be due to the diffuse nature of 
the tumour (Hargrave et al., 2008). However, the contribution of tNAA in in vivo 
metabolite profiles of PA requires further investigation. Decreased tNAA did not aid brain 
tumour differentiation in this cohort. 
 
 
103 
 
Myo-inositol (mIns) 
Myo-inositol was increased in AA and CPP and also a prominent feature of DIPG and EP. It 
has been previously reported as prominent feature of EP (Davies et al., 2008, Panigrahy 
et al., 2006) and studies have demonstrated trends in higher mIns in low grade tumours 
and lower in high grade tumours , also seen in this analysis (Castillo et al., 2000). 
The role of mIns in brain tumours is not fully understood but it is believed to be involved 
in the synthesis of cell membranes and myelin sheets. The increased mIns seen in 
tumours is thought to be as a result of the activation and proliferation of glial cells 
(Hattingen et al., 2008b, Callot et al., 2008). Myo-inositol, synthesised from glucose is 
involved in various signalling cascades (Downes and Macphee, 1991). It contributes to the 
formation of a phosphorylated form of phosphatidylinositol which is broken down to 
form secondary messengers, diacylglycerol and inositol 1,4,5-triphospate. The resulting 
diacylglycerol activates protein kinase C and a cascade of proteolytic enzymes that 
regulate a diverse set of cellular processes including proliferation, apoptosis, cell survival 
and migration all of which contribute to tumourigenesis. Inositol 1,4,5-triphospate 
activates a calcium (Ca2+) signalling system control mechanism that also controls cellular 
processes including cell proliferation. It also forms inositol 3,4,5-triphosphate that is 
involved in generating membrane lipids (Wymann and Schneiter, 2008, Castillo et al., 
2000). 
The elevated levels of mIns seen in EP, particularly grade II and CPP is consistent with the 
expected findings in low grade tumours. The high standard deviation (6.14±4.9) of mIns 
seen in EP demonstrates the variability seen in the same tumour type. Myo-inositol 
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transportation is said to be facilitated by the choroid plexus and the presence of a CPP 
limits the ability of transportation hence the accumulation of mIns. Choroid plexus 
carcinomas are thought to have a less efficient uptake of mIns explaining the reason why 
this is not seen as a feature (Panigrahy et al., 2006). The elevated levels also seen in AA 
and DIPG do not fit the expected trend, but interestingly both tumours have features of 
prominent mIns and low lipid+MMs. With mIns known to be involved in the generation of 
membrane lipids, does this eliminate this pathway of tumourigenesis in these tumours 
thereby eliminating a pathway for targeted treatment? Are grade III EP tumours using 
mIns to generate membrane lipids hence the accumulation of lipids+MMs seen? Further 
work is warranted to establish whether these pathways are upregulated in those tumours 
that demonstrate low levels of the metabolite and explore their potential as targets for 
novel agents. 
Glutamine (Gln), Glutamate (Glu) and Glutamate+Glutamine (Glx) 
The quantitation of Gln and Glu can be determined independently with use of simulated 
basis sets (Kanowski et al., 2004). This is particularly useful at low field strengths where 
they closely overlap. However, the use of various quantitation methods in spectral 
analysis has resulted in the metabolites being reported as a sum, Glx.  
Gln was seen at similar concentrations across all tumour types. The lowest levels were 
observed in CPP and highest in GBM. Glu was highest in GER and AA with low levels seen 
in Cranio and GBM. Low levels of Gln has been previously reported in CPP (Panigrahy et 
al., 2006). Significantly lower Glu and significantly higher Gln have been observed in PA 
when compared to MB (Davies et al., 2008). 
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Gln is an amino acid precursor and storage form of Glu (Panigrahy et al., 2010a) and is 
involved in every metabolic task of proliferating tumour cells including bioenergetics, 
supporting cell defences against oxidative stress and complementing glucose metabolism 
(DeBerardinis and Cheng, 2010). Glu is known to activate a number of processes via its 
roles as a major excitatory neurotransmitter (Prickett and Samuels, 2012).  
Gln provides energy for tumours and is involved in the process of glutaminolysis, where 
Gln is converted to Glu. Glu then either enters the TCA cycle or is a precursor for other 
metabolic intermediates. The use of Gln provides a less efficient process of energy 
production but is favoured by cancer cells because it not only provides ATP but a number 
of by-products such as lipids, fatty acids, NADPH, Cit and amino acids including Gly that 
aid in tumour cell proliferation (Teicher et al., 2012, Lu et al., 2010). Myc, an oncogene 
known to be dysregulated in many cancers including MB is a major regulator of Gln 
metabolism. It is speculated that multiple signalling pathways activated by Gln contribute 
to tumour growth (Daye and Wellen, 2012, Guessous et al., 2008).  
Glu has recently been shown to aid rapid proliferation of malignant gliomas and 
accelerate destruction of normal brain tissue (Sontheimer, 2008). Manipulating the 
activation of multiple signalling nodes has been found to be responsible for glioma 
pathogenesis (de Groot and Sontheimer, 2011).  
The pivotal role of Gln and Glu and their close association makes it difficult to determine 
the role of these metabolites in individual tumours. With GBM possessing high levels of 
Gln, but low levels of Glu, it can be speculated that an alternative energy source is being 
utilised to aid tumour proliferation. There is a large body of evidence that GBM possess 
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areas of hypoxia particularly in adults but also seen in paediatrics (Yang et al., 2012, 
Donovan et al., 2012). There is evidence to suggest that that these cells preferentially use 
aerobic glycolysis known as the ‘Warburg effect’, to survive and rapidly proliferate, a 
possible explanation for the increase Gln levels observed (Wolf et al., 2010). 
Taurine (Tau) 
Taurine is observed to be highest in MB and GER with low concentrations seen in GBM 
and ATRT. Tau has been previously identified as a differential marker of MB (Kovanlikaya 
et al., 2005) and a marker of malignancy (Peeling and Sutherland, 1992). It has also been 
observed as a feature in germinomas (Harris et al., 2011). 
Tau has been speculated to be correlated with apoptosis in gliomas (Opstad et al., 2009) 
but also been found to decrease in the stages of apoptosis (Valonen et al., 2005). It has 
also been shown to have an important role in osmoregulation and volume regulation in 
the central nervous system (Vitvitsky et al., 2011). Tau is generated from Glc through the 
diversion of the glycolytic intermediate 3-phosphoglycerate (3PG) into the serine 
synthesis pathway where serine is converted to cysteine. Cysteine is then converted to a 
number of intermediates before being made into Tau. The high level of Tau in MB (WHO 
IV) correlates with malignancy as expected but does not explain the low levels seen in 
GBM and ATRT. The mechanisms of Tau in tumour pathogenesis are poorly understood, 
in particular the link with apoptosis, thereby requiring further work for clarification. 
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Glucose (Glc) 
High Glc was observed in AA, DIPG and PA and low levels observed in CNS PNET and 
Cranio. High Glc levels have been reported in MB, in disagreement with this study’s 
findings (Panigrahy et al., 2006). 
Glc provides energy for all proliferating cells. Low Glc concentrations found in malignant 
tumours is speculated to be due to the large energy requirements of tumour cells for 
rapid proliferation (Panigrahy et al., 2006). This affects closely related metabolites 
including the levels of Lac. The data shows no correlation of low Glc for more malignant 
tumours. 
Lactate (Lac) 
Lactate was found to be high in GBM and CNS PNET and low in DIPG and AA. Lac is a 
known feature of pathology (Panigrahy et al., 2010b) and has been detected in many 
tumours including PA (Davies et al., 2008, Panigrahy et al., 2006). It should be noted that 
although the use of a basis set accounts for the different components of the spectrum, 
there will be an overlap between LMM1.3 and Lac if the lipid component dominates. This 
can make it difficult to quantitate Lac reliably. To overcome this some studies perform 
long TE spectroscopy where the short T2 of lipids results in a decay of the  lipid signals 
and an inverted Lac peak is observed (Graaf, 2010). 
Lac production is a known feature of abnormal glucose metabolism. Multiple pathways 
result in the production of Lac that explains the variability seen in different tumours 
(Hirschhaeuser et al., 2011). The elevated concentrations of Lac in GBM are in keeping 
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with the tumours favouring aerobic glycolysis of which Lac is a by-product. The decreased 
Lac seen in DIPG and AA could be inferred as the tumours favouring other energy sources 
for proliferation. Evidence has shown that when DIPG are biopsied, a rarely performed 
procedure for these tumours, the largest histopathological grouping is found to be 
anaplastic astrocytomas (30%) demonstrating their close association (Perez-Gomez et al., 
2010). 
Tumour cells undergo a cyclic variation in hypoxic and aerobic conditions that results in 
the differences in Lac levels. It is the adaptation of tumour cells to their regional 
environment that enables them to continue proliferating. Excess Lac used by aerobic cells 
generates 18 ATP (Teicher et al., 2012) via oxidative phosphorylation. Under hypoxic 
conditions Glc conversion to Lac is highly upregulated by HIF-1 (Semenza, 2008) resulting 
in two ATP (Teicher et al., 2012). The acidic environment created by the presence of Lac 
provides several growth advantages for tumours (Munoz-Pinedo et al., 2012). Hypoxic 
tumours have been found to be more resistant to treatment resulting in a poor prognosis 
for the patient (Semenza, 2008). 
Citrate (Cit) 
Citrate is present at high concentrations in AA and DIPG. Low levels of the metabolite are 
detected in the other tumour types. Literature findings support the presence of a 
prominent citrate peak in DIPG (Costello et al., 1999, Seymour et al., 2008). It is also 
reported to increase in grade II astrocytomas that show malignant progression (Blüml et 
al., 2011). 
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In cancer cells, de novo lipid and sterol synthesis is known to be enhanced with the 
support of citrate making it a key regulator of energy production (Icard et al., 2012, 
Teicher et al., 2012). However, under hypoxic conditions tumours increase glycolytic 
energy production and decrease mitochondrial function thereby favouring glycolysis 
which may explain the observed accumulation of citrate (Blüml et al., 2011).  
The close association of citrate with lipid synthesis supports the accumulation of citrate 
and low levels of lipids+MM seen in both DIPG and AA. This however suggests aerobic 
glycolysis is favoured rather than glutaminolysis but observed Lac levels for these 
tumours are low demonstrating an unclear observation. 
Glycine (Gly) 
Glycine was seen to be highest in MB and lowest in DA and PA. Reports of Gly in 
paediatric tumours are limited, however Davies et al. (2009) identify the peak as a feature 
of paediatric brain tumours with increasing levels found to be correlated with WHO 
grade. MB and GBM were found to possess the highest concentrations (Davies et al., 
2009). This cohort also demonstrates significantly elevated levels in high grade tumours. 
Gly functions as an inhibitory neurotransmitter and antioxidant (Govindaraju et al., 2000, 
Davies et al., 2009). Like Tau, Glc metabolism is diverted via 3PG for the conversion of 
serine to Gly providing several advantages for cell growth including limiting production of 
ATP and TCA cycle intermediates that may contribute to tumour pathogenesis (Locasale 
et al., 2011). The elevated levels of Gly seen in MB and its close association with Tau, 
suggests glucose is favoured as an energy source in these tumours. 
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Scyllo-inositol (sIns) 
Scyllo-inositol was found to be low in most tumours. The highest concentrations were 
seen in MB and EP. Scyllo-inositol has been previously identified as a feature in brain 
tumour spectra but not specific for any tumour type (Panigrahy et al., 2006). It has also 
been found to be associated with a poor prognosis in brain tumours (Wilson et al., 2013). 
The role of sIns is mostly unknown. Most findings in the literature report mIns as a 
precursor of sIns and so speculate it to be related to membrane synthesis and/or to the 
function of inositol phosphates as secondary messengers in cellular signal transduction 
(Swanson et al., 2003). This suggests a positive correlation between the two metabolites 
thus the findings are often reported in the context of myo-inositol metabolism (Kaiser et 
al., 2005). Evidence in the literature demonstrates sIns as a marker of poor prognosis 
(Wilson et al., 2013) whereas mIns has been found to be a marker of good prognosis 
(Castillo et al., 2000) which does not fit with the suggested positive correlation of two 
metabolites. Pearson’s correlation analysis, testing the relationship between the sIns and 
mIns in the 1.5T cohort of tumours identified no relationship (r=0.22), where 1 
determines a strong positive correlation and 0 no correlation. It could be speculated that 
these metabolites have different roles in different tumours, hence the discrepancy in 
correlation seen in cohorts of pooled heterogeneous tumours. 
Alanine (Ala) 
Alanine was detected in low levels in most brain tumours and elevated in CPP (with high 
variability) and MB. There are very few reports of Ala in paediatric brain tumours, it is 
however a known feature of adult meningiomas (Howe et al., 2003). 
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Ala is synthesised via two different routes either from glucose through the diversion of 
3PG to pyruvate and finally Ala (Locasale et al., 2011) or in the absence of glucose from 
Gln (Le et al., 2012). The elevated Ala seen in tumours is speculated to be as a result of 
the use of Gln as an energy substrate rather than glucose (Howe et al., 2003). The 
catabolism of Gln to Lac has been demonstrated to be accompanied by secretion of Ala. 
Re-routing metabolism via Gln was found to provide survival advantage for cells 
(DeBerardinis et al., 2007). Elevated Ala seen in MB is in keeping with favouring of 
glucose as an energy source. 
Guanidinoacetate (Gua) 
Guanidinoacetate was highest in MB and ATRT with low levels in PA. Gua has been 
previously seen as a feature in brain tumours. Panigrahy et al. also reported high levels of 
the metabolite in MB (Panigrahy et al., 2006). 
Gua is a precursor of Cr synthesis and its link with Cr associates increased Gua with 
malignant progression (Longo et al., 2011). While the assignment of Cr in brain tumour 
spectra is tentative, some studies have acquired spectra from patients with creatine 
deficiency syndromes. Studies have found while Cr in these patients is markedly 
decreased, a peak around 3.8 ppm speculated to be assigned to Gua is elevated 
demonstrating its close association (Bianchi et al., 2007, Schulze et al., 1997). The 
elevated Gua seen in two highly malignant tumours, MB and ATRT and decreased levels 
in a low grade tumour PA support the association with malignancy.  
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Lipids+MMs (LMM) 
Elevated levels of lipid+MMs were found in GBM and ATRT with ATRT having a 
particularly elevated peak at 1.3 ppm. Low level lipids+MMs were seen in DIPG and PA. 
Interestingly, the increase in LMM1.3 seen in EP from grade II to grade III was also 
observed (Figure 5.7b and c). A number of studies have identified the association of 
elevated lipid levels with high grade tumours and poor prognosis but they have also been 
reported as highly variable in the same tumours (Wilson et al., 2013, Panigrahy et al., 
2006). Reports in literature demonstrate high levels of mobile lipids to correlate with 
malignancy in paediatric brain tumours (Astrakas et al., 2004).  
Lipid synthesis occurs as a result of using Gln as an energy source, particularly under 
hypoxic conditions. The inverse correlation between intra-cellular Gln and mobile lipids 
has provided evidence for the link between Gln and lipogenesis (Wilson et al., 2013, 
Teicher et al., 2012). A number of metabolites including elevated Glc, increased Gln and 
decreased Glu and increase Cit link with aerobic glycolysis and in turn explain the 
elevated lipids+MMs seen in GBM and ATRT. The presence of lipids in tumour spectra 
have been identified as markers of both necrosis (Catalaa et al., 2006, Tzika et al., 2002) 
and apoptosis (Blankenberg et al., 1997, Tzika et al., 2003). Studies have demonstrated 
links to Sonic Hedgehog (SHH) pathway, which activates the Rb/E2F tumour suppressor 
complex that promotes lipogenesis (Teicher et al., 2012). 
An increasing body of evidence demonstrates that paediatric brain tumours can be 
stratified by the molecular subgroups. With the current focus on MB, it will become 
increasingly more important to link metabolic changes with genetic alterations to aid the 
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understanding of tumour pathogenesis (Taylor et al., 2012). Monitoring these 
metabolites may help in the future for the evaluation of treatment strategies. 
5.4.2 MRS as a diagnostic tool 
The use of conventional MRI in the pre-operative diagnosis of brain tumours, although 
key, is often challenging and can result in a number of differential diagnoses (Panigrahy et 
al., 2006, Panigrahy and Bluml, 2009). This highlights the need for MRI to be 
supplemented with additional methods such as MRS to aid in diagnosis.  
Significant differences in mean metabolite concentrations are seen between tumours. 
However, box and whisker plot analysis identifies no discriminatory variables 
differentiating any of the tumours often included in the differential diagnoses on MRI. 
The large number of differences in mean concentrations quantitated demonstrates 
paediatric brain tumours consist of a heterogeneous population of tumour types. While 
these findings highlight the important metabolite features of specific tumours, there is a 
great overlap in metabolite means and for some metabolites a high variability in 
concentrations within groups. This emphasises the difficulty in using this information to 
discriminate between tumour types, findings that have been a previously reported by a 
number of studies (Panigrahy et al., 2006). This provides evidence for the infectiveness of 
using single metabolites for diagnosis. Interestingly Tau, a known marker of 
differentiation between MB and All Other (Kovanlikaya et al., 2005) does not discriminate 
between MB and PA or MB and EP when using a box and whisker plot of Tau levels in this 
analysis. This is likely to be explained by the fact Tau is not observed and quantified in 
every MB in this cohort so although the presence of Tau proposes MB as a probable 
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diagnosis when assessing spectroscopy of new cases, the absence of the metabolite does 
not rule out MB as a diagnosis. This demonstrates the disadvantage of using single 
variables for discrimination. 
An alternative approach using measured concentrations plotted against either other 
metabolite concentrations or concentration ratios has been employed in other studies 
(Harris et al., 2007, Panigrahy et al., 2006). However, ratios eliminate determining the 
usefulness of metabolite used as the denominator and assume it remains unchanged. 
With more than one metabolite being used to aid discrimination it was envisaged that 
this would be a more successful method for classification. However, this has been less 
well integrated into clinical practice and practicality of the method requires testing. 
The use of simple pattern recognition methods with metabolite profiles for classification 
has proven to be a useful method for discriminating tumour groups. The success of 
multivariate analysis techniques is shown by the high classification accuracy achieved, 
thus exhibiting MRS to be more useful if all the metabolite information is used. The LDA 
plot (Figure 5.11c) provides a visual diagnostic aid showing how well cases fit in with 
other profiles of the same tumour type and the posterior probability determines how 
well the case fits with the classified group. A number of studies have used similar 
classification methods of brain tumours and reported classification accuracies (Vicente et 
al., 2013, Davies et al., 2008), for example over 80% in paediatric posterior fossa tumours 
(Davies et al., 2008).  
In a clinical setting, radiologists often qualitatively assess new patient spectra against a 
cohort of mean spectra. This has been particularly applied to the three most common 
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brain tumours (MB, PA and EP) but is increasingly being supplemented for rare tumours. 
The use of mean spectra given in the analysis may prove to be a useful diagnostic aid for 
radiologists but needs to be formally tested to prove the benefits. 
5.4.3 Scanner comparisons and quality control 
Two metabolites were found to be significantly different between the four scanners, one 
of which Gua, is a less well determined metabolite at 1.5 T. The second metabolite Cr, 
was found to be significantly higher in MB spectra acquired on the Siemens Avanto and 
GE Signa Excite. Recent evidence has shown that MB consist of heterogeneous subgroups 
that differ in prognosis (Taylor et al., 2012). With the small number of cases seen in these 
two groups, it is possible that some subtypes may have predominated on particular 
scanners and the unknown bias in the case mix may be resulting in the differences in Cr 
observed. This requires further investigation and has been preliminarily investigated and 
discussed in Chapter 7. The similarity in metabolite concentrations seen between 
scanners provides justification for combining multi-scanner datasets for increasing cohort 
numbers for analysis.  
The analysis demonstrates MRS from a heterogeneous group of tumours with varying 
concentrations of metabolites seen in each tumour type. However, evidence has shown 
that metabolite profiles between different brain tumours can overlap and spectral 
regions of the same brain tumour type can also vary (Panigrahy et al., 2006, Davies et al., 
2008). A number of studies have shown that differences in metabolic information can be 
explained by tumour location and prognosis (Wilson et al., 2013, Harris et al., 2008). It 
should be noted, for example that although PA in this analysis has been pooled as one 
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group, there are reported differences in metabolites when comparing tumour location 
and NF-1 status (Orphanidou-Vlachou et al., 2013, Harris et al., 2008).  
Out of a total of 464 spectra, 183 spectra from 130 cases were excluded from this study 
based on seven main categories of quality control. These included SNR (n=104), artefact 
or distorted peaks (n=29), Q fit (n=23), voxel positioning (n=17), broad peaks (n=8) and 
FWHM (n=2). Over half the cases (n=66) that were excluded on SNR were acquired from 
tumours that are known to exhibit a low cellularity (PA and Cranio and low grade 
gliomas). Voxel positioning was mostly problematic in PA and low grade gliomas resulting 
in 11 out of 17 being excluded for normal brain contamination or incorrect placement 
and 12 of the 29 spectra excluded as result of distortions and/or artefact peaks were 
acquired on the GE scanner. 
The experience of collecting spectroscopy data over 9 years has shown that spectra that 
fail QC do not necessarily fail as a limitation of the technique, the characteristics of the 
tumour also play a role in the results obtained. In total 66 of the cases that failed QC 
were either PA or pilomyxoid astrocytoma. PA seems to be a particularly challenging 
tumour to obtain spectra from both in terms of voxel placement due to its highly cystic 
properties and small solid components (Gan and Haas-Kogan, 2010). The low cellularity of 
low grade tumours results in spectra of low SNR making it difficult to assess the 
metabolite profile, previously also reported in a number of studies (Gupta et al., 2000, 
Harris et al., 2008). When speculating the diagnosis of low grade tumours these factors 
should be taken into consideration to determine tumour diagnosis rather than assuming 
the spectra are of no value. While having less stringent QC criteria would include these 
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cases, determining metabolite peaks would become inherently more difficult. Inevitably 
this would affect metabolite concentrations and introduce error into the analyses. It is 
important to note that MRS cannot be interpreted in isolation and should be used in 
combination with conventional MRI sequences. 
5.5 Conclusions 
This analysis consists of a large cohort of common and rare paediatric brain tumours 
where spectroscopy has been acquired pre-diagnosis on multiple scanners. The study 
includes a large range of tumour types where spectroscopy has been acquired at short 
and long echo time and two field strengths (1.5 T and 3 T). It has been established that 
single metabolite variables are unable to discriminate reliably between brain tumours 
whereas pattern recognition methods incorporating all available metabolite information 
are superior. The similarity of MB metabolite profiles has shown multi-scanner analyses 
to be a robust method for increasing cohort size. Qualitative assessment of mean spectra 
may also be a useful diagnostic aid for radiologists. The mean spectra, metabolite 
concentrations and classifier analysis constructed for brain tumours using statistical 
analysis methods provides diagnostic information that can be used alongside 
conventional MRI sequences. It should be noted that MRS should be used in combination 
with MRI. Single voxel spectroscopy is shown to be a valuable characterisation tool for 
use in paediatric brain tumours. 
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CHAPTER 6 
6 DIAGNOSING RELAPSE IN CHILDREN’S BRAIN TUMOURS USING 
METABOLITE PROFILES 
6.1 Introduction 
Brain tumours are the most common solid tumours in children (Bleyer, 1999) . Whilst 
some brain tumours have a very good prognosis, others continue to present major 
challenges and brain tumours are now the leading cause of death from cancer in children 
(Stiller C, 2007). Children who relapse following treatment for a malignant brain tumour 
commonly have a very poor prognosis. The diagnosis of relapse is made by using the 
indications from clinical course of the disease and by examining changes on imaging 
without a biopsy. However, it is well documented that changes can occur on an MRI as a 
result of treatment that may not represent tumour recurrence or progression (van den 
Bent et al., 2011). A more accurate non-invasive diagnosis of relapse would enhance the 
clinical management of these tumours (van den Bent et al., 2011, Mehta et al., 2011, 
Quant and Wen, 2011, Sundgren, 2009, Warren et al., 2000).   
The Macdonald criteria, where an increase in the size of an enhancing tumour on 
consecutive MRI scans, together with clinical assessment, has been used to determine 
tumour recurrence (Clarke and Chang, 2009, Macdonald et al., 1990). However, not all 
tumours enhance and changes in enhancement can result from treatment effects, in 
particular radiotherapy. These treatment related changes are often referred to as 
pseudo-progression and are due to secondary oedema and vessel permeability changes 
(Hygino da Cruz et al., 2011). Further challenges have arisen with the introduction of new 
therapeutic agents which alter the permeability of the blood-brain barrier and 
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demonstrate a dramatic improvement in enhancement, rather than a true tumour 
response or ‘pseudo-response’ (Batchelor et al., 2007). The recognition of pseudo-
progression, particularly in adults with high grade glioma, led to the agreement of the 
Response Assessment in Neuro-oncology criteria or RANO criteria which have also been 
extended to low grade gliomas in adults (Wen et al., 2010, van den Bent et al., 2011). The 
RANO criteria provide an improved assessment of disease progression and treatment 
response by addressing the limitations of the Macdonald criteria. However, they are still 
restricted in their ability to diagnose relapse accurately and there are currently no similar 
guidelines for diagnosing relapse which are specific to children and a need for these has 
been identified (Warren et al., 2013).  
As discussed previously, MRS has been used extensively in the assessment of brain 
tumours (Peet et al., 2012). MRS in adults has investigated the methods for diagnosis and 
evaluating tumour recurrence (Tate et al., 2006, García-Gómez et al., 2009, Julià-Sapé et 
al., 2012, Smith et al., 2009). Brain tumours in children have a different spectrum of 
disease to those diagnosed in adults (Jones et al., 2011). Potentially, MRS could be used 
to aid the identification of tumour at suspected relapse, however, the diversity of 
metabolite profiles seen across tumour types ensures that simple rules based on single 
metabolites or ratios of metabolites are unlikely to be successful in identifying relapsed 
tumour in all children (Panigrahy et al., 2006). One approach would be to use the 
metabolite profile of the tumour at diagnosis to inform the interpretation of MRS during 
surveillance but it is unknown how the metabolite profiles of brain tumours in children 
differ between diagnosis and relapse. As it is known that alterations in the biology of 
tumour cells can occur between diagnosis and relapse, for example chromosomal 
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changes accumulate in ependymomas (Puget et al., 2009) , large changes in the MRS 
profile could potentially occur and this possibility needs to be investigated.  
The main purpose of this chapter is to determine whether large changes occur in 
metabolite profiles of malignant childhood brain tumours from diagnosis to relapse and if 
so to identify these. A secondary aim was to confirm that significant differences do exist 
between the MRS of tumours at diagnosis and non-tumour lesions observed in the same 
patients at follow-up. The potential of MRS to aid the confirmation of relapse when 
added to conventional MRI and clinical course was explored. 
6.2 Method 
6.2.1 Patients 
This is a retrospective analysis from a study in which single voxel MRS was performed on 
children between July 2003 and July 2011 during routine MRI for a suspected brain 
tumour prior to treatment and at subsequent MRI where a lesion was identified. The 
inclusion criteria for this study were all children with a histologically diagnosed grade II-IV 
brain tumour that demonstrated progression or relapse and had good quality MRS. 
Diffuse pontine gliomas were excluded due to the known difficulties of identifying 
progression on conventional MRI (Hargrave et al., 2008) and the previously reported 
evolution of MRS with subsequent disease progression (Panigrahy et al., 2008). 19 
patients were identified (Table 6.1). The cohort consisted of seven different tumour types 
with a mean age of 7 years and included four glioblastoma multiforme (four male, mean 
age 11 years), 4 medulloblastomas (three male, one female, mean age 5.6 years), four 
diffuse astrocytomas (four male, mean age 8.6 years), three ependymomas one of which 
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was an anaplastic ependymoma (two male, one female, mean age 1.8 years) , two central 
nervous system primitive neuroectodermal tumours (CNS PNETs) (two male, mean age 
5.6 years), one atypical teratoid rhabdoid tumour (ATRT) (male, age 0.1 years) and one 
patient with gliomatosis cereberi (male, age 16.3 years) giving a total of 15 male and four 
female patients.  
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Table 6.1 A summary of clinical data from a cohort of 19 cases included in the MRS study. 
Abbreviations: GTR, gross total resection; SR, subtotal resection, Status D=died, A=alive 
No. Sex Diagnosis Treatment 
(prior to 
relapse) 
Surgery 
at 
diagnosis 
Relapse 
site 
Surgery 
at 
relapse 
Status No. of 
days 
follow-
up 
1 M Glioblastoma Focal 
radiotherapy and 
chemotherapy 
SR Distant None D  676 
2 M Glioblastoma Chemotherapy GTR Local None D  194 
3 M Glioblastoma Focal 
radiotherapy and 
chemotherapy 
SR Local None D  282  
4 M Glioblastoma Focal 
radiotherapy and 
chemotherapy 
SR Local None D  483 
5 M Ependymoma  Focal  
radiotherapy and 
chemotherapy 
GTR Local SR D  935 
6 F Ependymoma  Focal 
radiotherapy 
SR Local 4 surgeries 
SR 
 
D  1074 
7 F Anaplastic 
Ependymoma  
Chemotherapy SR Local None D  576 
8 M Atypical Teratoid 
Rhabdoid Tumour  
Chemotherapy SR Local None D  213 
9 F Medulloblastoma Focal 
radiotherapy and 
chemotherapy 
SR Local None  D  1245 
10 M Medulloblastoma  Cranio-spinal 
radiotherapy and 
chemotherapy 
SR Distant None D  816 
11 M  Medulloblastoma  Chemotherapy GTR Distant  None D  539  
12 F Large Cell 
Anaplastic 
Medulloblastoma  
Cranio-spinal 
radiotherapy and 
chemotherapy 
GTR Local None D  764 
13 M CNS Primitive 
Neuroectodermal 
Tumour 
Focal 
radiotherapy and 
chemotherapy 
SR Distant SR D  465 
14 M Supratentorial 
Primitive 
Neuroectodermal 
Tumour 
Chemotherapy Biopsy Distant None D  596 
15 M Diffuse 
Astrocytoma 
Focal 
radiotherapy and 
chemotherapy 
Biopsy Local  None D  571 
16 M Diffuse 
Astrocytoma 
Chemotherapy SR Local None A  2268 
17 M Diffuse 
Astrocytoma 
Focal 
radiotherapy and 
chemotherapy 
Biopsy Distant None D   756 
18 M Diffuse 
Astrocytoma 
Chemotherapy SR Local None D  170 
19 M Gliomatosis 
Cerebri 
Radiotherapy and 
chemotherapy 
Biopsy Distant None D  227 
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Following the MRI at presentation, all patients underwent surgery. Following surgery, an 
MRI scan was performed within one to three days and formal radiological reporting 
together with review in a multi-disciplinary team meeting was used to determine the 
extent of tumour excision (gross total or subtotal resection). Four had a gross total 
resection by surgical opinion and post-operative MRI, 11 had a subtotal resection and 
four had a biopsy for diagnosis alone. All children underwent adjuvant treatment with 
either focal or craniospinal radiotherapy and/or chemotherapy depending on their 
tumour type and prognostic stratification (Table 6.1).  
6.2.2 Assessment of disease progression 
Disease progression confirmation in the cohort was taken as the decision made by the 
neuro-oncology multi-disciplinary team from a combination of clinical and radiological 
features. The criteria were that progression is diagnosed if there is an increase in the size 
of the tumour of more than 25% measured in two dimensions on the MRI scan; the 
appearance of tumour in a previously uninvolved area or clear clinical evidence of disease 
progression in combination with an equivocal MRI. Follow-up scans were then performed 
every one to three months depending on case scenario to determine patient status. MRS 
was performed if a lesion, either local or distant to the tumour identified at diagnosis, 
was large enough for SVS (>1.5 cm3). During suspected tumour relapse, MRS processed 
by the scanner was made available to the clinical multi-disciplinary team and qualitatively 
analysed by them. However, a quantitative comparison with the diagnostic MRS was not 
made available. If the consensus decision was that the patient demonstrated tumour 
relapse, optimal treatment strategies were discussed. Neurosurgery at relapse was only 
performed if it was felt to be beneficial to the patient taking account of outcome and 
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quality of life. Only three cases had surgical intervention at first relapse for comparison 
with histopathological diagnosis at presentation. In all cases, the histology was in keeping 
with that at diagnosis. At the end of the study 18 patients had died of disease progression 
and one patient was alive with stable disease. The mean time from diagnosis to relapse 
was 15 months and mean time from diagnosis to death was 19 months.  
6.2.3 MRS acquisition and quantitation of metabolite concentrations and lipid 
intensities 
MRS was carried out on a 1.5 T MR scanner (GE Excite, Siemens Symphony or Siemens 
Avanto) after conventional MRI. A single voxel MRS protocol was used with PRESS 
localisation, TE time of 30 ms and TR of 1500 ms. A water unsuppressed acquisition was 
also acquired as a concentration reference. Cubic voxels were used with either 2 cm or 
1.5 cm side length and 128 or 256 repetitions acquired, respectively. Voxel placement 
was entirely within the tumour as delineated by the conventional MRI with the enhancing 
component maximised. Local relapses were at the site of the primary tumour, whilst 
distant relapses were taken to be at any other location. All spectra were assessed using 
the QC criteria (section 4.3). In addition to the 19 cases included, one case was excluded 
due to unstable baseline on the relapse MRS. 
6.2.4 Statistical analysis 
Metabolite concentrations (mM) were quantified using TARQUIN (version 3.2.2) (Wilson 
et al., 2011). Statistical analysis excluded aspartate and GABA. The lipid and 
macromolecular components were included in the analysis as both individual 
components so  lipids at 1.9 ppm (L0.9),  sum of lipids at 1.3 ppm so  lip1.3a+lip1.3b 
(L1.3), lipids at 2.0 ppm (L2.0) and as combined components with macromolecules at 0.9 
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ppm (LMM0.9), 1.3 ppm (LMM1.3) and 2.0 ppm (LMM2.0).  A power analysis calculation 
showed that 19 samples would detect a large effect size (Cohen d=0.68) for a two tailed 
paired t-test at a significance level of 0.05 with a power of 0.8. Paired Student’s t-tests 
were performed to investigate differences between metabolite profiles at diagnosis and 
relapse. The comparison was also performed separately for local and distant relapse. Box 
and whisker plots were constructed for differences between absolute concentrations of 
variables at diagnosis and relapse. Line plots were constructed to visualise differences 
between levels of four main variables (tCho, mIns, NAA and lipids at 1.3 ppm) at diagnosis 
and relapse. Wilcoxon signed rank test was used for the paired analysis of metabolites in 
non-tumour lesions at follow-up and tumours at diagnosis due to the smaller numbers of 
cases and lack of information on the Gaussian nature of the distribution. 
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6.3 Results  
Table 6.2 Mean metabolite concentrations for diagnosis vs. relapse (n=19), diagnosis vs. local relapse 
(n=12) and diagnosis vs. distant relapse (N=7), showing no significant differences between any of the 
three groups using a two-tailed Student’s t-test (n.s, not significant).  
Mean metabolite concentrations(mM)  
Metabolite P  values Diagnosis vs. relapse at any 
location 
Diagnosis vs. local 
relapse 
Diagnosis vs. distant 
relapse 
Ala n.s 0.27 vs. 0.37 0.32 vs. 0.48 0.20 vs. 0.18 
Cit n.s 0.64 vs. 1.10 0.79 vs. 1.32 0.39 vs. 0.71 
Cr n.s 2.73 vs. 3.14 2.53 vs. 2.66 3.08 vs. 3.96 
PCh + GPC n.s 1.98 vs. 1.99  1.78 vs. 1.73 2.31 vs. 2.45 
GPC n.s 1.25 vs. 1.24 1.16 vs.1.19 1.39 vs. 1.34 
PCh n.s 0.73 vs. 0.75 0.62 vs. 0.54 0.92 vs. 1.11 
Glc n.s 1.82 vs. 1.31 1.74 vs. 1.28 1.97vs. 1.35 
Gln n.s 3.19 vs. 3.02 3.88vs. 3.21 2.01 vs. 2.72 
Glu n.s 2.16 vs. 2.84 2.22 vs. 2.42 2.01 vs. 3.57 
Glu + Gln n.s 5.35 vs.5.87 6.10 vs. 5.62 4.06 vs. 6.29 
Gly n.s 2.20 vs. 2.11 2.42 vs. 2.33 1.83 vs. 1.74 
Gua n.s 0.61 vs. 0.68 0.62 vs. 0.70 0.59 vs. 0.65 
mIns n.s 2.81 vs.3.01 2.75 vs. 3.87 2.90 vs. 1.54  
Lac n.s 2.16 vs.1.67 2.62 vs. 2.35 1.37 vs. 0.51 
sIns n.s 0.30 vs. 0.35 0.31 vs. 0.36 0.28 vs. 0.32 
Tau n.s 1.02 vs. 0.94 0.55 vs. 0.74 1.83 vs. 1.28 
NAA+NAAG n.s 1.27 vs. 1.54 1.15 vs. 1.25                             1.48 vs. 2.03 
LMM0.9 n.s 6.61 vs.7.95 7.30 vs. 8.90 5.43 vs. 6.33 
L 0.9 n.s 3.32 vs. 3.78 4.01 vs. 3.98 2.13 vs. 3.44 
MM 0.9 n.s 3.29 vs. 4.17 3.29 vs. 4.91 3.30 vs. 2.90 
LMM1.3 n.s 15.32 vs. 19.13 19.83 vs. 22.69 7.60 vs. 13.52 
L1.3 n.s 13.32 vs.16.44 17.30 vs. 18.52 6.50 vs. 12.87 
MM 1.3 n.s 2.00 vs. 2.88 2.53 vs. 4.17 1.01 vs. 0.65 
LMM2.0 n.s 10.30 vs. 9.66 11.28 vs. 9.44 8.63 vs. 10.05 
L2.0 n.s 3.70 vs. 3.07 4.48 vs. 2.94 2.36 vs. 3.28 
MM 2.0 n.s 6.61 vs. 3.36 6.80 vs. 6.49  6.27 vs. 6.77 
No significant differences in metabolites or lipids and macromolecules were found 
between diagnosis and relapse (n=19) (P>0.05, paired Student’s t-test). Sub-group 
analyses of local relapse (n=12) and distant relapse (n=7) also showed no significant 
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differences in metabolites or combined and individual macromolecules and lipid 
components in either of these two groups (P>0.05, paired Student’s t-test). However, 
lipids at 1.3 ppm were close to significance (6.5 vs. 12.9, P=0.07) in the group where MRS 
was of a distant relapse (Table 6.2) 
In addition, no significant differences (Student’s t-test, P>0.05) were found when 
comparing MRS at diagnosis and relapse in specific tumour types. The tumour types 
tested were those that had four or more cases per tumour type, glioblastomas (n=4), 
medulloblastomas (n=4) and diffuse astrocytomas (n=4).  
 
Figure 6.1 Box and whisker plots of a) the differences in metabolite concentration at diagnosis and 
relapse and b) difference in lipid and macromolecular concentrations at diagnosis and relapse (n=19). 
Differences in metabolite, lipid and MM levels at diagnosis and relapse are demonstrated 
in Figure 6.1 as a box and whisker plot. Although there are some metabolites which 
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change by a large amount from diagnosis to first relapse, there are no tumours for which 
this occurs for several metabolites, lipids or macromolecules indicating that for all 
tumours, the majority of the MRS profile is the same at relapse as at diagnosis.  
Figure 6.2 Line plots of changes in metabolite concentration levels at diagnosis and relapse for 
individual patients a) tCho b) NAA c) mIns and d) lipids at 1.3 ppm. 
Figure 6.2 shows changes in metabolite concentrations from diagnosis to relapse for four 
main variables, tCho, NAA, mIns and lipids at 1.3 ppm. Again, for most cases there is little 
change in the levels of these metabolites between diagnosis and relapse. However, for a 
small number of cases there is a large change in a specific metabolite. 
For five of the cases, the MRS indicated the presence of tumour prior to a diagnosis of 
relapse being made by the multi-disciplinary team using clinical information, conventional 
MRI and histology where available. The median time from MRS indicating the presence of 
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tumour to diagnosis of relapse was three months in these five cases. Four of the cases 
were astrocytomas and one was an ependymoma.   
 
Figure 6.3 Comparison of MRS acquired from a brain tumour a) pre-diagnosis with an insert of a 
coronal T1 weighted image showing the voxel location and b) MRS obtained from the same tumour at 
relapse from a distant site with an insert of a T1 weighted imaging showing the voxel location (Case 1).  
Figure 6.3 demonstrates the similarity of MRS at diagnosis and distant relapse in a patient 
with glioblastoma multiforme who had two surgical resections followed by radiotherapy. 
Tumour progression was seen at 536 days. An additional MRI was performed following 
radiologically confirmed progression at 654 days at two different distant tumour sites. 
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Figure 6.4 Evolution of MRS of an ependymoma at a) diagnosis and b) after subsequently confirmed 
relapse with inserts of a sagittal MRI images including voxel location for both spectra (Case 6). 
Figure 6.4 illustrates spectra from a patient with multiply relapsed ependymoma. After 
diagnosis, the patient underwent surgical resection followed by focal radiotherapy but 
later developed local tumour progression. This patient had four surgical resections, two 
at diagnosis, one at first relapse and another at a subsequent relapse. Diagnosis at initial 
presentation was grade II ependymoma, but at first and second relapse the tissue 
samples were increasingly cellular and demonstrated an increasing proliferative rate. The 
final sample was suggestive of an anaplastic ependymoma (grade III). Spectroscopy was 
performed at each relapse with the last 908 days after diagnosis. The spectra show high 
levels of mIns and low levels of lipids at first relapse in keeping with the MRS at diagnosis 
(Figure 6.4a) but a decline in mIns and an increase in lipids on the last spectrum (Figure 
6.4b). 
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Figure 6.5 Comparison of MRS acquired from a patient with a classic medulloblastoma a) pre-diagnosis 
showing elevated tCho and Tau and b) from the same patient after completion of treatment with 
surgery, chemotherapy and radiotherapy in a region with pseudoprogression with a c) T1 weighted 
post contrast axial image showing location of voxel corresponding to spectrum in 5a and d) T1 
weighted post contrast axial image showing an enhancing lesion in the posterior fossa with the 
position of the voxel indicated which corresponds to spectrum 5b. 
In addition to the cases where relapse occurred, a further five cases had MRS at diagnosis 
and of a lesion which appeared post treatment but where extended follow-up confirmed 
that they were not relapsed tumour. The MRS in all these cases was very different on 
visual inspection from the MRS at diagnosis. An example is presented in Figure 
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6.5.Analysis of nine MRS profiles during surveillance paired with the MRS at initial 
diagnosis showed a significantly higher tCho, Gly, Lac and Tau at initial diagnosis 
(Wilcoxon signed rank test, P<0.05). 
6.4 Discussion 
This analysis investigated metabolite profiles of childhood brain tumours at diagnosis and 
suspected first relapse at either local and/or distant sites using short echo time MRS and 
found no significant differences in any metabolite, lipid or macromolecule level with a 
paired Student’s t-test. In five cases there was diagnostic uncertainty based on the clinical 
and conventional MRI appearances with relapse only being confirmed one to six months 
later. MRS profiles of brain tumours recorded at diagnosis for these cases helped to 
confirm relapse prior to MRI and therefore has the potential to aid the diagnosis of 
relapse.  
In adults with gliomas, simple ratios of metabolites such as tCho/Cr or tCho/tNAA are 
used to identify tumour (McKnight et al., 2007). However, paediatric neuro-oncology 
practice is not dominated by one single tumour type and a number of studies 
characterising metabolite profiles of paediatric brain tumours have identified key 
differences depending on the diagnostic subtype (Davies et al., 2008, Panigrahy et al., 
2006, Harris et al., 2008). This study implies that for paediatric brain tumours, the MRS at 
diagnosis would be a useful aid in identifying tumour on follow-up scans. In any given 
case, a small number of metabolite values may change substantially from diagnosis to 
relapse but the overall pattern of metabolite levels tends to be very similar. 
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Whilst this study shows that metabolite profiles are similar at first relapse to diagnosis, 
there are some indications that alterations towards a more aggressive metabolite 
phenotype can occur in some circumstances. It might be expected that the greatest 
changes are seen in the distant relapses and there is a tendency towards higher lipids in 
these cases although this is not significant (P=0.07). The tendency for the MRS changes to 
be small from diagnosis to relapse even when the relapse is at a distant site are 
illustrated by case 1 which had both a local and a distant relapse (Figure 6.3). It may be 
expected that changes in tumour metabolite profiles accumulate over time and there is 
evidence for this in case 6 (Figure 6.4) which had subsequent relapses and showed 
evolving changes in the MRS profiles mirroring changes in histology. The decreasing mIns 
and increasing lipids at subsequent relapses are consistent with this evolution of grade. 
MRS of grade II ependymoma (Figure 5.7b) tend to have a prominent mIns peak seen at 
3.6 ppm, in keeping with studies of adults with gliomas where there are trends towards 
lower levels of mIns at higher grade (Figure 6.4) (Castillo et al., 2000, Harris et al., 2008, 
Davies et al., 2008, Panigrahy et al., 2006). In addition, a number of previous studies have 
investigated the levels of lipids in paediatric brain tumours and found mobile lipids to 
correlate with malignancy across a range of paediatric brain tumours and associated 
them with necrosis, which is a histological characteristic of high grade tumours (Peet et 
al., 2007a, Sibtain et al., 2007a, Astrakas et al., 2004). Similar changes in MRS are likely to 
occur in tumours which are known to change from low to high grade as the disease 
progresses and this is consistent with findings for diffuse intrinsic pontine glioma 
(Panigrahy et al., 2008). 
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Whilst this study has established that the MRS of relapsed children’s brain tumours is 
very similar to that at diagnosis, the degree of certainty with which MRS can be used to 
diagnose relapse also depends on the MRS characteristics of other lesions in the brain 
occurring in these patients. It is therefore reassuring that significant differences were 
seen in several metabolites between the MRS of tumours at diagnosis and non-tumour 
lesions observed in the same patients at follow-up. The feature of elevated lipids 
observed is likely to be as a result of radiation necrosis (Tzika et al., 2003).Caution does 
need to be taken when interpreting the spectra in these circumstances, in particular it is 
important to ensure that the voxel does not contain significant amounts of normal brain 
and that the spectra meet the quality control criteria. 
It is encouraging that MRS was able to detect recurrent tumour in several cases where 
the clinical scenario and the conventional MRI were not able to diagnose relapse with 
confidence. The spectra was made available to the multidisciplinary team as part of their 
clinical information during the study and it may be that there were cases where MRS 
aided the diagnosis of relapse, although data was not collected systematically on this. It is 
interesting that none of the cases where MRS indicated the presence of tumour early 
were medulloblastomas or other primitive neuroectodermal tumours. Certainly, 
diagnostic dilemmas following treatment have been best documented in gliomas and it 
may be that post treatment abnormalities which mimic tumour on conventional MRI are 
rarer in primitive neuroectodermal tumours although this may change with increasing 
intensity of treatment in those with high risk disease (van den Bent et al., 2011, Clarke 
and Chang, 2009).  
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Analysis of MRS which includes the comparison of MRS at follow-up with that at diagnosis 
is now routinely used to inform the clinical decision making for these patients at the 
Birmingham Children’s Hospital in combination with clinical information and conventional 
MRI. The role of other modalities such as perfusion imaging also warrant investigation 
although this technique is not as well established in children as it is in adults. The 
optimum combination of imaging techniques is yet to be formally established. 
6.5 Conclusions and future investigations 
This chapter’s analysis found that the MRS metabolite profile of a child’s brain tumour 
(grade II-IV) was not significantly different at first relapse to that at diagnosis, therefore 
aiding the confirmation of the presence of tumour on follow-up MRI. This finding is 
particularly relevant to the clinical management of these children given that radiotherapy 
and chemotherapy are known to cause abnormalities on MRI which are difficult to 
distinguish from recurrent tumour. A large multi-centre study should be undertaken to 
clearly define the role of MRS in distinguishing tumour relapse from treatment related 
effects and its added value compared with conventional MRI and other imaging 
modalities. 
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CHAPTER 7 
7 NOVEL BIOMARKERS OF PROGNOSIS FOR MEDULLOBLASTOMA USING 
1H MAGNETIC RESONANCE SPECTROSCOPY  
7.1 Introduction 
Medulloblastoma (MB), a common primitive neuroectodermal tumour arising from the 
cerebellum is a major cause of morbidity and mortality in paediatric neuro-oncology. The 
classification of MB is performed on histopathology with five main variants of the disease 
including classic medulloblastoma, desmoplastic/nodular medulloblastoma, 
medulloblastoma with extensive nodularity, anaplastic medulloblastoma and large cell 
medulloblastoma with the last two more commonly grouped as one. Since 1969 these 
tumours have additionally been staged through the Chang classification, from M0 to M4. 
M0 describes a local tumour expansion with no evidence of metastases; M1 includes 
identification of tumour cells in the cerebrospinal fluid; M2 describes spread to other CNS 
areas; M3 includes gross nodular seeding in the spinal cord and finally M4 includes 
widespread metastases in particular outside the CNS (Kim et al., 2011) thus 
demonstrating a heterogeneous population of tumours. This staging and subsequent risk 
stratification is crucial in the management of MB. 
Current MB risk stratification identifies three clinical characteristics associated with 
prognosis; patient age at diagnosis, extent of surgical resection and evidence of 
metastatic disease (de Haas et al., 2008). Patients below the age of three years, with 
residual disease greater than 1.5 cm3 and metastatic disease are associated with high risk 
and poor prognosis. However, patients older than three years with minimal or no residual 
disease and no evidence of metastatic disease are associated with lower risk and a more 
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favourable prognosis (Kim et al., 2011, Carlotti et al., 2008). Histopathologically, it has 
long been known that the desmoplastic variant of medulloblastoma is associated with a 
better prognosis, whereas a large-cell anaplastic variant is associated with a shorter 
survival. In addition, a number of molecular markers have been identified over the last 
decade that has lead to further work and interest into medulloblastoma risk-stratification 
with a biological basis (Monje et al., 2011). 
More recently, wide scale genomic and gene expression analysis have identified multiple 
signalling pathways to be associated with the growth and development of MB providing 
evidence for a genetically heterogeneous population (Carlotti et al., 2008, Taylor et al., 
2012). The current consensus is that MB falls into four main molecular subgroups; WNT, 
SHH, Group 3 and 4 named after the signalling pathway thought to play a dominant role 
in the pathogenesis of the group. Each subgroup differs by patient demographic, genetics 
and clinical outcome. The WNT subgroup of MBs, thought to driven by the WNT signalling 
pathway is the best understood. The subgroup is mostly associated with a classic 
morphology and a very good prognosis when compared to the other groups. The SHH 
subgroup initiated by the Sonic Hedgehog pathway consists mainly of 
desmoplastic/nodular MB with a good to intermediate prognosis. Group 3 demonstrates 
a high expression of MYC amplification and consists of classic MB but pre-dominantly 
large cell MB. The group is associated with metastatic disease and increased disease 
recurrence thereby a poor prognosis. Group 4 has a less clear molecular pathology and is 
the least understood out of the subgroups however demonstrates enough difference to 
be grouped separately. Those that fall in this group demonstrate an intermediate risk. 
Multiple publications have recognised an increased expression of genes involved in 
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neuronal differentiation and neuronal development (Guessous et al., 2008, Gilbertson et 
al., 2001, Taylor et al., 2012). There is increasing interest in understanding how changes 
in metabolite profiles are correlated with genetic alterations and how they are related to 
metabolic pathways and provide information on tumour pathogenesis. 
Generating a more accurate and precise stratification system will allow for greater 
discrimination between high-risk and standard-risk groups. Magnetic resonance 
spectroscopy is known to provide non-invasive biomarkers of tumour aggressiveness but 
studies are lacking in elaborating on specific tumour types and with long term follow-up 
for survival. This chapter investigates whether metabolite differences in children with MB 
can identify prognostic biomarkers by investigating metabolite differences as a function 
of survival time. 
7.2 Method  
7.2.1 Patients 
Single voxel 1H MRS was performed on 42 children between January 2003 and July 2011 
during routine MRI scans for a suspected brain tumour prior to treatment at the 
Birmingham Children’s Hospital. Following QC (section 4.3), the cohort included three of 
the medulloblastoma variants: classic MB (n=32), desmoplastic/nodular MB (n=2) and 
large cell MB (n=2). The cohort consisted of Chang stages M0 to M3 of which 18 patients 
were staged as M0, four as M1, four as M2 and 10 as M3. The mean age at diagnosis for 
the whole cohort was 7±3.7 years (mean ± SD) (Figure 7.3). Maximum patient follow-up 
was 8.5 years with an average of follow up of three years. 
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Table 7.1 Patient demographics of the medulloblastoma cohort. Abbreviations: M, Male; F, Female; 
MB, medulloblastoma; DN MB, desmoplastic nodular medulloblastoma; LC MB, large cell 
medulloblastoma; D, died; A, alive; U, unknown. 
Case Sex Diagnosis Chang stage Age at diagnosis Status No. of days follow up Tumour size(cm
3
) 
1 F MB M0 8.5 A 501 12.2 
2 M MB M0 7 A 2287 U 
3 M MB M0 4.6 U U 100 
4 F DN MB M0 2 A 511 44.1 
5 M MB* M0 4.9 D 477 12.16 
6 M MB M0 4.1 D 279 84.28 
7 M MB M0 13.8 D 932 62.8 
8 F MB M0 7.1 D 1245 97.02 
9 M MB M0 10.9 A 1985 88.9 
10 M MB M0 6.1 A 414 124.2 
11 M MB M0 10.1 A 1025 100.8 
12 M MB M0 12.4 A 823 36.2 
13 M MB M0 4 A 389 U 
14 F MB M0 1.75 A 366 76.5 
15 M DN MB M0 12.75 A 1514 U 
16 F MB M0 4 A 2723 32.19 
17 M MB M0 2.4 D 790 77.57 
18 F LC MB M0 8.4 D 764 70 
19 M MB M1 2.8 D 416 70.84 
20 M MB M1 3.4 A 1724 U 
21 M MB M1 5.4 A 2532 52 
22 M MB M1 3.25 D 307 12.67 
23 M MB M2 10.4 D 1155 U 
24 M MB M2 12 D 1561 12.16 
25 F LC MB M2 15 D 736 62.58 
26 M MB M2 8.1 D 2436 33 
27 M MB M3 8.5 A 364 94 
28 M MB M3 11 D 464 23.6 
29 F MB M3 11.4 A 3103 U 
30 M MB M3 5.75 D 1737 103.68 
31 F MB M3 6.3 A 1769 74.8 
32 M MB M3 5.9 A 1624 U 
33 M MB M3 5 D 727 U 
34 M MB M3 4.9 D 550 70.17 
35 F MB M3 2.5 A 595 U 
36 F MB M3 4 D 507 16.9 
 
Note: - * Medulloblastoma with Rhabdomyoblastic Differentiation 
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7.2.2 MRS acquisition and quantitation of metabolite concentrations and lipid 
intensities 
Single voxel MRS was carried out after conventional MRI prior to treatment on a 1.5 T MR 
system (GE Excite, Siemens Symphony or Siemens Avanto). Core protocol consisted of TE 
30 ms and TR 1500 ms. Cubic voxels were either 2 cm or 1.5 cm side length with 128 or 
256 repetitions acquired respectively. Voxel placement delineated using conventional 
MRI was on the primary tumour. 
 Metabolite concentrations were determined using TARQUIN (version 3.2.2 with 
extended basis set) (Wilson et al., 2011). The lipid and macromolecular components were 
included in the analysis as individual components with the lipids at 1.3 ppm as 
lip1.3a+lip1.3b (L1.3) summed and as combined components at 0.9 ppm (LMM0.9), 1.3 
ppm (LMM1.3) and 2.0 ppm (LMM2.0). All spectra were assessed using the QC criteria 
(section 4.3). From the 42 MRS studies performed, 36 met the quality control criteria with 
two cases failing due to inappropriate voxel location and four for distortions within the 
spectra.  
7.2.3 Statistical Analysis 
35 out of the 36 cases had follow-up data available. 17 of these patients developed 
tumour progression and subsequently died as a result. The mean time from diagnosis to 
last follow-up or death was 1123 days. Mann-Whitney U-test (Mann and Whitney, 1947) 
was performed to compare metabolite concentrations of MB patients currently alive 
(n=18) with those that had progressed and died (n=17). With 23 variables tested, a 
Bonferroni corrected significance of 0.002 (P<0.002) was calculated. Survival analysis 
(using R package survival) was performed using Cox-Regression modelling (Cox, 1972) 
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using a multivariate and univariate approach. Cox-Regression was performed on each 
quantified metabolite and using a multivariate model of survival with model 
simplification performed using backward elimination. Following this, the most significant 
metabolites from the univariate analysis were used to construct a model based on the 
linear co-efficients and an optimal cut-off determined using a ROC curve. The AUC was 
also reported for each ROC curve (Egan, 1975). Kaplan-Meier curves (Kaplan and Meier, 
1958) were constructed for significant metabolites in the univariate analysis and the 
combined model using a ROC cut-off. Each Kaplan-Meier curve was tested using a log-
rank test (Mantel, 1966) for significant differences in survival.  
Cox-Regression analysis was performed on other factors in particular those that are used 
in treatment stratification. These included testing patient gender (male vs. female), 
extent of resection (complete resection vs. near complete resection (<1.5 cm3) vs. 
incomplete resection (>1.5 cm3), age at diagnosis (< 5 years vs. > 5 years) and Chang stage 
(M0 vs. M1-M3 and M0 vs. M1 vs. M2 vs. M3 and M0-M1 vs. M2-M3) for prognostic 
variables. These were also tested using Kaplan-Meier curve analysis and log-rank test for 
significance. 
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7.3 Results 
7.3.1 Spectral features 
 
Figure 7.1 Mean spectral profiles for a) M0 MB (n=17) b) M1 MB (n=4) c) M2 MB (n=4) d) M3 MB 
(n=10) with standard deviations indicated by the shaded regions. Embedded arrow indicates variable 
LMM1.3 region. 
Figure 7.1 illustrates mean spectra from the whole cohort split into their respective 
Chang stages, M0 to M3. The spectra, in general, exhibit very similar metabolite profiles 
but there are a few differences to be noted that could be of interest. For example, the 
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M0 spectra exhibit a more variable metabolite profile compared to the other Chang 
stages, which is shown by high standard deviations indicated by the shaded region. In 
addition to this the LMM1.3 region of the spectra appears to differ between Chang 
stages.  
 
 Figure 7.2 Box and whisker plot of levels of lipid+MMs at 1.3 ppm (LMM1.3) for Chang stages M0-M3 
Figure 7.2 demonstrates Chang stages M0 to M3 to have similar levels of LMM1.3. 
Interestingly, the M0 cohort consists of three cases with very high levels of LMM1.3, 
represented as outliers on the box and whisker plot. All three patients developed tumour 
progression soon after diagnosis and died within a short follow-up period. 
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7.3.2 Univariate analysis 
Table 7.2 A summary of mean metabolite concentrations (mM ± SD) comparing MB currently alive and 
MB that died of tumour progression using Mann-Whitney U-test. Significant metabolites are 
highlighted in bold. 
 
 
 
Significantly lower levels of Cr and Gua were seen in those patients that developed 
tumour progression and died as a result (Mann Whitney U-test analysis, P=0.02 and P 
=0.04 respectively). No other metabolites were significant including tCho (P=0.15) (Table 
7.2). 
7.3.3 Survival Analysis 
Table 7.3 A summary of univariate survival hazard ratios and p values of those metabolites that were 
significant when tested using a likelihood ratio test (P<0.05).  
Metabolite Hazard 
ratio 
P value 
tCho 0.611 0.008 
MM20 0.724 0.02 
Cr 0.64 0.03 
 
Table 7.4 A summary of metabolites included in the final stepwise Cox-Regression model with survival 
hazard ratios and significance values. The likelihood ratio test was used for testing the significance of 
the model. 
Metabolite Hazard ratio P value 
Cr 0.602 0.03 
tCho 0.580 0.01 
Likelihood ratio test p value=0.002 
Cr, tCho and macromolecules (MMs) at 2.0 ppm from the univariate model were found to 
be significant predictors of survival based on the likelihood ratio test. Subjects with 
higher values of the variables were associated with a lower hazard (Table 7.3). Cr and 
tCho were the only significant metabolites in the stepwise Cox-Regression model with 
Metabolites (mM) p values MB currently alive (n=18) MB died (n=17) 
Cr 0.02 3.42+1.5 2.56+1.0 
tCho 0.15 3.98+1.7 3.16+1.4 
Gua 0.04 1.24+0.9 0.67+0.6 
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higher values associated with lower hazard P=0.002 for the final model (Table 7.4). The 
combination of Cr, tCho and MMs at 2.0 ppm yielded a highly significant model when 
tested using the likelihood ratio test (P=0.003). The area under the ROC curve (AUC) for 
Cr, tCho, MMs at 2.0 ppm and combined model was 0.73, 0.64, 0.61 and 0.76 
respectively. 
 
Figure 7.3 Kaplan-Meier survival distributions for a) Cr b) tCho c) MM at 2.0 ppm and d) a combined 
model of the linear co-efficients of Cr, tCho and MM at 2.0 ppm. Cut-offs were determined using ROC 
curves and significance values (P) tested using a log-rank test.                                         
The corresponding Kaplan-Meier curves demonstrated significant differences in survival 
for Cr (P=0.003), MMs at 2.0 ppm (P=0.00002) and near significance for tCho (P=0.06) 
with lower values of the three variables having a worse survival. A combined model of 
metabolites was also significant (P=0.0009) (Figure 7.3). 
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Figure 7.4 Kaplan-Meier survival distributions for a) patient gender (F vs. M) b) extent of tumour 
resection (complete resection vs. near complete resection (<1.5 cm3) vs. incomplete resection (>1.5 
cm3) c) age of patient at diagnosis (≤5 vs. >5) and d) Chang stage ((M0+M1) vs. (M2+M3)). Significance 
values were tested using log-rank test. Abbreviations: F, Female; M, Male.  
Cox-Regression modelling of clinical characteristics exhibited no significant variables 
when comparing gender, extent of resection and Chang stage. Age at diagnosis was the 
only significant variable (≤5 years vs. >5 years, likelihood ratio test, P=0.03). Kaplan-Meier 
curve analysis confirmed no significant variables amongst patient gender (P=0.4), extent 
of resection (P=0.1) and Chang stage (M0 vs. M1-M3, p=0.8 and M0 vs. M1 vs. M2 vs. M3, 
P=0.5 and M0-M1 vs. M2-M3, P=0.5). Age at diagnosis was significant (P=0.02) with 
young patients below the age of five doing worse (Figure 7.4). Patients below the age of 
five had significantly lower tCho (P=0.004) and Gly (P=0.03). 
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7.4 Discussion 
This analysis has shown that metabolites detected non-invasively using 1H MRS are 
prognostic biomarkers in paediatric cohorts of patients with MB. Cr and tCho have been 
identified to be significant prognostic markers in these tumours with decreased levels 
associated with a poor prognosis. This study also found using a combinatorial model of 
metabolite markers Cr, tCho and MM at 2.0 ppm was able to predict survival of MB 
patients (Figure 7.3). 
Creatine, often reported as tCr due to contributions from two compounds, creatine and 
phosphocreatine (PCr) is an organic acid that is an essential component of energy 
metabolism and marker of the energy state of cells (Martinez-Bisbal and Celda, 2009). Cr 
metabolism occurs through the creatine/creatine kinase system where Cr, through PCr, 
provides phosphate for ATP catalysed by the enzyme creatine kinase. It is hypothesised 
that the down regulation of creatine kinase is responsible for the decrease in creatine in 
tumours and therefore is the likely pathway utilised in tumourgenesis (Patra et al., 2012). 
There is reported evidence of low creatine concentration in several malignant cell types 
(Davies et al., 2008, Martinez-Bisbal and Celda, 2009, Panigrahy et al., 2006). Yerli et al. 
demonstrated that tCr levels tended to be lower in high grade populations (Yerli et al., 
2007). Tzika et al. found tCr to be the strongest predictor of active tumour in their study 
(Tzika et al., 2001). The current understanding is that very malignant active tumours have 
a high metabolic rate of activity that results in hypoxia and depletion of energy stores 
which results in decreased levels of creatine in tumours (Rao, 2008, Tzika et al., 2001). 
However, it is difficult to differentiate Cr and PCr using the field strength of clinical 
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scanners. It is unclear from the measure of tCr whether this mechanism is driven by 
increased expression of creatine kinase or decreased creatine kinase as either will result 
in the decrease of one metabolite and increase of another (Patra et al., 2012) . 
The tCho signal resonances seen in MRS consist of three major components; 
phosphocholine (PCh), glycerophosphocholine (GPC) and free choline. It is well known 
that choline containing compounds are involved in cell membrane synthesis and 
breakdown and during malignant transformation this process becomes abnormal 
(Astrakas et al., 2004). Tumours that exhibit high levels of tCho are usually associated 
with increased cell proliferation, aggressive tumours and poor outcome. Previous 
literature MRS studies have demonstrated increased levels of tCho to be associated with 
increased tumour grade (Astrakas et al., 2004, Loening et al., 2005) but not always for 
example paediatric optic pathway gliomas despite being low grade tumours exhibit 
elevated tCho (Orphanidou-Vlachou et al., 2013). Though an increased tCho 
concentration is usually associated with a poor prognosis, this result does not fit the 
expected trend. However, it should be noted that the field strength of clinical scanners 
cannot separate out the major peak components and it is the proportion of contribution 
of these metabolites that better explains the results observed. Previous literature 
findings have demonstrated that tumours with a greater contribution of PCh than GPC 
seen for the tCho peak are correlated with oncogenic and malignant transformation and 
as a result have a more aggressive course (Hattingen et al., 2008a, Podo, 1999).  
The assignment of MMs at 2.0 ppm as a prognostic marker although of importance, is 
difficult to determine accurately. This region of the spectra in vivo overlaps highly with 
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other metabolites for example Glu, Gln, lipids and macromolecules. The accurate 
assignment of the prognostic marker in this region will be best determined using in vitro 
high-resolution spectroscopy methods such as magic angle spinning (HR-MAS) (Wilson et 
al., 2009a). 
ROC curves are often used in medical diagnostics to develop clinical decision making 
tools. Previous studies have reported results using this method for MRS to aid diagnosis, 
prognosis and treatment monitoring in paediatric brain tumours (Harris et al., 2007, 
Orphanidou-Vlachou et al., 2013, Smith et al., 2009, Astrakas et al., 2004, Marcus et al., 
2007). The advantage of using this method is that it provides a numeric threshold that 
can be interpreted alongside conventional MRI. An ideal test would identify survivors and 
non-survivors from the ROC curve cut-off demonstrating no overlap of metabolite 
concentrations between the two groups.  However, overlap is inevitable and can result in 
the mis-classification of cases. While the AUC provides a value for the diagnostic accuracy 
of the test thus assessing the sensitivity and specificity, it does no assess the selected cut-
off value demonstrating advantages and disadvantages of using this method like many 
tests. A future approach of validating the findings would be to assess the biomarkers 
established from the retrospective cohort on a prospective cohort of patients with the 
disease (Zou et al., 2007, Linnet et al., 2012). 
There are very few studies in the literature that have investigated the metabolic changes 
seen in subgroup specific tumours. To aid the understanding of tumour pathogenesis and 
treatment requires the development of tumour mouse models. A recent study 
demonstrated the development of a MB SMO mouse, SMO a receptor in the SHH 
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pathway seen to be highly activated in SHH tumours (Hatton et al., 2008). The mutations 
in the patched (Ptch) gene in the SHH pathway contribute to SMO mice developing 
subclinical MB by two months of age. High resolution in vitro spectroscopy was 
performed on the tumour tissue excised from the SMO mouse and results demonstrated 
decreased NAA and elevated levels of tCho, taurine and glycine.  The elevated levels of 
metabolites observed are in agreement with an aggressive and highly malignant tumour 
(Hekmatyar et al., 2010). While there is currently no evidence in the literature for the 
metabolic changes observed for a WNT tumour to our knowledge, the WNT pathway 
plays a role in cancer progression, including tumour initiation, tumour growth, cell 
senescence, cell death, differentiation and metastasis (Anastas and Moon, 2013). It is 
known that tumours belonging to this subgroup have a good prognosis and it can be 
speculated that elevated tCho levels is likely be observed but vary in the contribution of 
components to the peak in comparison to SHH pathway tumours.  A greater contribution 
of GPC to PCh maybe observed for the less malignant tumour. 
 With the confirmation of molecular subgroups of MB, the next challenge has been to 
develop rapid diagnostics tests to accurately determine grouping (Li et al., 2013). The 
combination of histopathology methods, immunohistochemistry and cytogenetics of new 
cases has recently been used at BCH to determine a limited number of genetic 
aberrations. The high variability of the LMM1.3 and high standard deviations seen in MB 
spectra provides preliminary evidence for subgroups of MB existing particularly within 
the M0 Chang stage. Interestingly, the three outliers seen in Figure 7.2 that exhibited high 
levels of LMM1.3 all had a poor survival. Currently no retrospective cytogenetic analysis 
has been performed in these cases so no genetic information is available. Analysis in 
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Chapter 5 identified Cr to be significantly different between spectroscopy acquired on 
different scanners in a cohort of MB with the highest levels measured on the GE and 
Siemens Avanto. Interestingly, the group acquired on the Siemens Avanto consisted of 
five out of six patients with no MYC or MYCN amplification (1 had no information 
available) suggesting a cohort of patients with good prognosis (Taylor et al., 2012). A 
combination of retrospective and prospective confirmation of genetic subgroups would 
be intriguing to establish in future studies. Evaluation of MB spectra results in the 
majority of cases passing the set QC criteria. It should be noted that a small number of 
cases fail due to low spectral SNR. However, it has been previously identified that low 
SNR in spectra acquired from tumours can be as result of low cellularity (Harris et al., 
2007). This is particularly true of desmoplastic nodular medulloblastoma that exhibits a 
less aggressive clinical course and is known to have a better prognosis compared to other 
MB subtypes (Gulino et al., 2008). As a result their pre-diagnostic spectra are often noisy 
and consist of low metabolite levels thus failing the set QC criteria. Additionally the study 
does not capture spectroscopy on every MB that presents at the centre. Patients that 
present initially at a different centre, present acutely unwell or have an MRI scan under a 
scanner operator whose experience of MRS is limited are less likely to have a 
spectroscopy sequence performed. Consequently this study demonstrates a study bias 
eliminating a few cases including those inherently known to have a better prognosis and 
speculatively those with more aggressive tumours. 
For future studies it may be beneficial to also perform 31P spectroscopy to measure the 
relative concentrations of PCh and GPC because of the greater chemical shift separation 
between the two metabolites (Loening et al., 2005). There is an increasing body of 
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evidence demonstrating the benefits of high field scanners for imaging and spectroscopy 
and 31P looks like a promising aid in the investigation of the biology of tumour cell 
proliferation (Qiao et al., 2006) but is hindered by low SNR (Albers et al., 2005). An 
alternative method for validating these findings would be to confirm the in vivo results 
with ex-vivo HR-MAS data. A recent study found a good correlation between metabolite 
quantities detected by HR-MAS and in vivo MRS for brain tumours (Wilson et al., 2009b). 
With the increased spectral resolution of HR-MAS it would be easier to determine the 
components of the significant peaks. 
7.5 Conclusions and future investigations 
In conclusion, this analysis has demonstrated the MRS detection of increased levels of Cr 
and tCho to be biomarkers of good prognosis in MB. Recent evidence supports the 
existence of four main molecular subgroups of MB that differ in prognosis thus providing 
interesting preliminary findings of a possible association. These non-invasive biomarkers 
may help in the future to stratify treatment in patients. However further work including 
analysis of tumour tissue and confirmation of biological subgroups is required to validate 
this work. 
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CHAPTER 8 
8 A MULTI-CENTRE STUDY OF 1H MAGNETIC RESONANCE SPECTROSCOPY 
IN THE CHARACTERISATION OF BRAIN STEM TUMOURS IN CHILDREN 
8.1 Introduction 
Brain stem tumours (BST) account for 10-25% of brain tumours in children. The 
management of brain stem tumours is particularly challenging for clinicians as tumours in 
this region are usually unresectable and difficult to biopsy (Hargrave et al., 2006). Four 
main tumour types are found in the brain stem, and fall into two major categories of 
either diffuse or focal. The most common tumour of the brainstem is diffuse intrinsic 
pontine glioma (DIPG), which make up 80% of all brain stem gliomas (Donaldson et al., 
2006). These tumours are not biopsied and have a particularly poor prognosis with a 
median survival of only nine months. Over the past 30 years, while the prognosis and 
survival time for many cancers including other brain tumours has considerably improved, 
this has remained unchanged for DIPG and they are now a major cause of death by brain 
tumour in children (Hargrave et al., 2006). However, amongst these cases there are a few 
long term survivors of DIPG but currently no conventional imaging characteristics that are 
able to identify this good prognostic group at diagnosis (Liu et al., 2009). The lack of 
available biopsy material from this tumour hinders the opportunity to determine 
biological markers for prognosis (Leach et al., 2008). Tectal plate gliomas (TPG) are also 
diagnosed solely on imaging with no biopsy performed but demonstrate an indolent 
course. If the tumours are focal or not typical of DIPG or TPG they are biopsied and most 
are diagnosed as high grade glioma, low grade glioma and occasionally other rarer types.  
Due to the difficulty of obtaining tumour tissue in these regions of the brain and the risks 
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of sampling error from small biopsies, improved non-invasive methods, which can give 
diagnostic, prognostic and biological information, would provide a significant advance in 
their management.  
With the importance of imaging in brain stem tumours, spectroscopy holds promise as a 
diagnostic modality. As these tumours are extremely rare, very few studies have been 
focused on childhood brain stem lesions thereby requiring a multi-centre approach to 
obtain enough cases for robust statistical analysis. However, the difficulties arise when 
standardising data acquisition and analysis across different scanners demonstrating the 
need for MRS to developed and tested across multi-centre cohorts (Vicente et al., 2013, 
García-Gómez et al., 2009). The low incidence of focal tumours in the brain stem presents 
a challenge in specifying the MRS profile of these tumours. However, an approach where 
comparisons have been made with MRS of tumours with the same histology in other 
locations has been previously used and warrants further exploration (Panigrahy et al., 
2008). 
The increasing body of evidence of the poor correlation of conventional imaging markers 
with patient survival (Hargrave et al., 2008, Yamasaki et al., 2011, Liu et al., 2009) has 
resulted in an increasing interest in using MRS for determining prognosis. A number of 
studies have identified markers of prognosis for DIPG. High tCho/NAA values in a cohort 
of DIPGs was found to be associated with poor prognosis and an increase over 
subsequent scans was associated with greater risk of death compared to patients who 
had stable or decreased tCho/NAA (Steffen-Smith et al., 2011). An increased tCho/NAA at 
subsequent time points was predictive of shorter survival (Hipp et al., 2011). 
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A recently published study has identified lactate as a marker of poor prognosis in a cohort 
of DIPG that consisted mainly of children but also included adults (Yamasaki et al., 2011). 
These studies consist of data that has been acquired at long echo time so the number of 
quantifiable metabolites is restricted (Steffen-Smith et al., 2011, Yamasaki et al., 2011). 
Also there are currently no biomarkers for identifying the few long term survivors of 
DIPG. Short echo time MRS detects more metabolites and has successfully identified 
novel metabolite biomarkers of prognosis in children’s brain tumours (Wilson et al., 
2013). The use of short echo time MRS for investigating brain stem tumours in children 
may therefore give rise to distinct MRS profile differences and requires further 
investigation.  
This chapter describes a study that is large compared with previous analyses. Whereas 
most published studies have collected and analysed data from a single centre, the work 
reported here is multi-centre data. A recent multi-centre study has shown that 1H MRS 
can yield high diagnostic accuracy in children’s brain tumours and represents the first 
application of this strategy to brain tumours in children (Vicente et al., 2013). This 
chapter investigates potential diagnostic and prognostic metabolite differences in 
childhood brain stem tumours on a multicentre cohort. It examines the differences 
between diffuse and focal tumours diagnosed in both the brainstem and elsewhere in the 
brain. The analysis includes follow-up of patients to allow the determination of 
prognostic markers. 
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8.2 Method 
8.2.1 Patients 
Single voxel 1H MRS was performed on 35 children with brain stem tumours during 
routine MRI scans prior to treatment at four centres across the UK. These included BCH, 
QMC, GOS and RMH. All cases underwent central radiology review by three radiologists 
experienced in the review of children’s brain tumours. Imaging characteristics of all 
tumours were documented including the presence of necrosis and/or haemorrhage.  
Diagnosis was made on the basis of central pathology review where tissue was available 
or central radiology review where there was no tissue. Only five patients were diagnosed 
on the basis of histopathology, one of which proved to be non-diagnostic. The diagnosis 
of DIPG was made without biopsy on the basis of clinical presentation and conventional 
imaging. Diagnostic criteria on MRI for DIPG included the tumour occupying at least 50% 
of the pons mostly with or without local tumour extension. In addition to this the T1 
weighted MRI characteristics of the tumour were that of a hypointense lesion and 
homogenous on T2 weighted MRI. The cohort consisted of 14 DIPG (seven male and 
seven female, mean age 7 years), four focal low grade brain stem tumours (two male and 
two female, mean age 11 years), five focal high grade brain stem tumours (three male 
and two female, mean age 11 years) and six tumours of the brain stem with no definitive 
or consensus diagnosis (five male and one female, mean age 10 years). 29 cases were 
included in the final analysis with six cases failing spectral quality control (Table 8.1). MRS 
profiles of the brain stem cases was compared with those from 31 PA (17 male and 14 
female, mean age 7 years) and eight HGG (six male and two female, mean age 8 years) 
outside the brain stem, all diagnosed on histopathology. 
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8.2.2 MRS acquisition and quantitation of metabolite concentrations and lipid 
intensities 
MRS data was acquired prior to treatment on either a 1.5 T or 3 T MR scanner (echo time 
30 ms or 38 ms; TR 1500 ms at 1.5 T and 2000 ms at 3 T). Raw spectroscopy data was 
processed using TARQUIN (Wilson et al., 2011). Metabolite levels were determined 
relative to a water reference spectrum. For cases where a water reference spectrum was 
not available, spectra were normalised to the sum of all metabolite levels. All spectra 
were assessed using the QC criteria (section 4.3).  
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Table 8.1 Brain stem tumour cohort characteristics 
* Diagnosis made on the basis of histopathology 
 
No. Age (Yrs.) Sex 
 
Hospital Tumour Site 
Best Diagnosis (Central 
Pathology → Local 
Pathology  → Central 
Radiology) 
Differential diagnosis Certainty 
of 
diagnosis 
Imaging features 
      
  
 1 4.8 M BCH Pons Diffuse pontine glioma Astrocytoma  75% Non-enhancing 
      grade 1 (25%)   
2 5.5 F BCH Pons Diffuse pontine glioma  High grade  75% Haemorrhage 
      glioma grade 1    
      (25%)   
3 14 M BCH Pons Diffuse pontine glioma    - 99% Haemorrhage 
4 7.1 M BCH Pons Diffuse pontine glioma - 99% Enhancing 
5 4.1 M BCH Pons Diffuse pontine glioma - 99% Non-enhancing 
6 12.2 M BCH Pons Glioblastoma  Diffuse pontine  75% Necrotic 
     multiforme* glioma grade 3   
      (25%)   
7 6.1 M BCH Midbrain Anaplastic   99% Haemorrhage, enhancing 
     
astrocytoma*   and necrotic 
8 10.9 M BCH Tectal Plate Tectal plate glioma Primitive  90% Enhancing 
      neuroectodermal   
      tumour   
9 11 M BCH Midbrain/Tectum Pilocytic astrocytoma 
Pilomyxoid 
astrocytoma 
99% 
Enhancing  
10 5.5 F BCH Pons Diffuse pontine glioma  99% Non-enhancing 
11 15.5 M BCH Cerebello/ponto/  Diffuse astrocytoma* Diffuse  99% Non-enhancing 
    medullary  astrocytoma   
      grade 3   
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12 8 F BCH Pons Diffuse pontine glioma - 99% Non-enhancing 
13 4.8 F BCH Pons Pilocytic astrocytoma Astrocytoma  90% Non-enhancing 
      grade 3   
14 4.5 F BCH Pons Diffuse pontine glioma - 99% Non-enhancing 
15 6.2 F BCH Pons Diffuse pontine glioma - 99% Necrotic 
16 4.8 M BCH Pons Diffuse pontine glioma - 99% Non-enhancing 
17 0.4 M GOSH Pons Ependymoma Low grade  50% Non-enhancing 
      glioma (25%)/    
      High grade    
      glioma (25%)   
18 5.1 F GOSH Pons Diffuse pontine glioma   Enhancing 
19 0.8 M GOSH Midbrain Medulloblastoma 
High grade glioma 
(25%) 
75% 
Enhancing 
20 14.6 F GOSH Medulla Glioblastoma  Pilocytic  75% Enhancing 
     multiforme astrocytoma   
      (25%)   
21 10.4 M GOSH Medulla Pilocytic astrocytoma No alternative  90% Enhancing 
22 14.5 M GOSH Pons Diffuse pontine glioma  99% Non-enhancing 
23 13.2 F GOSH Pons Glioblastoma  Pilocytic  75% Non-enhancing 
     multiforme Astrocytoma   
      (25%)   
24 7.7 F QMC Pons Diffuse pontine glioma  99% Non-enhancing 
25 10.1 F QMC Pons Ganglioglioma* Diffuse glioma  75% Non-enhancing 
      grade 3 (25%)   
26 6.1 M QMC Medulla Diffuse pontine glioma  99% Non-enhancing 
27 10.3 F RMH Centred on Pons Diffuse low grade  Low grade  75% Non-enhancing 
     glioma glioma grade 1    
      (25%)   
28 22.2 M RMH Centred on Pons 50% DIPG grade 3  As best diagnosis 50%/50% Necrotic 
     
/ 50% HGG grade 4   
 29 9.4 M RMH Centred on Pons 50% Diffuse astrocytoma  As best diagnosis 50%/50% Non-enhancing 
     
/ 50% HGG   
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8.2.3 Statistical Analysis 
Metabolite quantitation was performed using TARQUIN (version 3.2.1) (Wilson et al., 
2011). One way analysis of variance (ANOVA) and Student’s t-tests were performed to 
assess the differences between DIPG, focal LGG and focal HGG within the brain stem. The 
known histopathology of focal tumours of the brain stem compares with histopathology 
of focal brain tumours found elsewhere and for this reason were seen as the ideal 
comparator group. ANOVA was also performed to compare DIPG, PA and HGG outside 
the brain stem. Student’s t-tests were used to compare focal low and high grade tumours 
of the brain stem and also to compare PA and HGG outside the brain stem. With 23 
variables tested, a Bonferroni corrected significance of 0.002 (P<0.002) was calculated. A 
diagnostic classifier for discriminating DIPG, PA and HGG was constructed using 
metabolite concentrations with lipids and MMs as separated variables, first as inputs into 
PCA followed by LDA of PCA scores. Accuracy of the classifier was determined using 
LOOCV (Geisser, 1975). 
Survival data was available for the whole cohort of brain stem tumours with a minimum 
follow-up of three years from diagnosis. Analysis was performed separately on three 
groups, the DIPG cohort (14 patients), the unbiopsied brain stem cohort (25 patients) and 
the whole brain stem cohort (29 patients). Prognostic markers from characteristics seen 
on MR imaging and MRS variables were tested for using Mann Whitney U-tests 
comparing those patients that survived less than one year with those that survived more 
than one year for each of three groups. Optimal cut-offs for significant variables were 
determined using ROC curves for Kaplan Meier curve analysis. Significant differences in 
survival were assessed using a log-rank test. 
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8.3 Results 
8.3.1 Spectral features 
 
Figure 8.1 Mean spectral profiles for a) diffuse pontine gliomas (n=12) (b) low grade gliomas in the 
brain stem (n=4) (c) high grade gliomas in the brain stem (n=5) (d) pilocytic astrocytomas outside the 
brain stem (n=31) and (e) high grade gliomas outside the brain stem (n=8) with standard deviations 
indicated by the shaded regions.  
Figure 8.1 shows mean spectra from the different tumours that were compared in the 
statistical analysis. The main features of the DIPG mean spectrum (Figure 8.1a) on 
qualitative analysis, that distinguished it from the spectra of other BST and non-BST was 
high mIns, prominent Cit and low LMM1.3 and LMM0.9. The brain stem low grade glioma 
(Figure 8.1b) and high grade glioma mean spectra (Figure 8.1c) exhibited low SNR as a 
result of small sized tumours. The increased metabolite variability seen at most positions 
can be explained by the small number of cases in each cohort. Spectral features that 
distinguished PA (Figure 8.1d) from HGG (Figure 8.1e) included detectable levels of NAA, 
readily detectable Lac and low Cr at 3.0 ppm. The main features of the HGG mean spectra 
(Figure 8.1d) were high tCho, low NAA and high lipids+MMs in particular at 1.3 ppm. The 
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highest variability in all tumour types appeared to be in the lipid+MMs area at 0.9 ppm 
and 1.3 ppm. 
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The mean values of the metabolites and lipids and/or MM of most interest have been 
reported in Table 8.2 for the different tumour groups. Cit and sIns were the only two 
metabolites that were significantly different between all three tumour groups in the brain 
stem. The highest concentrations were seen in DIPG followed by focal LGG with focal 
HGG having the lowest concentrations (ANOVA, P<0.01, P<0.05 respectively). Significantly 
higher mIns in focal LGG of the brain stem was the only discriminator between focal HGG 
of the brain stem (Student’s t-test; P<0.05). Significantly elevated tCho and decreased Gly 
were found in LGG in the brain stem compared to PA elsewhere in the brain (Student’s t-
test, P<0.01, P <0.05 respectively). Significantly decreased Cit, Lac and LMM2.0 
concentrations were found in HGG in the brain stem compared to HGG found elsewhere 
in the brain (Student’s t-test, P <0.01, P<0.05, P<0.05 respectively) (not reported in table). 
Significant differences in all major metabolites, lipids and macromolecules were found on 
comparison of DIPG, non-bst HGG and non-bst PA (ANOVA, P<0.05). Key discriminatory 
metabolites included Cit, Cr and mIns, all of which were significantly higher in DIPG than 
in HGG and lowest in PA. Lipids were seen to be significantly higher in HGG and lowest in 
DIPG. 
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8.3.2 Univariate analysis 
Table 8.2 ANOVA and t-test analysis results with estimated metabolite concentrations of diffuse pontine gliomas, high grade and low grade gliomas of the 
brain stem with estimated metabolite concentrations of high grade gliomas and pilocytic astrocytomas found elsewhere in the brain. 
Abbreviations: BST, brain stem cohort.  
 Mean  Concentration (mM)  
Metabolites ANOVA 
DIPG vs. 
Focal BST 
(P  value) 
ANOVA  
DIPG vs. 
Focal 
outside BST 
(P  value) 
 
 
Diffuse 
Pontine 
Glioma 
focal tumours of the 
brain stem 
focal tumours outside the brain 
stem 
T-test  
Focal BST 
(P  value) 
T-test  
Focal 
outside BST 
(P value) 
High Grade 
Gliomas 
(HGG) 
Low Grade 
Gliomas 
(LGG) 
High Grade 
Gliomas 
(HGG) 
Pilocytic 
astrocytomas 
(PA) 
Cit  <0.01 <0.0001  0.89  0.23  0.67  0.68  0.34  >0.05 0.05 
Cr  > 0.1 <0.0001  2.96  2.11  2.21  1.42  0.88  > 0.1 > 0.1 
GPC+PCh/ tCho > 0.1 <0.01  1.34  1.36  1.64  1.99  1.00  > 0.1 > 0.1 
Gly  > 0.05 <0.001  2.70  0.35  0.07  1.45  0.43  > 0.1 0.05 
mIns  > 0.1 <0.0001  4.53 1.22  4.11  0.77  0.61  <0.05 > 0.1 
Lac  > 0.1 <0.001  0.84  1.20  1.61  3.91  2.12  > 0.1 > 0.1 
sIns <0.05 <0.001 0.26 0 0.18 0.09 0.04 > 0.1 > 0.1 
Lipids at 0.9 ppm  > 0.05 <0.001 0.79  1.71  1.70  2.84  1.65  > 0.1 <0.05 
MMs at 0.9 ppm  > 0.1 <0.0001  1.34  2.77  1.99  5.72  2.70  > 0.1 >0.05 
Lipids at 1.3 ppm  0.1 <0.0001  1.87  6.03  4.48  11.98  5.25  > 0.1 <0.001 
Lipids at 2.0 ppm  > 0.1 <0.05  0.94  1.85  3.61  3.85  2.12  > 0.1 > 0.1 
MMs at 2.0 ppm  > 0.1 <0.001  4.98  5.70  6.52  7.59  4.05  > 0.1 <0.0001 
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8.3.3 Pattern classification 
 
 
Figure 8.2 Three-way classifier between diffuse pontine gliomas and focal tumours outside the brain 
stem, pilocytic astrocytomas and high grade gliomas including a) a scatter plot of the discriminant 
function scores for each tumour type, b) discriminant function 1 coefficients and c) discriminant 
function 2 coefficients of the standardised metabolite profile  
The three-way classifier showed a good separation between DIPG and the other tumours 
with one overlapping HGG case (Figure 8.2). The cluster separation between the HGG and 
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PA although well overall, was less clear with, 1 HGG case clustering with the PA group and 
three PA clustering with the HGG group. DIPG scored highly in discriminant function 1, 
characterised by high mIns, Gly and Cr and low concentrations of Glx, Lac, LMM0.9, 
LMM1.3, and LMM2.0 (Figure 8.2b). Discriminant function 2 distinguished PA from HGG. 
PA were characterised by high Glc, NAA and Glx. HGG were characterised by higher 
LMM1.3 and also have a higher contribution of mIns than PA (Figure 8.2c). LOOCV used to 
evaluate the three-way classifier, demonstrated a success rate of 83% with the correct 
classification of 26 out of 31 all with a posterior probability above 80%. 
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8.3.4 Survival Analysis of conventional MRI characteristics 
 
Figure 8.3 Kaplan-Meier survival distribution curves of a) enhancement b) haemorrhage and c) 
necrosis in DIPG and d) enhancement e) haemorrhage and f) necrosis in the unbiopsied brain stem 
cohort and g) enhancement h) haemorrhage and i) necrosis in whole brain stem cohort. 
Abbreviations: UBST, unbiopsied brain stem cohort; BST, brain stem cohort. 
No significant differences were seen between those patients that demonstrated necrosis, 
haemorrhage or enhancement (Wilcoxon signed rank test, P>0.05) for the DIPG, 
unbiopsied brain stem and whole brain stem cohorts when comparing those patients that 
survived less than one year with those that survived more than one year. There was also 
no significant difference seen using Kaplan Meier survival curve analysis for the three 
imaging characteristics (P>0.1, log-rank test) (Figure 8.3). 
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8.3.5 Survival Analysis of metabolite profiles 
 
Figure 8.4 Kaplan-Meier survival distribution curve of Tau levels in the DIPG cohort. A cut-off of 
0.932mM was determined using a ROC curve (ROC curve not shown) significance value tested using a 
log-rank test.                                              
In the DIPG cohort, significantly higher Glx (5 vs. 3, P=0.05), Gln (3 vs. 0.7, P<0.05), 
LMM2.0 (6 vs. 4, P=0.05) and lower levels of Tau (0.1 vs. 1.2, P<0.05) were found in those 
cases surviving less than one year (Wilcoxon signed rank test). Kaplan-Meier curve 
survival analysis for Tau demonstrated a significant difference (P<0.01) in survival with a 
cut-off of 0.932 mM (Figure 8.4). There were no significant differences in metabolite 
variables for the whole brain stem cohort. The unbiopsied brain stem cohort showed 
significantly lower levels of Tau in those cases surviving less than one year (0.1 vs. 0.7, P 
=0.05). Two patients with MRS profiles which were substantially different from the DIPG 
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but who had diffuse pontine tumours, one biopsied diffuse astrocytoma and one in the 
DIPG cohort, were alive at three years. 
8.4 Discussion 
This analysis shows a successful collection and investigation of MRS data on a multi-
centre cohort of important and rare tumours. MRS identified differences between 
metabolite levels in DIPG and focal high and low grade tumours of the brain stem and 
elsewhere in the brain. The presence of a prominent Cit peak and a high mIns are spectral 
characteristics of DIPG that can be readily identified in a clinical setting. The significant 
differences seen in the metabolite profiles of these tumour groups demonstrate 
spectroscopy to be a useful non-invasive diagnostic tool for brain stem tumours.   
Citrate in particular was significantly different between the three groups of brain stem 
tumours, being highest in DIPG. In a previous study of 85 paediatric brain tumours, Cit 
was found to be highest in brain stem gliomas and concentrations were found to 
significantly declined over time in progressing brain stem gliomas (Seymour et al., 2008). 
Cit has also been found to be a marker of the malignant progression in astrocytomas in 
keeping with the characteristics and clinical course of DIPG (Blüml et al., 2011). The only 
DIPG survivor in this study had low levels of Cit at diagnosis. When comparing the DIPG 
with the focal tumours of the brain stem, Gly and sIns were also found to be high and 
these metabolites have been linked to high grade and poor prognosis in children’s brain 
tumours (Davies et al., 2009, Wilson et al., 2013). The results show DIPG metabolite 
profiles at diagnosis are associated with aggressive tumours and poor prognosis, in 
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keeping with their subsequent behaviour. Focal LGG in the brain stem had higher levels of 
mIns than the brain stem HGG in keeping with studies of astrocytomas in adults (Castillo 
et al., 2000) and supratentorial pilocytic astrocytomas (Harris et al., 2008). 
A small number of metabolites differed as a result of tumour location. Higher tCho in BST 
LGG than PA elsewhere in the brain was in keeping with their more aggressive nature. 
Reduced Lac and lipids seen in BST HGG compared to HGG elsewhere, metabolites 
associated with hypoxia and necrosis respectively, may reflect the larger tumour size of 
supratentorial tumours. Very few studies have investigated the differences between 
normal brain stem and other regions of the brain in paediatric patients. To the best of our 
knowledge these have been predominantly performed in adults (Tong et al., 2004, 
Hattingen et al., 2009). Spectroscopy is only likely to be acquired from the brain stem in 
paediatric patients if clinically indicated explaining the lack of studies. This could be an 
approach for a possible future multicentre study. 
Panigrahy et al. (2008) reported comparisons of brain stem gliomas with anaplastic and 
grade IV astrocytomas elsewhere in the brain show significantly different levels of Cr, 
tCho and Glx but not mIns (Panigrahy et al., 2008). These metabolite differences may give 
an interesting insight into the biology of brain stem tumours and how it varies with 
tumour location. Overall, metabolite profiles were similar between tumours of the brain 
stem and their counterparts in other locations. In particular, the most discriminatory 
metabolite between HGG and LGG in the brain stem, mIns, was not significantly different 
174 
 
 
 
between brain stem tumours and similar tumours in other locations. These findings 
confirm that it is reasonable to interpret MRS of the brain stem by referring to MRS of 
tumours elsewhere in the brain. A diagnostic classifier based on MRS metabolite profiles 
and constructed using this approach, showed a good accuracy for diagnosing DIPG, HGG 
and PA and may provide a more formal aid to diagnosis than inspection of the spectra.  
The three-way classifier demonstrated a number of interesting classifications. Case 7 was 
initially diagnosed from a tumour biopsy as a PA. As a result the patient was treated on a 
low grade tumour protocol but rapidly developed an increase in tumour size that resulted 
in the decision to perform a surgical resection. However, the diagnosis from the surgical 
tumour tissue was changed to anaplastic astrocytoma in keeping with the classifier result 
of HGG (80% posterior probability). This provides evidence that spectroscopy is able to 
identify features of a high grade tumour. Case 8 had imaging appearances in keeping with 
a high grade tectal plate lesion with a differential diagnosis of primitive neuroectodermal 
tumour. The case classified as a PA with a 92% probability and the patient is currently 
alive. Spectroscopy is shown to demonstrate low grade tumour features where 
conventional imaging is equivocal. None of the conventional MRI characteristics were 
related to survival demonstrating that MR imaging alone is unable to yield prognostic 
markers of brain stem tumours. This is in agreement with the findings of previous studies 
(Hargrave et al., 2008, Yamasaki et al., 2011).  
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Perez-Gomez et al. investigated the clinical features of paediatric patients that 
underwent stereotactic guided biopsy for brain stem tumours (Perez-Gomez et al., 2010). 
The histopathological entities of these tumours were either anaplastic astrocytomas 
(30%), or fibrillary and pilocytic types (25%) with low grade astrocytomas, high grade 
astrocytomas and even normal tissue. Clearly this needs to be studied with larger 
cohorts, but the mixed diagnoses identified confirms that brain stem tumours are not a 
single entity and do not all have the same prognosis. Several metabolites have been 
previously identified to be associated with prognosis in paediatric brain tumours. In this 
study, Tau was found to be a biomarker of good prognosis in the DIPG cohort. Tau is a 
diagnostic marker of primitive neuroectodermal tumours (Kovanlikaya et al., 2005). These 
tumours tend to respond to radiotherapy and have a better prognosis than HGG 
(Gottardo and Gajjar, 2008). Since the DIPG cohort was not biopsied, it is not possible to 
comment on whether any of the cases were primitive neuroectodermal tumours but it 
would be interesting to establish whether high Tau levels are associated with 
radiosensitivity across a range of tumours. Whilst Tau was the only individual metabolite 
which was significantly associated with improved survival, other metabolites undoubtedly 
have some association. Two patients surviving at three years with poor prognosis 
tumours had metabolite profiles which were different from the rest of the group as 
established in a PCA. One of the cases had the highest mIns in the group, which is further 
evidence for it being a marker good prognosis (Harris et al., 2008).  
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Small cohort numbers in the BST LGG (4 vs. 31) and spectra with a low SNR may explain 
the differences seen between focal non-BST and focal BST. Standard deviations at most 
metabolite positions in these spectra varied greatly making comparisons difficult 
particularly in the lipid, lactate and choline regions (Figure 8.1b and Figure 8.1c). Previous 
analyses have shown that lipid assignment in tumour types is extremely variable, also 
seen in the focal tumour spectra (Panigrahy et al., 2006). Previous studies investigating 
brain stem tumours in children have been few and have consisted of small cohorts and a 
multi-centre approach in this analysis has been used to overcome this. This multi-centre 
study highlights the importance of using MRS as an adjunct to conventional MRI and the 
role of Tau in DIPG warrants further understanding. 
8.5 Conclusions and future investigations 
Many tumours of the brain stem are diagnosed without a biopsy but it is often difficult to 
obtain a definitive consensus diagnosis. This analysis has been performed using a multi-
centre approach to increase cohort numbers thereby increasing robustness of findings. 
MRS identifies key differences between tumours of the brain stem and can aid the 
characterisation of these tumours. In addition, whilst conventional MRI provides no 
markers of prognosis, Tau is significantly associated with a better prognosis in DIPG and 
metabolite profiles can also identify cases which become long term survivors. It has 
become apparent, that the lack of DIPG tumour tissue is hindering the understanding of 
tumour pathogenesis. In the future, high resolution in vitro spectroscopy methods 
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performed on tumour tissue may be able to confirm the presence of taurine and 
determine differences in long term survivors. 
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CHAPTER 9 
9 SINGLE VOXEL PROTON MRS IN THE BRAIN SHOWS IMPROVED 
METABOLITE QUANTITATION AT 3 T IN PAEDIATRIC PATIENTS 
9.1 Introduction 
With the increasing use of 3 T MRI scanners in clinical practice, there is an ever increasing 
interest in how 1H MRS at 3 T can provide improvements over 1.5 T. A higher field 
strength in theory should provide 100% increase in SNR and increase in spectral 
resolution enabling better quality data to be acquired in a shorter time period thus 
providing improved discrimination between different brain pathologies (Wardlaw et al., 
2012). 
Single voxel MRS is a promising technique that has been used in a number of studies to 
aid the characterisation of brain pathology in adults at 1.5 T (Smith et al., 2009, Howe and 
Opstad, 2003, Hattingen et al., 2008a) with more studies now being performed at 3 T 
(Wallis et al., 2007, Jeun et al., 2005, Hattori et al., 2002, Kim et al., 2006). The technique 
has also been well established in paediatric patients at 1.5 T (Harris et al., 2011, 
Panigrahy et al., 2010b, Davies et al., 2008, Kovanlikaya et al., 2005) with a limited 
number of studies performed at 3 T (Klomp et al., 2004). However, difficulties can arise 
when using the technique to differentiate between brain tumours as shown in chapter 5 
and also between different brain pathologies (Hourani et al., 2006, Callot et al., 2008, 
Smith et al., 2009). The use of high field provides promise for aiding in these clinical 
scenarios. A number of groups have performed comparisons with spectroscopy data 
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collected at 1.5 T and 3 T to evaluate its use (Kim et al., 2006, Barker et al., 2001) but this 
comparison has not been performed in the paediatric population to our knowledge. 
The purpose of the work presented in this chapter was to determine whether higher field 
strength of 3 T demonstrates an improvement in metabolite determination and quality of 
data acquired at 1.5 T in paediatric patients. 
9.2 Method 
Single voxel MRS was performed during September 2003 and October 2012 on 4 different 
cohorts of paediatric patients. Spectroscopy was acquired at 5 different centres. 
9.2.1 MRS acquisition and quantitation of metabolite concentrations and lipid 
intensities 
MRS data was acquired prior to treatment where the core acquisition protocol at 1.5 T 
for all cohorts comprised of TE 30 ms, TR 1500 ms and 128-256 NSA depending on voxel 
size and at 3 T TE 36-40 ms, TR 2000 ms and 96-128 NSA. All spectra were assessed using 
the QC criteria (section 4.3).  
9.2.2 Statistical analysis  
Metabolite quantitation was performed using TARQUIN (version 4.2.10 with extended 
basis set) (Wilson et al., 2011). Mann-Whitney U-tests (Mann and Whitney, 1947) were 
performed to compare five QC parameters calculated by TARQUIN. These included SNR, 
SNR max, water linewidth (Hz), water linewidth (ppm) and Q fit. SNR and SNR MAX per 
unit acquisition time were also compared between the two field strengths. The brain 
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tumour cohorts comprised of data acquired from different voxel volumes and as a result 
varying NSA. To account for these differences, SNR per unit voxel volume, SNR max per 
unit voxel volume and SNR per unit voxel volume per unit time and SNR max per unit 
voxel volume per unit time were also compared between the two field strengths. 
Metabolite concentrations (mM) and CRLB (SD) were compared using a Wilcoxon signed 
rank test where the analysis was paired and Mann-Whitney U-test for unpaired analyses 
(Mann and Whitney, 1947, Wilcoxon, 1945). Box and whisker plots were constructed to 
compare CRLB of metabolites at both 1.5 T and 3 T.  
Table 9.1 A cohort summary of the paediatric patients included within the MRS study. 
Cohort Number of 
cases@1.5 T 
Number of 
cases@3 T 
Age range 
(years) 
Mean age 
(years) 
Paired 
Analysis? 
1. Inherited metabolic disorders 7 7 1-7  3.6 Yes 
2. Medulloblastoma 41 7 1.2-15  6.5 No 
3. Pilocytic Astrocytoma 34 10 0.2-16.4 7.6 No 
4. Low grade gliomas 6 6 06-8.9 3.3 Yes 
9.3 Cohort 1: Inherited metabolic disorders 
Cohort one consisted of seven paediatric patients (all male, Table 9.1) with inherited 
metabolic disorders all scanned at BCH. Patient diagnoses were either Methylmalonic 
acidaemia or X-linked adrenal leukodystrophy. The core acquisition protocol at 1.5 T 
comprised of TE 30 ms, TR 1500 ms and 128 NSA and at 3 T TE 38 ms, TR 2000 ms and 
128 NSA. The ROI for each acquisition was 8 cm3. Voxel locations for the patients were 
either located on the left basal ganglia or right parietal white matter with matched 
locations at both field strengths. All spectra acquired from patients with inherited 
metabolic disorders passed the set QC criteria. 
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9.3.1 Results 
 
Figure 9.1  Quality control (QC) parameter plots show differences between 1.5 T and 3 T for a) SNR, b) 
SNR max, c) water linewidth (Hz), d) water linewidth (ppm) and e) Q fit. 
Table 9.2 Wilcoxon signed rank test analysis comparisons for QC parameters calculated using 
TARQUIN. 
QC parameters P values 1.5 T 3 T 
SNR * 17.6 26.1 
SNR max * 28.7 47.4 
water linewidth (Hz) ** 4.6 6.7 
Water linewidth (ppm) * 0.07 0.05 
Q fit n.s 1.9 2.0 
Note: - n.s not significant, * P<0.05, ** P <0.01  
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Figure 9.2 Box and whisker plots demonstrating the differences between CRLB at 1.5 T and 3 T for 16 
metabolites. 
An increase in SNR and SNR max was seen from 1.5 T to 3 T (Figure 9.1 a) and b) and 
Table 9.2). Significantly higher SNR with an overall increase of 48% equivalent to a 13% 
increase per unit acquisition time was found. Although both SNR per unit acquisition time 
(5.4 vs. 6.2, P>0.05) and SNR max per unit acquisition time (10.1 vs. 12.1, P>0.05) were 
higher at 3 T, these differences were not found to be statistically significantly. 
Significantly higher water linewidth in Hz at 3 T and water linewidth in ppm at 1.5 T was 
found (Figure 9.1 c) and d) and Table 9.2) resulting in an improved spectral resolution as 
seen in Figure 9.3. No difference was seen in Q fit between the two field strengths (Figure 
9.1 e) and Table 9.2).  
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Table 9.3 Estimated metabolite concentrations and CRLB (SD) comparing 1.5 T vs. 3 T using a Wilcoxon 
signed rank test. 
       Metabolite concentrations                  CRLB (SD) 
Metabolites p values 1.5 T vs. 3 T (mM) P values 1.5 T vs. 3 T (mM) 
Ala n.s 0.33 vs. 0.11 * 0.43 vs. 0.12 
Cit n.s 0.57 vs. 0.23 n.s 0.15 vs. 0.10 
Cr n.s 4.79 vs. 5.82 * 0.16 vs. 0.05 
GPC n.s 1.23 vs. 1.33 n.s 0.23 vs. 0.06 
Glc n.s 4.25 vs. 1.96 * 0.36 vs. 0.16 
Gln n.s 2.03 vs. 0.23 * 0.74 vs. 0.29 
Glth * 0.66 vs. 1.96 * 0.22 vs. 0.10 
Glu n.s 5.28 vs. 6.68 * 0.77 vs. 0.34 
Gly n.s 1.16 vs. 0.15 * 0.53 vs. 0.09 
mIns n.s 1.89 vs. 2.48 * 0.47 vs. 0.14 
Lac n.s 0.10 vs. 0.49 * 0.33 vs. 0.14 
NAA n.s 5.70 vs. 5.94 * 0.35 vs. 0.05 
NAAG n.s 0.73 vs. 0.54 * 0.22 vs.0.06 
PCh n.s 0.09 vs. 0.21 n.s 0.23 vs. 0.07 
sIns n.s 0.08 vs. 0.05 * 0.10 vs. 0.03 
Tau n.s 1.35 vs. 1.09 n.s 0.36 vs. 0.22 
Note: - n.s not significant, * P<0.05  
Glutathione was the only significant different metabolite between the two field strengths 
(Table 9.3). CRLB were shown to be lower at 3 T than 1.5 T (Figure 9.1) and this was 
significant (P<0.05) for 12 out of 16 metabolites (Table 9.3). These included Cr, Glu, Gln, 
Gly, mIns and tNAA, metabolites known to be important in brain pathology. 
9.4 Cohort 2: Medulloblastoma (MB) 
Table 9.4 Core summary protocol for MB cohort. 
MB 1.5 T protocol 3 T protocol 
TE (ms) 30 37-40 
TR (ms) 1500 2000 
NSA 128-256 128 
Voxel volume range (cm3) 3.4-8 3.4-8 
Average voxel volume (cm3) 6.7  5.7 
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Cohort 2 consisted of 41 MB patients (Table 9.1) scanned at 1.5 T (12 female, 29 male, 
age range: 1.7-15 years, mean age: 6.8 years) compared with seven different cases at 3 T 
(four female, three male, age range: 1.2-8.3 years, mean age: 4.6 years) scanned at five 
centres. The core acquisition protocol at 1.5 T and 3 T for the MB is shown in Table 9.4. 
The ROI for each acquisition varied depending on protocol specified by the radiologist 
and the size of lesion to ensure that the voxel contained only the lesion of interest. All 
voxels were located over the primary tumour lesion. Six cases were excluded from the 
analysis of spectra acquired from MB patients. 
9.4.1 Results 
Comparison of quality control parameters between 1.5 T and 3 T demonstrated a 
significantly increased water linewidth in Hz (6.43 vs. 8.31 respectively, P<0.01) and 
decreased water linewidth in ppm at 3 T (0.1 vs. 0.07 respectively, P<0.001). A trend 
towards greater SNR and SNR max was seen at 3 T although this was not found to be 
significant. No difference was found in Q fit. No significant difference between SNR and 
SNR MAX per unit acquisition time was found. SNR per unit voxel (3.8 vs. 5.2, P=0.05) and 
SNR max per unit voxel volume (5.5 vs. 8.8, P<0.01) were found to be significantly higher 
at 3 T. SNR per unit voxel volume per unit time (1.0 vs. 1.2, P>0.05) was not significantly 
different but SNR max per unit voxel volume per unit time (1.5 vs. 2.0, P=0.05) was 
significantly higher at 3 T. 
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14 out of the 16 metabolites analysed were well determined at either both or one of the 
two field strengths. Out of those 14 metabolites, 12 were better determined at 3 T than 
1.5 T however, this was only significant for three metabolites, Cr, Glutathione and Gly. 
9.5 Cohort 3: Pilocytic Astrocytoma (PA) 
Table 9.5 Core summary protocol for PA cohort. 
PA 1.5 T protocol 3 T protocol 
TE (ms) 30 37-40 
TR (ms) 1500 2000 
NSA 128-256 128 
Voxel volume range (cm3) 3.4-8 2.7-6 
Average voxel volume (cm3) 6.3 4 
Cohort 3 consisted of 34 PA patients (Table 9.1)  scanned at 1.5 T (16 female, 18 male, 
age range: 0.2-16.4 years, mean age: 7.4 years) compared with eight different cases at 3 T 
(four female, four male, age range: 6.9-11.6 years, mean age: 8.4 years) scanned at five 
centres. The core acquisition protocol is given in Table 9.5. Voxel was located over the 
primary tumour lesion. 40 patients were excluded from the analysis of spectra acquired 
from PAs. 
9.5.1 Results 
The only significant QC parameter was linewidth in Hz found to be higher at 3 T than at 
1.5 T (7.97 vs. 6.47, P<0.01). No significant difference between SNR or SNR max per unit 
acquisition time was found however, SNR per unit voxel volume (1.7 vs. 2.5, P<0.05), SNR 
max per unit voxel volume (2.3 vs. 3.1, P<0.05), SNR per unit voxel volume per unit time 
(0.4 vs. 0.6, P<0.05) and SNR max per unit voxel volume per unit time (0.5 vs. 0.7, P<0.05) 
were all significantly lower at 1.5 T than 3 T. 
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Out of the 16 metabolites analysed, 11 metabolites were well determined at either both 
or one of the two field strengths. However out of the 11 metabolites only two were 
better determined at 3 T and neither of these were significant.  
9.6 Cohort 4: Low grade gliomas (LGG) 
Table 9.6 Core summary protocol for LGG cohort. 
LGG 1.5 T protocol 3 T protocol 
TE (ms) 30 36-40 
TR (ms) 1500 2000 
NSA 128-256 96-128 
Voxel volume range (cm3) 3.4-8 2.2-8 
Average voxel volume (cm3) 5.7 4.7 
Cohort 4 consisted of six paediatric patients with LGG (Table 9.1) all scanned at BCH 
(three female, three male) at both 1.5 T and 3 T. The core acquisition protocol is given in 
Table 9.6. The voxel was located over the same lesion of interest at the two field 
strengths. 12 patients were excluded from the analysis of LGGs. 
9.6.1 Results 
No significant differences in quality control parameters between spectra acquired from 
LGG patients at 1.5 T and 3 T were found. A trend in increased SNR was seen at 3 T, 
however with a large standard error. No significant differences between SNR, SNR max 
per unit acquisition time, SNR per unit voxel volume or SNR max per unit voxel volume 
were seen. However, SNR per unit voxel volume per unit time (0.3 vs. 1.0, P<0.05) and 
SNR max per unit voxel volume per unit time (0.4 vs. 1.1, P<0.05) were all significantly 
higher at 3 T than 1.5 T. 
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12 out of 16 metabolites were better determined at either both or one of the two field 
strengths. Seven of these were better determined at 3 T and two demonstrated no 
difference. However, none of the differences were found to be significant  
9.7 Discussion 
Whilst the use of higher field strengths theoretically has many benefits for spectroscopy 
including increased spectral resolution, there are few studies that have demonstrated 
this within a clinical environment and none in children to our knowledge. A 13% increase 
in SNR per unit acquisition time at short echo time found in cohort 1 provides evidence 
for the improvement in metabolite quantitation which can be achieved at higher field 
strength in children with neurological disorders. Using equal voxel volumes and number 
of averages between both field strengths (cohort 1) provides a more robust comparison 
of the spectra. Cohorts 2-4 consist of the three most common brain tumour groups that 
present in children and demonstrate the same trends in quality control parameters. 
A number of adult spectroscopy studies have been published comparing 1.5 T and 3 T. 
Barker et al. (Barker et al., 2001) compared the spectroscopy of normal brain in adult 
volunteers and stated a 28% increase in SNR of the tNAA peak at 3 T. Kim et al. (Kim et 
al., 2006) compared the spectroscopy of brain tumours reporting a 49.4-72.6% increase in 
SNR for the most important metabolites in brain pathology (mIns, tCho, Cr, tNAA). 
Sjobakk et al. (Sjøbakk et al., 2006), however, found only minor improvements in SNR for 
short echo time and saw greater improvements in long echo time (20-50%). The overall 
consensus from these studies and the results presented in this chapter is that although 
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SNR increases with field strength it does not reach the expected theoretical gain of 100% 
for a two fold increase in field strength. 
 
Figure 9.3 Comparison of spectra from 1.5 T and 3 T acquired from case 1 a) MRS acquired from the 
left basal ganglia at 1.5 T b) MRS acquired from the left basal ganglia at 3 T c) coronal T2 weighted 
imaging and d) axial T2 weighted imaging showing voxel location which was the same at both field 
strengths. 
Figure 9.3 illustrates spectra from case 1 at 1.5 T and 3 T with the corresponding voxel 
positions. Qualitative analysis of the example case shows differences in the spectra that 
190 
 
 
 
would be beneficial for assessing brain pathology validating the findings. Peaks tNAA and 
Glx are better resolved on the 3 T spectrum and the peaks seen between tCho and 2nd Cr 
peak (3.9 ppm) including the Cr peak itself are better resolved at 3 T. This is explained by 
the narrower linewidth of the residual water peak in ppm. 
 
Figure 9.4  Comparison of spectra from 1.5 T and 3 T acquired from a patient with a tectal plate glioma 
a) MRS acquired at 1.5 T b) MRS acquired at 3 T c) axial FLAIR imaging and d) axial STEALTH imaging 
showing voxel location which was the same at both field strengths. 
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Figure 9.4 illustrates spectroscopy acquired from a patient with a low grade brain 
tumour. The spectra demonstrate a difference in the basis functions for mIns between 
the field strengths with a single feature seen at 1.5 T and two distinct peaks at 3 T. The 
few differences seen in metabolite concentrations imply the basis functions are able to 
allow for the differences in spectral appearance due to field strength. The separation 
between tNAA and Glx is seen to be greater at 3 T providing promise for aiding in brain 
tumour diagnosis and prognosis particularly where spectra overlap greatly (Davies et al., 
2008, Wilson et al., 2013).  
The significant decrease in CRLB seen at 3 T for cohort 1 demonstrates an improvement 
in spectral quantitation which is in agreement with the increased spectral dispersion, 
shown by the reduction in linewidth and increase in SNR (Tkáč et al., 2009, Posse et al., 
2007). Metabolites such as mIns which has been demonstrated as marker of good 
prognosis and glycine, a marker of poor prognosis could potentially be better resolved 
(Davies et al., 2009). Scyllo-inositol which has been identified as a marker of poor 
prognosis closely overlaps with Tau at 3.3 ppm and likewise glutamine and tNAA have 
been identified as markers of good prognosis but are closely overlapping at 1.5 T (Wilson 
et al., 2013). The increased spectral resolution achieved in the cohorts allows a better 
discrimination between the closely overlapping metabolites, mIns and Gly, sIns and Tau 
and tNAA and Glx. 
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Experience of acquiring spectroscopy data in a clinical setting has demonstrated that on 
average smaller volumes are selected. The use of smaller and more custom voxel sizes is 
often used taking advantage of the theoretical benefits of increased SNR as a result of 
increased field strength. This works well in clinical scenarios where the tumour volume at 
presentation may be smaller than 1.5 cm3, or consists of heterogeneous components, for 
example a tumour consists of a small solid component with predominantly cystic 
elements or small residual tumour at follow-up. Acquiring data from smaller voxels will 
ensure it does not contain normal brain and as a result is representative of the lesion of 
interest. Ensuring the data is acquired fully from within the lesion of interest is important 
for the interpretation of spectra. 
The confounding variables which include different voxel volumes and different numbers 
of averages acquired make it difficult to formally demonstrate the theoretical 
improvements of performing spectroscopy at 3 T for both unpaired and paired analysis in 
paediatric brain tumours patients (cohorts 2-4). The unexpected lack of difference seen 
between the field strengths for SNR and SNR max in the tumour cohorts (cohorts 2-4) can 
be explained by this. To allow for these differences SNR/SNR max per voxel volume and 
SNR/SNR max per unit voxel volume per unit time were calculated and have 
demonstrated a significant increase from 1.5 to 3 T for all the cohorts. Despite the 
differences in echo time between the two field strengths in particular slightly longer TE at 
3T, a 6-10 ms difference is likely to have very little impact on the spectral decay. It should 
be noted the differences in echo time between 1.5 T and 3 T are accounted for by 
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TARQUIN using the simulated basis set.  The analysis has also demonstrated that good 
quality MRS data can be acquired from small lesions at 3 T. 
Despite the expected advantages of higher field strengths, an increase in magnetic field 
heterogeneity and susceptibility artefacts hinders the ability to obtain the expected 
theoretical 100% gain in SNR. A reduction in T2 explains the increased metabolite 
linewidth in Hz seen at 3 T (Wardlaw et al., 2012). 
The promising results seen in this cohort of paediatric patients where equivalent 
protocols were used and QC parameters compared, provides evidence for the advantages 
of using this technique at higher field strength. A close review of the 3 T data has shown 
that acquiring MRS from small lesions is of greater importance than reducing acquisition 
times in a clinical setting. This explains the reasoning behind the limited increase in 
spectral resolution seen. With ever-improving access to advanced processing MRS should 
become more widely used in non-specialist centres in the future. 
9.8 Conclusion 
1H MRS acquired at 3 T from a cohort of paediatric patients with neurological disorders 
shows an overall increase of 48% equivalent to a 13% increase per unit acquisition time 
as well as an increase in spectral resolution. For inherited metabolic disorders where the 
same patient was scanned on two scanners, an improvement in spectral resolution, SNR 
and metabolite determination is seen at 3 T. For brain tumours where different patients 
are compared at 1.5 T and 3 T there is an improvement in resolution and determination 
194 
 
 
 
of some metabolites but not SNR. At 3 T, the current practice shows a trend towards the 
use of smaller voxels to acquire metabolic information from smaller lesions of interest. As 
a consequence, the expected advantages of increased spectral quality and SNR are not 
observed. 
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CHAPTER 10 
10 CONCLUSIONS AND FUTURE WORK 
This thesis has systematically demonstrated multi-centre spectroscopy data acquired 
from paediatric brain tumours can aid in their characterisation. Mean spectra, metabolite 
concentrations and classifier analysis constructed using statistical analysis methods 
provide diagnostic information that can be used with conventional MRI sequences. It has 
also been shown for the first time that MRS metabolite profiles of grade II-IV brain 
tumours at first relapse are not significantly different to those at diagnosis, aiding in the 
confirmation of tumour presence on follow-up MRI. Subtype specific prognostic markers 
in MB were also established. The key differences in metabolite profiles between tumours 
of the brain stem were identified and able to aid in characterisation. With conventional 
MRI providing no markers of prognosis for DIPG, Tau was found to be significantly 
associated with a better prognosis in these tumours. Data acquired at 3 T showed 
improved resolution and determination of metabolites in paediatric patients. 
The conclusions drawn from this work and future directions include: 
1) Qualitative and quantitative analysis of metabolite profiles shows differences 
between paediatric brain tumours that can aid in characterisation in a multi-
scanner cohort. It has been established that in vivo concentrations of metabolites 
differ between brain tumours and variations in these metabolite pathway 
intermediates are likely to be explained by tumour biology. However, the number 
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of metabolites quantified in vivo is limited and although the links to metabolic 
pathways and cancer pathogenesis have been preliminarily explored, further 
validation is required. Performing in vitro tumour tissue analysis using higher field 
strength methods such as magic angle spinning can provide a greater spectral 
resolution. Using a combination of in vivo, ex-vivo and genetic subtyping 
information, these findings can be validated and probed further. Understanding 
the underlying biological reasons and mechanisms for these differences is 
currently of great interest. 
2) Mean metabolite profiles differ between tumour types but no discrimination can 
be made between tumours based on individual metabolites. Using MRS as a 
diagnostic tool with mean metabolite profiles, classifiers and metabolite ratios is 
promising but the added value of this in clinical practice requires formally testing. 
This can be performed by providing a small group of radiologists with test cases 
firstly with MRI alone to provide a diagnosis, followed by the addition of MRS and 
MRS analysis results to provide a diagnosis and comparing this with the ‘gold 
standard’ histopathology results. This could be performed both retrospectively 
and prospectively.  
3) Finding no significant differences in metabolite profiles of children’s brain 
tumours (grade II-IV) at diagnosis and first relapse revealed that spectroscopy can 
aid in the confirmation of the tumour on follow-up MRI. Having now established 
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for the first time that diagnostic and relapse tumour spectra exhibit similar 
characteristics, it would be beneficial to test this on a prospectively on a larger 
cohort of patients and compare with other methods which may be useful in 
tumour detection such as diffusion and perfusion imaging. With a great interest in 
diffusion and perfusion methods to explore lesion cellularity and blood supply 
respectively, it is hoped quantitative analysis of imaging characteristics comparing 
diagnosis and follow-up may provide complementary information. These 
techniques are likely to be more beneficial to small lesions as they are not limited 
by voxel size like MRS. The optimum combination of imaging techniques is yet to 
be formally established. More detailed metabolite analysis is required to detect 
more subtle differences that may occur between diagnosis and relapse and this 
would be aided by paired tumour tissue analysis from local and national tumour 
tissue banks. 
4) The search for prognostic markers in tumour subgroup medulloblastoma showed 
increased levels of Cr and tCho and a feature around 2.0 ppm attributed to 
macromolecules to be associated with a good prognosis. Brain tumour subtype 
specific markers of prognosis have not been previously reported. However, this is 
particularly intriguing as many recent publications have provided evidence that 
although these tumours are diagnosed as the same histopathological entity, they 
consist of heterogeneous molecular subgroups that differ in prognosis. This 
provides promise that spectroscopy would be able to identify this information 
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non-invasively. The accurate assignment of the prognostic markers particularly in 
the region of 2.0 ppm will be best determined in tissue samples from tumour 
tissue banks using in vitro high-resolution spectroscopy methods. Since molecular 
subtypes of MB can be determined on paraffin embedded tumour tissue, 
combining this with in vitro HR-MAS would be intriguing to explore. Confirming in 
vivo findings and identifying metabolites that may correlate and mapping these 
with the preferred metabolic networks being utilised by these tumours is of great 
interest. It would also be beneficial to correlate spectroscopy findings with genetic 
subgroup information. 
5) Spectroscopy is able to identify key differences between tumours of the brain 
stem for example Cit, mIns and low lipids seen in DIPG. This provides further 
evidence for the technique as a useful tool for characterisation. This is particularly 
pertinent for these tumours as they are often diagnosed without a biopsy thereby 
making them clinically challenging to diagnose. Taurine was found to be 
associated with a significantly better prognosis in DIPG identifying cases which 
become long term survivors. With the increasing interest in biopsying DIPG and 
understanding the underlying biology of brain tumours HR-MAS may be able to 
confirm the presence of taurine and differences in long term survivors. This could 
be explored by obtaining archived tumour tissue samples from local and national 
banks of either biopsied DIPGs and/or tumours at autopsy. Another possible 
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source of tumour tissue would be histopathological diagnoses that match autopsy 
samples so anaplastic astrocytomas and high grade gliomas. 
6) Single voxel spectroscopy at 3 T has shown an improvement in spectral resolution 
and metabolite determination for some metabolites when compared to 1.5 T. SNR 
shows improvement when comparing the same patients on the same scanner but 
not when comparing different patients at the two field strengths. To the best of 
our knowledge, this is the first study comparing spectroscopy at different field 
strengths in paediatric patients. The advantages of the theoretical increase in SNR 
with increasing field strength have been used to acquire metabolic information 
from smaller lesions of interest to answer clinical questions rather than save 
scanner protocol time as originally envisaged. Establishing if obtaining more pre-
treatment spectroscopy data on paediatric patients at 3 T can demonstrate 
further differentiation of tumour types and whether it can eliminate the use of 
two echo times for metabolite determination would be an approach to explore. 
10.1 Summary of findings 
This thesis demonstrates why single voxel magnetic resonance spectroscopy is a valuable 
adjunct to conventional MRI sequences in the evaluation of childhood brain tumours. The 
additional information provided by this technique is summarised in Figure 10.1 
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Figure 10.1 Summary of results  
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APPENDIX 1 METABOLITE BASIS FUNCTIONS USED IN TARQUIN  
1.5 T 
Ala 
group independance T1 lineshape alpha beta 
  
    
1 1 0 l 2.5 0 
  
    
2 2 0 l 2.5 0 
  
    
group symmetry spin chemical shift 
   
    
1 1 0.5 3.7746 0 
   
    
2 1 0.5 1.4667 7.234 0 
  
    
2 1 0.5 1.4667 7.234 -14.366 0 
 
    
2 1 0.5 1.4667 7.234 -14.366 -14.366 0     
Asp 
group independance T1 lineshape alpha beta 
  
    
1 1 0 l 2.5 0 
  
    
2 2 0 l 2.5 0 
  
    
3 3 0 l 2.5 0 
  
    
group symmetry spin chemical shift 
   
    
1 1 0.5 3.8914 0 
   
    
2 1 0.5 2.8011 3.647 0 
  
    
3 1 0.5 2.6533 9.107 -17.426 0 
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Cr 
group independance T1 lineshape alpha beta 
  
    
1 1 0 l 2.5 0 
  
    
2 2 0 l 2.5 0 
  
    
group symmetry spin chemical shift 
   
    
1 3 0.5 3.027 0 
   
    
group symmetry spin chemical shift 
   
    
2 2 0.5 3.913 0 
  
    
Cit 
group independance T1 lineshape alpha beta 
 
    
1 1 0 l 2.5 0 
 
    
2 2 0 l 2.5 0      
group symmetry spin chemical shift 
   
    
1 1 0.5 2.6735 0 
  
    
2 1 0.5 2.5265 16.1 0      
-CrCH2 
group independance T1 lineshape alpha beta 
 
    
1 1 0 l 2.5 0 
 
    
group symmetry spin chemical shift 
   
    
1 -2 0.5 3.913 0 
  
    
GABA 
group independance T1 lineshape alpha beta 
 
    
1 1 0 l 2.5 0 
 
    
2 2 0 l 2.5 0 
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3 3 0 l 2.5 0 
 
    
group symmetry spin chemical shift 
   
    
1 1 0.5 3.0128 0 
  
    
1 1 0.5 3.0128 -12.021 0      
2 1 0.5 1.889 5.372 10.578 0     
2 1 0.5 1.889 7.127 6.982 -13.121 0    
3 1 0.5 2.284 0 0 7.755 6.173 0   
3 1 0.5 2.284 0 0 7.432 7.933 -10.744 0  
Glc 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 1 0 l 2.5 0      
3 1 0 l 2.5 0      
4 1 0 l 2.5 0      
5 1 0 l 2.5 0      
6 1 0 l 2.5 0      
7 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 0 0.5 5.216 0       
2 1 0.5 3.519 3.8 0      
3 1 0.5 3.698 0 9.6 0     
4 1 0.5 3.395 0 0 9.4 0    
5 1 0.5 3.822 0 0 0 9.9 0   
6 1 0.5 3.826 0 0 0 0 1.5 0  
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7 1 0.5 3.749 0 0 0 0 6 -12.1 0 
Gln 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 2 0 l 2.5 0      
4 2 0 l 2.5 0      
5 2 0 l 2.5 0      
group symmetry spin chemical shift        
1 1 0.5 3.753 0       
2 1 0.5 2.129 5.847 0      
3 1 0.5 2.19 6.5 -14.504 0     
4 1 0.5 2.432 0 9.165 6.324 0    
5 1 0.5 2.454 0 6.347 9.209 -15.371 0   
Glu 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 2 0 l 2.5 0      
4 2 0 l 2.5 0      
5 2 0 l 2.5 0      
group symmetry spin chemical shift        
1 1 0.5 3.7433 0       
2 1 0.5 2.0375 7.331 0      
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3 1 0.5 2.12 4.651 -14.849 0     
4 1 0.5 2.3378 0 6.413 8.478 0    
5 1 0.5 2.352 0 8.406 6.875 -15.915 0   
Gly 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 1 0.5 3.5480 0       
GPC 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 3 0 l 2.5 0      
4 3 0 l 2.5 0      
5 3 0 l 2.5 0      
6 4 0 l 2.5 0      
7 2 0 l 2.5 0      
8 4 0 l 2.5 0      
9 4 0 l 2.5 0      
group symmetry spin chemical shift        
1 9 0.5 3.212 0       
group symmetry spin chemical shift        
2 1 0.5 3.605 0       
2 1 0.5 3.672 -14.78 0      
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3 1 0.5 3.903 5.77 4.53 0     
4 1 0.5 3.871 0 5.77 0 0    
4 1 0.5 3.946 0 4.53 0 -14.78 0   
5 0 0.5 0 0 0 0 6.03 6.03 0  
group symmetry spin chemical shift        
6 0 0.5 4.312 0       
6 0 0.5 4.312 -9.32 0      
7 1 0.5 3.659 3.1 5.9 0     
7 1 0.5 3.659 5.9 3.1 -9.32 0    
8 0 1 0 2.67 2.67 0 0 0   
9 0 0.5 0 6.03 6.03 0 0 0 0  
Gua 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 2 0.5 3.78 0       
mIns 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 1 0 l 2.5 0      
3 1 0 l 2.5 0      
4 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 1 0.5 3.5217 0       
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2 0 0.5 4.0538 2.889 0      
1 1 0.5 3.5217 0 3.006 0     
3 1 0.5 3.6144 0 0 9.997 0    
4 1 0.5 3.269 0 0 0 9.485 0   
3 1 0.5 3.6144 9.998 0 0 0 9.482 0  
Lac 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
group symmetry spin chemical shift        
1 0 0.5 4.0974 0       
2 1 0.5 1.3142 6.933 0      
2 1 0.5 1.3142 6.933 0 0     
2 1 0.5 1.3142 6.933 0 0 0    
Lip09 
group independance T1 lineshape alpha beta      
1 1 0 g 0 283.4      
group symmetry spin chemical shift        
1 3 0.5 0.89 0       
Lip13a 
group independance T1 lineshape alpha beta      
1 1 0 g 0 325.2      
group symmetry spin chemical shift        
1 2 0.5 1.28 0       
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Lip13b 
group independance T1 lineshape alpha beta      
1 1 0 g 0 114.5      
group symmetry spin chemical shift        
1 2 0.5 1.28 0       
Lip20 
group independance T1 lineshape alpha beta      
1 1 0 g 0 325.3      
2 1 0 g 0 578.3      
group symmetry spin chemical shift        
1 1.33 0.5 2.04 0       
1 0.67 0.5 2.25 0 0      
2 0.87 0.5 2.8 0 0 0     
MM09 
group independance T1 lineshape alpha beta      
1 1 0 g 0 283.4      
group symmetry spin chemical shift        
1 3 0.5 0.91 0       
MM12 
group independance T1 lineshape alpha beta      
1 1 0 g 0 325.3      
group symmetry spin chemical shift        
1 2 0.5 1.21 0       
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MM14 
group independance T1 lineshape alpha beta      
1 1 0 g 0 417.8      
group symmetry spin chemical shift        
1 2 0.5 1.43 0       
MM17 
group independance T1 lineshape alpha beta      
1 1 0 g 0 325.3      
group symmetry spin chemical shift        
1 2 0.5 1.67 0       
MM20 
group independance T1 lineshape alpha beta      
1 1 0 g 0 325.3      
2 1 0 g 0 578.3      
group symmetry spin chemical shift        
1 1.33 0.5 2.08 0       
2 0.33 0.5 2.25 0 0      
1 0.33 0.5 1.95 0 0 0     
2 0.4 0.5 3 0 0 0 0    
NAA 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 3 0 l 2.5 0      
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4 3 0 l 2.5 0      
group symmetry spin chemical shift        
1 3 0.5 2.008 0       
group symmetry spin chemical shift        
2 0 0.5 4.3817 0       
3 1 0.5 2.6727 3.861 0      
4 1 0.5 2.4863 9.821 -15.592 0     
NAAG 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 3 0.5 2.042 0       
PCh 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 2 0 l 2.5 0      
4 3 0 l 2.5 0      
5 3 0 l 2.5 0      
6 3 0 l 2.5 0      
7 3 0 l 2.5 0      
group symmetry spin chem shift        
1 9 0.5 3.208 0       
group symmetry spin chem shift        
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2 0 0.5 4.2805 0       
3 0 0.5 4.2805 -14.89 0      
4 1 0.5 3.641 2.284 7.326 0     
5 1 0.5 3.641 7.231 2.235 -14.19 0    
6 0 1 0 2.68 2.772 0 0 0   
7 0 0.5 0 6.298 6.249 0 0 0 0  
sIns 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chem shift        
1 6 0.5 3.34 0       
Tau 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 1 0 l 2.5 0      
group symmetry spin chem shift        
1 1 0.5 3.4206 0       
1 1 0.5 3.4206 -12.438 0      
2 1 0.5 3.2459 6.742 6.403 0     
2 1 0.5 3.2459 6.464 6.792 -12.93 0    
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3 T 
Ala 
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
2 2 0 l 2.5 0 
  
   
group symmetry spin chemical shift 
   
   
1 1 0.5 3.7746 0 
   
   
2 1 0.5 1.4667 7.234 0 
  
   
2 1 0.5 1.4667 7.234 -14.366 0 
 
   
2 1 0.5 1.4667 7.234 -14.366 -14.366 0    
Asp 
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
2 2 0 l 2.5 0 
  
   
3 3 0 l 2.5 0 
  
   
group symmetry spin chemical shift 
    
   
1 1 0.5 3.8914 0 
   
   
2 1 0.5 2.8011 3.647 0 
  
   
3 1 0.5 2.6533 9.107 -17.426 0 
 
   
Cit 
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
2 2 0 l 2.5 0      
group symmetry spin chemical shift 
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1 1 0.5 2.6735 0 
   
   
2 1 0.5 2.5265 16.1 0      
Cr 
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
2 2 0 l 2.5 0 
  
   
group symmetry spin chemical shift 
    
   
1 3 0.5 3.027 0 
   
   
group symmetry spin chemical shift 
    
   
2 2 0.5 3.913 0 
   
   
-CrCH2 
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
group symmetry spin chem shift 
    
   
1 -2 0.5 3.913 0 
   
   
GABA    
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
2 2 0 l 2.5 0 
  
   
3 3 0 l 2.5 0 
  
   
group symmetry spin chemical shift 
    
   
1 1 0.5 3.0128 0 
   
   
1 1 0.5 3.0128 -12.021 0 
  
   
2 1 0.5 1.889 5.372 10.578 0 
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2 1 0.5 1.889 7.127 6.982 -13.121 0    
3 1 0.5 2.284 0 0 7.755 6.173 0   
3 1 0.5 2.284 0 0 7.432 7.933 -10.744 0  
Glc 
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
2 1 0 l 2.5 0 
  
   
3 1 0 l 2.5 0 
  
   
4 1 0 l 2.5 0 
  
   
5 1 0 l 2.5 0 
  
   
6 1 0 l 2.5 0 
  
   
7 1 0 l 2.5 0 
  
   
group symmetry spin chemical shift 
    
   
1 0 0.5 5.216 0 
   
   
2 1 0.5 3.519 3.8 0 
  
   
3 1 0.5 3.698 0 9.6 0 
 
   
4 1 0.5 3.395 0 0 9.4 0    
5 1 0.5 3.822 0 0 0 9.9 0   
6 1 0.5 3.826 0 0 0 0 1.5 0  
7 1 0.5 3.749 0 0 0 0 6 -12.1 0 
Gln 
group independance T1 lineshape alpha beta 
  
   
1 1 0 l 2.5 0 
  
   
2 2 0 l 2.5 0 
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3 2 0 l 2.5 0 
  
   
4 2 0 l 2.5 0 
  
   
5 2 0 l 2.5 0 
  
   
group symmetry spin chem shift 
    
   
1 1 0.5 3.753 0 
   
   
2 1 0.5 2.129 5.847 0      
3 1 0.5 2.19 6.5 -14.504 0     
4 1 0.5 2.432 0 9.165 6.324 0    
5 1 0.5 2.454 0 6.347 9.209 -15.371 0   
Glu 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 2 0 l 2.5 0      
4 2 0 l 2.5 0      
5 2 0 l 2.5 0      
group symmetry spin chemical shift        
           
1 1 0.5 3.7433 0       
2 1 0.5 2.0375 7.331 0      
3 1 0.5 2.12 4.651 -14.849 0     
4 1 0.5 2.3378 0 6.413 8.478 0    
5 1 0.5 2.352 0 8.406 6.875 -15.915 0   
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Gly 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 1 0.5 3.5480 0       
GPC 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 3 0 l 2.5 0      
4 3 0 l 2.5 0      
5 3 0 l 2.5 0      
6 4 0 l 2.5 0      
7 2 0 l 2.5 0      
8 4 0 l 2.5 0      
9 4 0 l 2.5 0      
group symmetry spin chemical shift        
1 9 0.5 3.212 0       
group symmetry spin chemical shift        
2 1 0.5 3.605 0       
2 1 0.5 3.672 -14.78 0      
3 1 0.5 3.903 5.77 4.53 0     
4 1 0.5 3.871 0 5.77 0 0    
4 1 0.5 3.946 0 4.53 0 -14.78 0   
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5 0 0.5 0 0 0 0 6.03 6.03 0  
group symmetry spin chemical shift        
6 1 0.5 4.312 0       
6 1 0.5 4.312 -9.32 0      
7 1 0.5 3.659 3.1 5.9 0     
7 1 0.5 3.659 5.9 3.1 -9.32 0    
8 0 1 0 2.67 2.67 0 0 0   
9 0 0.5 0 6.03 6.03 0 0 0 0  
Gua 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 2 0.5 3.78 0       
mIns 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 1 0 l 2.5 0      
3 1 0 l 2.5 0      
4 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 1 0.5 3.5217 0       
2 1 0.5 4.0538 2.889 0      
1 1 0.5 3.5217 0 3.006 0     
3 1 0.5 3.6144 0 0 9.997 0    
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4 1 0.5 3.269 0 0 0 9.485 0   
3 1 0.5 3.6144 9.998 0 0 0 9.482 0  
Lac 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
group symmetry spin chemical shift        
1 1 0.5 4.0974 0       
2 1 0.5 1.3142 6.933 0      
2 1 0.5 1.3142 6.933 0 0     
2 1 0.5 1.3142 6.933 0 0 0    
Lip09 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1139      
group symmetry spin chemical shift        
1 3 0.5 0.89 0       
Lip13a 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1307      
group symmetry spin chemical shift        
1 2 0.5 1.28 0       
Lip13b 
group independance T1 lineshape alpha beta      
1 1 0 g 0 460.4      
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group symmetry spin chemical shift        
1 2 0.5 1.28 0       
Lip20 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1307      
2 1 0 g 0 2325      
group symmetry spin chemical shift        
1 1.33 0.5 2.04 0       
1 0.67 0.5 2.25 0 0      
2 0.87 0.5 2.8 0 0 0     
MM09 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1139      
group symmetry spin chemical shift        
1 3 0.5 0.91 0       
MM12 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1307      
group symmetry spin chemical shift        
1 2 0.5 1.21 0       
MM14 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1679      
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group symmetry spin chemical shift        
1 2 0.5 1.43 0       
MM17 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1307      
group symmetry spin chemical shift        
1 2 0.5 1.67 0       
MM20 
group independance T1 lineshape alpha beta      
1 1 0 g 0 1307      
2 1 0 g 0 2325      
group symmetry spin chemical shift        
1 1.33 0.5 2.08 0       
2 0.33 0.5 2.25 0 0      
1 0.33 0.5 1.95 0 0 0     
2 0.4 0.5 3 0 0 0 0    
NAA 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 3 0 l 2.5 0      
4 3 0 l 2.5 0      
group symmetry spin chemical shift        
1 3 0.5 2.008 0       
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group symmetry spin chemical shift        
2 1 0.5 4.3817 0       
3 1 0.5 2.6727 3.861 0      
4 1 0.5 2.4863 9.821 -15.592 0     
NAAG 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chemical shift        
1 3 0.5 2.042 0       
PCh 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 2 0 l 2.5 0      
3 2 0 l 2.5 0      
4 3 0 l 2.5 0      
5 3 0 l 2.5 0      
6 3 0 l 2.5 0      
7 3 0 l 2.5 0      
group symmetry spin chemical shift        
1 9 0.5 3.208 0       
group symmetry spin chemical shift        
2 1 0.5 4.2805 0       
3 1 0.5 4.2805 -14.89 0      
4 1 0.5 3.641 2.284 7.326 0     
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5 1 0.5 3.641 7.231 2.235 -14.19 0    
6 0 1 0 2.68 2.772 0 0 0   
7 0 0.5 0 6.298 6.249 0 0 0 0  
sIns 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
group symmetry spin chem shift        
1 6 0.5 3.34 0       
Tau 
group independance T1 lineshape alpha beta      
1 1 0 l 2.5 0      
2 1 0 l 2.5 0      
group symmetry spin chem shift        
1 1 0.5 3.4206 0       
1 1 0.5 3.4206 -12.438 0      
2 1 0.5 3.2459 6.742 6.403 0     
2 1 0.5 3.2459 6.464 6.792 -12.93 0    
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APPENDIX 2 LOW GRADE VS. HIGH GRADE 
Mean metabolite concentrations (mM) ± SD of short echo time pre-treatment low grade tumours 
(I+II) vs. high grade brain tumours (III +IV) at 1.5 T with p values determined using Mann-Whitney 
U-test. 
Metabolites concs (mM± SD) P values LG (n=65) HG(n=58) 
Ala n.s 0.36±0.63 0.41±0.73 
Asp **** 0.85±1.26 0.61±2.07 
Cit ** 0.44±0.38 0.64±0.57 
Cr *** 1.67±1.84 2.43±1.52 
GABA * 0.95±1.28 1.53±1.59 
tCho **** 1.25±0.84 2.89±1.69 
Glc **** 2.25±1.81 1.03±1.73 
Gln n.s 3.25±1.83 3.02±2.48 
Glu * 1.86±1.46 2.78±2.20 
Glx n.s 5.11±2.34 5.80±3.19 
Gly **** 1.17±2.01 2.68±2.27 
Gua **** 0.34±0.52 0.99±1.20 
mIns * 2.18±3.77 1.36±2.78 
Lac * 2.18±1.78 3.08±2.45 
LMM0.9 **** 4.31±2.76 7.32±3.83 
LMM1.3 **** 6.68±6.17 17.90±15.4 
LMM2.0 **** 7.67±4.62 10.86±3.22 
NAA n.s 1.46±0.81 1.20±0.82 
sIns **** 0.14±0.25 0.36±0.41 
Tau ** 0.66±0.93 1.94±2.25 
Note: - n.s not significant * P<0.05 ** P<0.01 *** P<0.001 **** P<0.00001 
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16thAnnual Scientific Meeting of the British Chapter of the ISMRM, Nottingham, September 2010 
A multi-centre study of 1H-Magnetic Resonance Spectroscopy  
in the diagnosis and prognosis of brain stem tumours in children 
SK Gill
1,2
,LM Harris
1,2
, NP Davies
1,2
, YSun
1,2
 , K Natarajan
1,2
, L MacPherson
1,2
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1,2
,D Hargrave
3,4
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Payne
3,4
 , MO Leach
3,4
 , FA Howe
5
 , P Morgan
6
, D Saunders
7
, DP Auer
6
 , T Jaspan
6
 , RG Grundy
6
, AC Peet 
1,2 
1
Cancer Sciences, University of Birmingham, Birmingham,
 2
Birmingham Children’s Hospital, Birmingham, 
3
Royal Marsden Hospital, Sutton, 
4
Institute of Cancer Research, Sutton,
 5
St. Georges, University of London, 
6
Children’s Brain Tumour Research Centre, Nottingham University Hospitals, 
7
Great Ormond Street 
Hospital, London, United Kingdom 
Introduction   
Brain stem tumours in children pose particularly difficult management challenges. Tumours can be either 
diffuse or focal. Diffuse Pontine Gliomas (DPG) are usually diagnosed on clinical and imaging grounds alone 
with no biopsy being performed and have a particularly poor prognosis with a median survival of 9 months. 
There are a few long term survivors of DPGs but there are no imaging characteristics which can identify this 
good prognostic group at diagnosis and the lack of biopsy material reduces the opportunity to determine 
biological markers of good prognosis. The establishment of novel imaging biomarkers which can aid with 
the diagnosis and characterization of childhood brain stem tumours and identify diffuse tumours with a 
good prognosis would be a significant clinical advance. However, the comparative rarity of these tumours 
mandates a multi-centre approach. This study investigates metabolite differences in childhood brain stem 
tumours from a multi-centre cohort which is large compared with previous studies and has follow-up of the 
patients to determine length of survival. 
Patients and Methods   
A multi-centre study was performed using single voxel MRS (1.5 T or 3 T, PRESS, TE 30 or TE 38ms, TR 
1500ms) on 30 children during routine MRI scans prior to treatment from 4 centres across the UK. 
Diagnosis was made on the basis of central pathology review where tissue was available or central 
radiology review. The cohort consists of 15 DPGs, 5 high grade gliomas (HGGs), 4 low grade gliomas (LGGs) 
and 6 tumours with no definitive consensus diagnosis. Spectra were processed using LCModel with a 
stimulated citrate component incorporated into the standard basis set of 16 metabolites and 9 lipids and 
macromolecules (LMM) components. 24 spectra met quality control and were analysed. All statistical 
analysis was performed using R Statistical Software and quantitation was relative to a water reference 
spectrum and normalised to sum of all metabolites. Two-tailed t-tests were performed to investigate 
significant differences between diffuse vs. focal tumours (where focal tumours are defined as HGGs and 
LGGs) and between HGGs vs. LGGs. ANOVA was performed to investigate significant differences between 
DPGs, HGGs and LGGs. Principal Component analysis was performed and also used for dimension reduction 
prior to linear discriminant analysis (LDA) for classification of undiagnosed cases.  Survival data was 
available for 22 out of the 30 cases with a minimum follow-up of 3 years. 
Results  
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From the figure, DPGs differ from HGG and LGG mean spectra showing high myo-inositol (mIns) and a 
prominent peak around 2.6ppm assigned to citrate. T-tests showed diffuse tumours had significantly higher 
mIns (6 vs 3, p= 0.01); scyllo-inositol (0.2 vs 0.06, p=0.003) and citrate (0.7 vs 0.3, p=0.003) but significantly 
lower LMM at 0.9ppm (4.2 vs 6.5, p= 0.05) and 2.0 ppm (7 vs 11, p=0.05). There were no significant 
differences between focal HGG and LGG. PCA of all brain stem tumours demonstrated that the loadings 
were dominated by lipids and mIns. LDA showed that diffuse and focal tumours could be separated with 
the largest linear discriminant co-efficient being citrate. Of those who were biopsied, there was no 
correlation between grade of astrocytoma and survival. In the group of DPG, LMM were significantly higher 
at 0.9, 1.3 and 2.0ppm in those surviving less than 1 year. Out of all the DPGs the only survivor, now at 3 
years, had the highest mIns in the group. Another patient who is still alive more than 5 years after diagnosis 
with a diffuse tumour of the pons had a markedly different MRS from the DPG group, confirmed by being 
an outlier on the PCA. Biopsy confirmed this case to be a diffuse astrocytoma which is consistent with the 
know histology of DPG.  
Conclusions  
MRS shows significant differences in the metabolite profiles between diffuse and focal tumours of the brain 
stem and this may be useful in aiding the non-invasive diagnosis of these tumours. The presence of a peak 
at 2.6ppm assigned to citrate and high myoinositol are spectral characteristics of DPGs which could be 
readily identified in a clinical setting. Of particular interest is that two patients who were thought to have a 
very poor prognosis but are currently doing well had spectral characteristics which set them apart from the 
group of DPG. The higher LMM in the DPGs surviving less than a year provides further evidence that lipids 
are bio-markers of poor prognosis. MRS is a useful adjunct to the characterisation of brain stem tumours 
and more widespread clinical evaluation of the method is warranted. 
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1H Magnetic Resonance Spectroscopy for characterising medulloblastomas in children 
SK Gill1,2, M Wilson1,2, NP Davies1,2,3, YSun1,2 , K Natarajan1,2,3, L MacPherson1,2, TN Arvanitis2,4, AC Peet 1,2  
1Cancer Sciences, University of Birmingham, Birmingham, 2Birmingham Children’s Hospital, Birmingham  
3Medical Imaging and Physics, University Hospital Birmingham. 4Electrical, Electronic and Computer 
Engineering, University of Birmingham  
Introduction  
Medulloblastomas (MBs) are highly aggressive tumours arising from the cerebellum accounting for 10-20% 
of all brain tumours in children. These tumours are staged through the Chang classification, from M0 to M4 
where increasing stage corresponds to degree of disease spread and poorer prognosis. However, not all 
patients with localised disease (M0) survive and identifying these patients at diagnosis is a key challenge in 
medulloblastoma research. In this study we hypothesise that MRS can distinguish between different stages 
of medulloblastoma and provide prognostic markers to identify patients with poor prognosis.  
Patients and Methods  
Single voxel MRS (1.5 T, TE 30, TR 1500ms) was performed on 30 children during routine MRI scans for a 
suspected brain tumour prior to treatment at the Birmingham Children’s Hospital where tumour diagnosis 
was made by histopathology. The cohort consists of Chang stages M0 to M3 , M0 (n=14),M1 (n=4), M2 
(n=4) and M3 (n=8). Spectra were analysed using TARQUIN with a stimulated citrate and glycine component 
incorporated into the standard basis set. Quality control measures were met by all cases. All statistical 
analysis was performed using R Statistical Software and quantitation was relative to a water reference 
spectrum. Two-tailed t-tests were performed to investigate differences between metabolite profiles of 
localised M0 MBs and metastatic (M1 to M3) MBs. Lipid and metabolite profiles were used as the input to a 
Principal Component Analysis which was also used for dimension reduction prior to linear discriminant 
analysis (LDA). Survival data was available for 28 out of the 30 cases, with follow-up being up to 7 years.  
Results  
  
Figure 1 a) An example spectrum of a patient with very high lipids that survived less than a year following 
diagnosis b) Kaplan Meier curves for patients with M0 MB comparing those high (> 20) and low lipid and 
MMs levels at 1.3ppm.  
Mean spectra generated from the four Chang Stages showed very little variability in metabolite profiles 
except in the lipid and macromolecular (MM) peak at 1.3ppm. Univariate analysis (T-test) between M0 and 
M1-M3 revealed that levels of lipids and MM at 1.3ppm were the only statistically significant difference 
between the two groups. High variability in these lipids and MMs was a strong feature of the M0 MBs not 
seen in the other Chang stages (fig 1a). Principal Component analysis and linear discriminant analysis were 
dominated by Lipids at 1.3ppm and cases with extremely high lipids were seen as large outliers to the main 
group of patients. For the M0 cases, 4 out of the 5 patients who were outliers on the LDA died whilst only 2 
of the remaining 8 patients died. A log rank test using only lipids at 1.3ppm for the M0 MB patients failed to 
reach statistical significance for the difference in survival (fig 1b).  
Conclusions  
Significant differences have been found in lipid and MM levels between localised (M0) and metastatic (M1-
3) medulloblastoma at diagnosis. A subset of the localised tumours have metabolite profiles which 
distinguish them from the other tumours mainly due to their very high lipid levels and this group is 
a) 
b) 
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associated with poor survival. MRS is a non-invasive tool that can improve characterisation of tumours and 
provides potential biomarkers of prognosis in M0 medulloblastomas.  
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Introduction 
Brain tumours are the most common solid tumour diagnosed in children. Whilst some brain tumours have a 
good prognosis, others have continued to present major challenges and are now the leading cause of death 
in children. Difficulties arise when trying to accurately diagnose abnormalities detected during tumour 
surveillance. Currently tumour assessment of high grade tumours is performed using the RANO criteria, 
where increases of 2D measurements  on consecutive MRI scans and clinical factors help determine the 
presence of tumour recurrence. In addition influences the decision of a tumour biopsy being performed. 
However, there are limitations to these criteria as not all changes are tumour growth specific and tumour 
biopsies are rarely performed at relapse. This study investigates how metabolite profiles of brain tumours 
analysed using TARQUIN software differ from diagnosis to first relapse of a tumour including clinical course 
of all patients to provide confirmation of tumour behaviour. Correct characterisation of tumour relapse is 
crucial to the management of brain tumours. 
Patients and Methods 
Single voxel 1H MRS (1.5 T, PRESS, TE 30ms, TR 1500ms) was performed on 20 children during routine MRI 
scans for a suspected high grade brain tumour prior to treatment at the Birmingham Children’s Hospital. 
Following MRI, 19 patients underwent either a tumour resection or biopsy and all patients underwent 
either focal or craniospinal radiotherapy and/or chemotherapy. Diagnosis was made on histopathology 
where tissue was available or on the basis of MR imaging alone (1 case). The inclusion criteria for the cohort 
was high grade tumours only with the exception of diffuse astrocytomas. The cohort consists of 7 different 
tumours types including 4 glioblastoma multiforme, 4 medulloblastomas, 4 diffuse astrocytomas, 3 
ependymomas , 2 CNS primitive neuroectodermal tumours, 1 atypical teratoid rhadbdoid tumour and 1case 
with gliomatosis cereberi. 19 cases met quality control (38 spectra from 19 cases). Spectra were processed 
using TARQUIN with a basis set of 18 metabolites and 9 lipids and macromolecules (LMM) including citrate 
and glycine with quantitation relative to a water reference spectrum. All statistical analysis was performed 
using R Statistical Software. Paired Student’s t-tests were performed between metabolite profiles at 
diagnosis and those at radiologically confirmed first relapse. This consisted of comparing all, comparing 
local first relapses only and distant first relapses only. Box and whisker plots were constructed to compare 
differences between metabolites, lipid and macromolecules at diagnosis and first relapse. Line plots were 
constructed to compare differences between levels of four variables  choline, myo-inositol, NAA and lipids 
at 1.3ppm at diagnosis and first relapse.  
Results 
Paired Student’s t-test analysis between pre-diagnostic metabolite profiles and those at first relapse (n=19) 
demonstrated no significant differences in metabolites or combined and individual lipid and 
macromolecules components at 0.9, 1.3 and 2.0ppm (p> 0.05). Analysis of pre-diagnostic metabolite 
profiles and those at first local relapse (n=12) demonstrated no significant differences in metabolites or 
combined and individual macromolecules and lipid components at 0.9, 1.3 and 2.0ppm (p> 0.05). Paired t-
test analysis between pre-diagnostic metabolite profiles and those at first distant relapse (n=7) also 
demonstrated no significant differences in metabolites or combined and individual macromolecules and 
lipid components at 0.9, 1.3 and 2.0ppm (p> 0.05). However, Lipids at 1.3ppm were close to significance 
(p=0.07, 6.5 vs. 12.9).  Box and whisker plot demonstrated no specific tumour type trends, however lipids 
and MMs&lipids at 1.3ppm demonstrated a large range of differences with 13 out of the 19 cases 
demonstrating higher levels at first relapse. Line plots of the 4 variables demonstrated relatively stable 
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levels between diagnosis and first relapse with only a few cases showing considerable change (of either 
increase or decrease).  
Conclusions 
MRS demonstrated no significant difference between pre-diagnostic metabolite profiles and those at first 
relapse (P>0.05). This study shows the metabolite profile of a tumour can aid the confirmation of tumour 
progression if the metabolite profile appears to be comparable to the diagnostic spectrum as opposed to 
post treatment effects. However, caution needs to be taken when interpreting the spectra. It is important 
that spectra meet the quality control criteria in particular ensuring the voxel does not contain normal brain. 
Interestingly there were a number of patients who, when compared on an individual case basis by 
qualitative analysis, demonstrated differences in metabolite profiles (particularly those with MRS over 
subsequent relapses). MRS is useful in characterising tumour progression. However, these findings need to 
be confirmed by a large multi-centre study, which ideally needs to be performed with cases grouped by 
tumour subtypes rather than grouped as a whole. Comparisons with MRS of post treatment related 
changes are also required as a comparator group to strengthen the analysis.   
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Introduction: In vivo 1H single voxel (SV) MRS is a promising technique used in characterising brain 
pathology in adults and children at 1.5 T. However, there are limited studies performed at 3T particularly in 
paediatric patients. The aim of this study was to determine whether higher field strength of 3T 
demonstrates an improvement in metabolite determination and quality of data acquired in paediatric 
patients. 
Methods:  SV MRS was performed on 5 paediatric patients with inherited metabolic disorders on both a 1.5 
T Siemens and 3T Phillips Achieva TX, using the PRESS sequence. Patients within the cohort were matched 
for voxel locations on both scanners. The core acquisition protocol at 1.5 T comprised of a TE/TR/NSA of 
30ms/1500ms/128 and at 3T 38ms/2000ms/128. All spectra passed QC criteria. Raw data was taken from 
the scanner and analysed with TARQUIN (Version 4.2.10), fitting to a linear combination of metabolite basis 
functions generated at the correct field strength and echo time [1]. 
Results 
 
 
 
 
 
 
 
 
 
Comparing MRS at 3 T and 1.5 T demonstrated significantly (t-test, p<0.05) higher signal-to-noise ratio 
(SNR) with an overall increase of 76% equivalent to a 32% increase per unit acquisition time. An improved 
spectral resolution was shown by a significant reduction in water line width (0.078 vs. 0.053 ppm, t-test, 
p<0.05). Comparing mean metabolite concentrations demonstrated no significant differences between 
metabolite concentrations at 1.5 T and 3 T (Wilcoxon signed rank test).  Cramer-Rao Lower Bounds (CRLBs) 
were significantly lower in 15 out of 27 metabolites at 3 T confirming improved metabolite quantification. 
These included creatine (Cr), glutamate (Glu), glutamine (Gln), glycine, myo-inositol (mIns) and N-acetyl-
aspartate(NAA), metabolites known to be important in brain pathology. Figure 1 shows an example case. 
Discussion: Whilst the use of higher field strengths theoretically has many benefits for MRS including 
increased spectral resolution, there are few studies that have demonstrated this within a clinical 
environment and none published in children to our knowledge. This study shows the improvement in 
metabolite profile quantification which can be achieved at a higher field strength of 3T in children with 
neurological disorders. The increased spectral resolution allows a better discrimination between closely 
overlapping metabolites for example myo-inositol and glycine. This distinction is particularly important in 
Figure 1 Spectra and TARQUIN fit obtained from 
the left basal ganglia in a patient with an inherited 
metabolic disorder at a) 1.5 T  and b) at 3T 
Figure  2 Spectra and TARQUIN fit obtained from a 
patient with a tectal plate glioma at a) 1.5 T  and b) 
at 3 T 
 
Chemical shift (ppm) Chemical shift (ppm) 
Chemical shift (ppm) Chemical shift (ppm) 
 
1b) 
1a) 2a) 
2b) 
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brain tumours since myo-inositol has been demonstrated to be a marker of good prognosis and glycine, a 
marker of poor prognosis [2]. Figure 2 demonstrates a case from a child with a brain tumour that was 
scanned pre-treatment at 1.5 T and 3 T. In this example the resonances are shown to be readily 
distinguishable only at the higher field strength. 
Conclusion: This study provides a promising initial indication of improvement in short echo time proton 
spectroscopy at 3T compared with 1.5 T in paediatric patients. Improved metabolite profile determination 
should lead to better tissue characterization encouraging the implementation of spectroscopy at 3T in a 
clinical environment. 
References: 1. Wilson M et al. 2011 MRM 65(1): 1-12.  2. Davies N. et al. 2009 NMR Biomed  23(1): 80-87. 
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Introduction 
Brain stem tumours in children are clinically difficult tumours to manage. Tumours can be either diffuse or 
focal. One subtype, Diffuse Pontine Gliomas (DPG) is usually diagnosed on clinical and imaging grounds 
alone with no biopsy being performed. They have a particularly poor prognosis, with a median survival of 9 
months. However, the group yields occasional long-term survivors with no current method of identifying 
these at diagnosis. As biopsies are rarely performed, no biological markers of prognosis can be determined. 
Novel imaging biomarkers are required to aid diagnosis and characterisation of brain stem tumours and 
identify good prognostic indicators at diagnosis. As these tumours are extremely rare, a multi-centre 
approach is required to obtain enough cases for robust statistical analysis. This multicentre study 
investigates potential diagnostic and prognostic metabolite differences in childhood brain stem tumours by 
comparison with diffuse and focal tumours elsewhere in the brain, TARQUIN software was used to quantify 
metabolite profiles allowing differences in echo time and field strength to be conveniently accounted for by 
simulation of appropriate basis sets. 
Patients and Methods  
A multi-centre study was performed using single voxel MRS (1.5 T or 3 T, PRESS, TE 30 or TE 38ms, TR 
1500ms) on 79 children during routine MRI scans prior to treatment at 4 centres across the UK. Diagnosis 
was made on the basis of central pathology review where tissue was available or central radiology review. 
The cohort consists of 15 DPGs, 12 high grade gliomas (HGGs), 52 pilocytic astrocytoma (PAs) and 6 
tumours with no definitive consensus diagnosis. Spectra were processed using TARQUIN with citrate (Cit) 
and glycine (Gly) in the basis set of 18 metabolites and 9 lipids and macromolecules (LMM) components. 59 
spectra met quality control criteria and were analysed. All statistical analysis was performed using R 
Statistical Software and quantitation was relative to a water reference spectrum and normalised to sum of 
all metabolites. Two-tailed t-tests were performed to investigate significant differences between diffuse vs. 
focal tumours (where focal tumours are defined as HGGs and PAs) and between HGGs vs. PAs. ANOVA was 
performed to investigate significant differences between DPGs, HGGs and PAs. Principal Component 
analysis was performed and also used for dimension reduction prior to linear discriminant analysis (LDA) for 
classification of undiagnosed cases. Within the DPG group, potential prognostic indicators were explored 
using two-tailed t-tests to compare between patients surviving more than and less than 1 year with follow-
up data available for up to three years. 
Results  
ANOVA demonstrated diffuse tumours to have significantly higher levels of  myo-inositol (mIns) (0.9 vs.0.7 
vs. 0.3 ,p < 0.01), total NAA (2.3 vs. 1.2 vs. 1.5,p < 0.01) and Creatine (Cr) (3 vs 1.42 vs. 0.9 ,p < 0.01) as well 
as Citrate (p < 0.01) , Gly (p < 0.01) and scyllo-inositol (p < 0.01) as shown in a previous study of brainstem 
tumours. Significantly higher levels of Gly (0.3 vs.0.6, p=0.04) and LMM at 0.9 ppm (4 vs 8, p=0.02), 1.3 ppm 
(6.5 vs 14, p<0.01) and 2.0 ppm  (6 vs. 11, p<0.01) were found in HGGs when compared to PAs. PCA of all 
the tumours demonstrated loadings dominated by lipids, glutamate and glutamine (Glx) and mIns. LDA 
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demonstrated scyllo-inositol to separate diffuse and focal tumours.  DPGs surviving less than 1 year 
demonstrated significantly higher levels of glutamine (Gln) (3 vs.0.7, p=0.007), lactate (1 vs.0.3, p=0.05), 
LMM at 2.0ppm (6vs. 4, p=0.05), tNAA (2.6 vs.1.7, p=0.05) and significantly lower levels of taurine (0.1 
vs.1.2, p=0.03) when compared to those surviving over 1 year. Of the DPG cohort only one survivor 
remains, now at 3 years, had the highest mIns in the group. Another patient who is still alive more than 5 
years after diagnosis with a diffuse tumour of the pons had a markedly different MRS from the DPG group, 
confirmed by being an outlier on the PCA. Biopsy confirmed this case to be a diffuse astrocytoma which is 
consistent with the known histology of DPG. 
Discussion and Conclusions  
MRS shows significant differences in the metabolite profiles between diffuse and focal tumours of the brain 
stem and this may be useful in aiding the non-invasive diagnosis of these tumours. The presence of a peak 
at 2.6ppm assigned to citrate and high myo-inositol are spectral characteristics of DPGs which could be 
readily identified in a clinical setting. Of particular interest is that two patients who were thought to have a 
very poor prognosis but are currently doing well had spectral characteristics which set them apart from the 
group of DPG. mIns is shown to be a marker of good prognosis. MRS is a useful adjunct to the 
characterisation of brain stem tumours and more widespread clinical evaluation of the method is 
warranted. 
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Introduction 
Magnetic resonance spectroscopy (MRS) is known to provide non-invasive biomarkers of tumour 
aggressiveness but studies are lacking in elaborating on specific tumour types and with long term follow-up 
for survival. Medulloblastomas (MB) are the most common malignant brain tumours of childhood and in 
this study we investigate whether MRS metabolite profiles can identify prognostic subgroups of this 
tumour. 
Patients and Methods 
Single voxel MRS (1.5 T, TE 30ms, TR 1500ms) was performed on 17 children with localised MB prior to 
treatment; patients were followed-up for a median of 3 years, 6 had died by the end of the study period. 
MRS was analysed using TARQUIN to provide metabolite concentrations. Principal component and linear 
discriminant analysis (PCA-LDA) were employed to determine metabolite profiles for good and poor 
prognosis groups. Kaplan Meier survival curves were constructed and pairwise correlation analysis 
(Pearson’s) performed on metabolite values.  
Results 
Metabolite profiles defined good and poor prognosis groups with 9/9 and 2/8 being alive at the end of the 
study, respectively. There was a significant difference in Kaplan Meier survival between the two groups (log 
rank test, p=0.03). The poor prognosis group had a higher tumour lipid/choline ratio (t-test, p = 0.03). 
Citrate levels correlated positively with glutamate+glutamine levels (Pearson’s correlation analysis p=0.001) 
in the good prognosis group but not in the poor prognosis group (p=0.5). 
Conclusions 
MRS metabolite profiles can be constructed that correspond to good and poor prognosis groups for MB, 
improving our understanding of these tumours and potentially allowing treatment to be refined. 
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and Andrew C. Peet1 
Abstract 
INTRODUCTION: Medulloblastomas (MBs) are highly aggressive tumours and not all patients with 
localised disease survive. Molecular markers from tumour tissue can define different prognostic 
groups and there is evidence that metabolism particularly related to glutamate could be 
important. This finding gives the opportunity to identify MB tumour subgroups non-invasively 
using magnetic resonance spectroscopy (MRS). In this study we investigate whether prognostic 
subgroups of M0 MB can be characterised by their MRS metabolite profiles. PATIENTS AND 
METHODS: Single voxel MRS (1.5 T, TE 30ms, TR 1500ms) was performed on 17 children with 
Chang stage M0 MB prior to treatment; patients were followed-up for a median of 3 years, 6 had 
died at the end of the study period. MRS data was analysed using TARQUIN software to provide 
metabolite concentrations and a combined principal component and linear discriminant analysis 
(PCA-LDA) used to determine metabolite profiles for good and poor prognostic groups. Kaplan 
Meier curves were constructed comparing these groups. Pair-wise correlation analysis (Pearson's) 
was performed on the metabolite values for the two groups. RESULTS: Metabolite profiles were 
constructed, which discriminated well between survivors and non-survivors with 9/9 and 2/8 
being alive in the good and poor prognosis groups respectively. There was a significant difference 
in Kaplan Meier survival between the two groups (log rank test, p = 0.03). The poor prognosis 
group had a higher tumour lipid/choline ratio (t-test, p = 0.03). Citrate levels were correlated with 
glutamate + glutamine levels (Pearson's correlation analysis p = 0.001) in the group that 
demonstrated a better prognosis but not in the poor prognosis group (p = 0.5). CONCLUSIONS: 
Non-invasive MRS metabolite profiles can be constructed that correspond to good and poor 
prognosis groups for M0 MB. The biomarkers identified concur with previous findings from in 
vitro molecular profiling of MB and MRS studies. 
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Purpose: Magnetic resonance spectroscopy (MRS) is known to provide non-invasive biomarkers 
of tumour aggressiveness but studies are lacking in elaborating on specific tumour types and with 
long term follow-up for survival. Medulloblastomas (MB) are the most common malignant brain 
tumours of childhood and in this study we investigate whether MRS metabolite profiles can 
identify prognostic biomarkers of this tumour. 
Methods: Single voxel MRS (1.5 T, TE 30ms, TR 1500 ms) was performed on 36 children with MB 
prior to treatment; patients were followed-up for a median of 4 years and 15 had died by the end 
of the study period. MRS was analysed using TARQUIN software to provide metabolite 
concentrations. Wilcoxon signed rank test analysis was used to compare metabolite profiles of 
those MBs currently alive compared with those that progressed and died and Cox regression 
analysis with overall survival was used to test each metabolite. Kaplan Meier curves were then 
constructed of those metabolites that demonstrated significance in the Cox regression analysis. 
Results: The poor prognosis group demonstrated lower levels of Creatine (Cr) (Wilcoxon 
signed rank test, p=0.003) and near significant lower levels of total choline (tCho) 
(p=0.06). Cox regression analysis also demonstrated only Cr and tCho to be significant with a 
lower hazard for those subjects with higher values. Kaplan Meier curves demonstrated significant 
differences in survival for both Cr (p=0.001) and tCho (p=0.01). 
Conclusion: Cr and tCho have been demonstrated as biomarkers of good prognosis and this may 
be useful for strategising treatment in MBs. The validation of these biomarkers with biological 
information is warranted. 
 
 
 
 
 
 
 
 
